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Abstract 
Hypoxia is defined by a low oxygen concentration state in biological tissue, resulting 
from an imbalance between oxygen supply and demand. Greater understanding of 
hypoxia in tumours is essential, as it is associated with disease progression and 
resistance to therapy, leading therefore to a poorer prognosis. Tumour hypoxia can be 
classified into two types: chronic and cycling, and this thesis focuses on characterising 
cycling hypoxia in colorectal carcinoma tumours in mice. For that, magnetic resonance 
imaging (MRI) was used, as it provides a non-invasive method to dynamically map 
blood oxygenation changes due to the different magnetic properties of oxygenated and 
deoxygenated blood.  
The first approach to characterise cycling tumour hypoxia consisted of a longitudinal 
study in which the influence of the tumour size on the occurrence, frequency and 
amplitude of cycling events was investigated. These observations were complemented 
with tumour vascular properties, inferred from applied vasoactive gas challenges, with 
blood sampling assessments, and with histological assessments.  
The influence of systemic variations in blood oxygenation in cycling tumour hypoxia 
was demonstrated through simultaneous acquisition of MRI and blood oxygen 
saturation trends. In particular, the computational implementation of independent 
component analysis (ICA) allowed the identification of the tumour regions that were 
simultaneously suffering from systemic and tumour-specific effects, and revealed links 
to tumour pathophysiology.  
The effect of a therapy on cycling tumour hypoxia was also assessed under the 
hypothesis of a “vascular normalisation” effect of the drug. In addition, the effects of 
the therapy on gas challenge response and on histological distributions were studied. 
This dynamic MRI technique and the ICA protocol were ultimately adapted to a 
translational study, where cycling hypoxia was investigated as a biomarker for early 
detection of prostate tumours.  
Overall, this thesis revealed that the stage of the tumour development can influence 
some aspects related to cycling hypoxia, and that its occurrence has a contribution of 
local and systemic effects. Also, it drew attention to the regional effects a therapy can 
have in tumours and provided a starting point to assess cycling tumour hypoxia in the 
clinic.  
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Introduction to the layout of contents 
This thesis consists of 8 chapters. The first two chapters give some theoretical 
background and motivation for the conducted work. The methodology implemented 
which is common to most experimental procedures is described in Chapter 3. The 
structure of experimental Chapters 4 to 7 consists of a brief introduction, where 
additional background information is given and where the aims and hypotheses are 
stated, relevant materials and methods to that chapter, results, discussion and a brief 
conclusion. General conclusions and future directions are given in Chapter 8.         
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1. Introduction 
Hypoxia is a condition characterised by low concentration of oxygen in the tissues 
(below 10 mmHg), resulting from an imbalance between oxygen supply and demand. 
Cancer and vascular diseases are amongst the leading causes of death worldwide [1], 
both being influenced by hypoxia. In the latter, the condition usually derives from the 
obstruction of a blood vessel, depriving the tissues of an adequate oxygen supply, 
consequently leading to infarction. In tumours however, the occurrence of hypoxia is a 
much more complex mechanism with several associated causes. Tumour hypoxia is of 
great importance, as it is associated with disease progression and resistance to 
conventional anticancer therapies, leading therefore to a poorer prognosis [2]. This 
chapter provides an overview of tumour hypoxia, with emphasis on cycling hypoxia, 
which is the subject of this thesis. Fundamental differences between tumours and 
normal tissues are highlighted, which are followed by an explanation of the different 
types of tumour hypoxia and their biological effects. Next, a description of the methods 
used so far to detect cycling hypoxia in tumours is presented. At the end of the chapter, 
the motivation for this thesis and its aim are summarised. 
 
1.1. Structural differences between tumour and normal tissues 
Tumour tissues exhibit a number of characteristics that are altered when compared to 
normal tissues. In the latter, vascular networks are well organised and possess linear 
blood vessels lined by a smooth layer of endothelial cells, with contractile pericytes 
enveloping the surface of the vessel to strengthen the vascular structure and regulate the 
microvascular blood flow. The extracellular matrix (ECM) is composed of a loose 
network of collagen and other fibres, and contains a limited number of fibroblasts 
(connective tissue cells that produce collagen) and macrophages (cells involved in the 
immune response). Lymph vessels are also present in normal tissues [3]. Conversely, 
tumour tissues contain disorganised vascular networks with abnormal blood vessels that 
are leaky and irregularly shaped, with varying diameters and many sac-like and dead-
end formations, as well as being loosely covered by abnormal pericytes [3-6]. These 
characteristics are the result of an imbalance in the elaborate collaboration between the 
factors involved in different stages of the angiogenic process, i.e., the process by which 
new blood vessels are formed, and contribute to inefficient blood flow and decreased 
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vessel stability and function [3-6]. Tumours also contain more fibroblasts and 
macrophages, as well as a denser network of collagen fibres, the action of which 
contributes to interstitial hypertension [3;7]. Furthermore, many tumours lack or have 
non-functional lymph vessels, hence interstitial fluid and soluble proteins are 
inefficiently removed and there is raised interstitial fluid pressure (IFP) [3;4]. These 
structural defects in tumours, and their associated impairments, represent serious 
barriers to capillary blood flow, thus compromising oxygen supply to the tissues [4].  
 
1.2. Tumour hypoxia: chronic and cycling 
The previous section summarised the structural impairments of tumour tissues that 
cause regions of tumour hypoxia. Classically, hypoxia in tumours can be classified into 
two types: chronic or cycling (acute) hypoxia. Although there might not be a complete 
distinction between both forms of hypoxia in given tumour regions, chronic hypoxia is 
generally found in cells at a distance from the blood supply, and is caused by limitations 
in oxygen diffusion from tumour microvessels into the surrounding tissue, whereas 
cycling hypoxia occurs closer to the blood vessels, and is mainly a result of temporary, 
local disturbances in perfusion [2;8-10].  
 
1.2.1. Chronic hypoxia 
Chronic hypoxia (also known as long-term or diffusion-limited hypoxia) is 
characterised by constant low partial pressure of oxygen (low pO2) as the result of 
chronic deficiencies of oxygen supply via the tumour vasculature [8;11;12]. Another 
factor that is possible to contribute to long-term hypoxia is the oxygen consumption rate 
of tumour cells. A few published studies have suggested that the most efficient method 
to reduce hypoxia is via a reduction in the oxygen consumption rate [13-15]. However, 
this is yet a debatable matter, as measurements of oxygen consumption rates of tumours 
were found to be in the midrange between normal tissues with high and low metabolic 
rates, thus opposing the claim that tumour hypoxia is the result of abnormally high 
oxygen consumption rates [8;16-18]. Several effects are associated with impaired 
oxygen supply to the tumour cells:  
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Solid tumours suffer from relatively high intervascular spacing when compared with 
the diffusion distance of oxygen [19], causing inadequate oxygen delivery to the cells 
most distant from the capillaries (the range of oxygen diffusion varies within the same 
tumour line and between tumour lines, with values between 40µm and 200µm being 
reported [8;19]).  
Intravascular hypoxia has also been reported, and is probably caused by steep 
longitudinal gradients in oxygen tension, i.e., declines in pO2 along the afferent path of 
blood flow, as opposed to the radial diffusion of oxygen [8;20].  This effect results from 
the lack of arteriolar supply (arterioles typically do not enter the tumour parenchyma), 
which may cause erythrocytes to be depleted of oxygen as they travel relatively long 
distances through the capillary network, combined with the fact that the blood in the 
tumour-feeding arterioles already suffers from partial deoxygenation before it enters the 
tumour parenchyma [8;20].  
Additionally, hypoxic red blood cells shrink and become denser and stiffer than 
normally oxygenated red blood cells, causing increased blood viscosity and 
consequently contributing to sluggish blood flow [8;21].  
Another important factor influencing chronic hypoxia is the disorganised geometry 
of tumour vascular networks [22]. Simulations performed by Secomb et al. [15] 
revealed impairments in the capacity of oxygen transport when considering the 
geometry of the tumour vasculature, even with adequate vascular density, leading to 
substantial regions of hypoxia. The tumour’s chaotic capillary geometry also leads to 
plasma channels, which do not carry red blood cells, and are thus an additional source 
of chronic hypoxia [8;23].   
 
1.2.2. Cycling hypoxia 
Cycling hypoxia (also known as acute, transient, intermittent, fluctuating or 
perfusion-limited hypoxia) is characterised by cycles of low oxygen tension with 
subsequent reoxygenation, and is the result of transient changes in oxygen delivery due 
to microregional instabilities in blood and red blood cell flow, including vascular stasis 
[8-10;24-26]. Total vascular stasis was observed in mammary tumours, although its low 
incidence (4%) suggests it is not a major cause of cycling hypoxia [23]. In contrast, 
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flow instabilities are a rather common phenomenon [25] and may result from a 
combination of several factors:  
Dewhirst et al. [23] observed temporal changes in the arteriolar diameter in 
mammary tumours which were coordinated with red cell flow oscillations. The 
investigators concluded that this vascular physiological motion (vasomotion) must be 
the factor causing the flow variations.  
Hemodynamic factors may also cause flow oscillations. Kiani  et al. [27] developed a 
mathematical model accounting for several hemodynamic effects of microvascular 
network blood flow. They found that the effects of non-linear flow properties of blood, 
non-uniform axial distribution of red blood cells within the vessel, and disproportionate 
cell partitioning at bifurcations relative to the blood flow partition can cause oscillations 
in flow parameters independent of other factors. Schmidt-Schönbein et al. [28] also 
developed a mathematical model of capillary network blood flow that accounted for the 
non-linear blood cell distributions and non-uniform flow rates. Similarly to Kiani et al. 
[27], they concluded that flow fluctuations could be the consequence of hemodynamic 
effects in capillaries without active changes in their diameters.  
Additionally, the rapid vascular remodelling observed in human colon 
adenocarcinomas was also suggested to contribute to oscillating tumour blood flow 
[29].  
Furthermore, the high permeability of tumour vessels causes high efflux into the 
tumour interstitium. The effect of this increased leakiness combined with poor 
lymphatic drainage, increased fibroblast-mediated tension in the fibres of the ECM, and 
cytokine release due to macrophage infiltration, leads to raised IFP in solid tumours 
[3;7;30]. In normal tissues, high IFP is usually compensated by the formation of 
oedema. Such mechanism is more restricted in tumours, probably due to the high 
density of collagen fibres that increases tissue rigidity [3]. It was demonstrated 
theoretically that high tumour IFP exerts a compressive force on the blood vessels, 
causing their partial or complete occlusion. This will, in turn, lead to an increase in 
pressure at the intravascular site of constriction, which will ultimately end in the 
reopening of the vessel. Blood flow assumes therefore an oscillatory behaviour [31] and 
contributes in this fashion to the observed cycling patterns of hypoxia. Solid stress 
generated by high cell density might also compress the capillaries, compounding the 
effects of high IFP [32;33]. 
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1.2.3. Spatiotemporal characteristics of cycling hypoxia 
Cycling hypoxia is a complex process with at least two characteristic time scales: one 
has fluctuating periods ranging from < 2 cycles/min to a few cycles per hour, and is due 
primarily to the rapid components of varying red blood cell flow, such as vasomotion, 
the differences in the distribution of red blood cells within the vessel and at vessel 
bifurcations, and the vessel occlusion/reopening cycling behaviour [9;10;27;34-37]. The 
second exhibits variations on a timescale of hours to days, and is possibly associated 
with vascular remodelling [9;10;38;39]. 
The complexity and heterogeneity of the tumour microenvironment additionally 
means that cycling tumour hypoxia is heterogeneously distributed across the tumour, 
with patterns that are tumour type-dependent [40]. Factors such as vessel immaturity 
and functionality can also play an important role [34;41]. 
 
1.3. Biological effects of tumour hypoxia 
1.3.1. Tumour hypoxia is a source of treatment resistance 
It has become evident that tumour oxygen deficiency has significant therapeutic 
implications. From levels of extreme tissue hypoxia up to a level of 2.6% oxygen (20 
mmHg), cellular radiosensitivity is markedly dependent on oxygen tension [42], which 
makes tumour hypoxia a major cause of resistance to radiation therapy [24;42-44]. In 
normal tissues, oxygen levels range from 3.4% to 6.8% oxygen (26.0 – 51.6 mmHg) 
[42]. In tumours, however, tissue oxygenation falls to values between 0.3% and 4.2% 
oxygen (2.0 – 32.0 mmHg), with almost all exhibiting oxygenation below 2%, and 
where a marked skewing towards the lower end of this distribution is observed (under 
1.3% oxygen (10 mmHg)) [42]. Oxygen sensitization is accepted as resulting from the 
interaction of oxygen with free radical species. Ionising radiation causes an increase in 
the production of free radicals due to the radiolysis of water. In the presence of oxygen, 
free radicals form highly reactive peroxy radicals which produce DNA damage, leading 
therefore to cell death. In the absence of oxygen, however, free radicals can be 
neutralised by interacting with hydrogen or by electron donation, consequently 
minimising radiation damage [45-47]. The reported measurable consequence of hypoxia 
in radiotherapy is that hypoxic cells are usually 2.5 to 3 times more radioresistant than 
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normally oxygenated cells [43], but can be up to 12 times more radioresistant in relation 
to fully oxygenated cells [48]. 
Tumour hypoxia also impacts negatively on the efficacy of systemically 
administered chemotherapeutic agents. One factor that contributes to this effect is the 
distance of cells from the blood supply, as drug penetration is limited and its toxicity 
decreases with distance from a functional vessel [49;50]. Additionally, hypoxic and 
nutrient-deprived cells can divide at slower rates, and so the effect of chemotherapeutic 
agents targeted at rapidly dividing cell populations is impaired [49]. Furthermore, the 
activity of many chemotherapeutic drugs is altered at low oxygen concentrations (e.g. 
cyclophosphamide, carboplatin, doxorubicin and bleomycin), thus further protecting 
hypoxic tumour populations [9;49;50]. Finally, tumour resistance to chemotherapy is 
probably enhanced by blood flow fluctuations, which hinder drug delivery [49-51]. The 
efficacy of some cytotoxic therapies is enhanced under hypoxic conditions, although 
these are exceptions to the more frequent effect of increased drug resistance [52]. 
Tumour hypoxia has additionally been shown to impair the efficacy of alternative 
anticancer therapies, such as immunotherapy and photodynamic therapy [50]. The latter 
has further (self) limitations regarding the induction of hypoxia by the therapy 
mechanism itself [50].  
 
1.3.2. Tumour hypoxia promotes metastatic disease and tumour 
proliferation 
Tumour hypoxia is associated with the mechanisms involved in increased 
malignancy and proliferative advantage of tumour cells, including the development of 
metastatic disease [2;53-55]. Hypoxia-induced tumour progression may occur as the 
result of alterations in gene expression or due to clonal selection [2;50]. Alterations in 
gene expression, namely the genes involved in the metastatic pathway, subsequently 
lead to changes in the proteome and/or in the genome, with a strong impact on tumour 
aggressiveness and proliferation [2;49;50]. Clonal selection, in turn, subjects tumour 
cells and proteins to a selection pressure, in which the populations that are better 
adapted to the hypoxic conditions thrive, further enhancing a malignant phenotype and 
the metastatic potential [49;50;56].  
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The selective pressure generated by hypoxia additionally generates tumour 
populations with reduced apoptotic potential, a mark of aggressiveness [57;58], and a 
more angiogenic phenotype. Enhanced angiogenesis is the result of hypoxia-mediated 
upregulation of growth factors, like vascular endothelial growth factor (VEGF), and is 
essential for tumour expansion and metastatic spread through the vasculature [49;50].  
These factors involved in metastasis formation and tumour proliferation are 
additionally important because they can further impair the efficacy of antitumour 
therapies [50]. 
 
1.3.3. The role of HIF-1 in tumour adaptation to hypoxia 
Of paramount importance to the processes mentioned above is the action of the 
transcription factor hypoxia-inducible factor-1 (HIF-1). HIF-1 is a key facilitator of 
cellular adaptation to hypoxic environments, being composed of two subunits: HIF-1α 
and HIF-1β [59]. Although the subunit HIF-1β is constitutively expressed, the presence 
of HIF-1α is dependent on growth factors [60] and cellular oxygenation [59]. In 
normoxia, the HIF-1α proteins are rapidly degraded. During hypoxia, however, HIF-1α 
becomes stabilised and translocates from the cell cytoplasm to the nucleus, where it 
dimerises with HIF-1β, making HIF-1 active and ready for transcription of genetic 
information [59]. HIF-1 activity on hypoxic tumour populations will then promote 
metabolic adaptation by switching to glycolytic metabolism, in which oxygen is not 
needed for the production of energy (ATP), and increasing glucose uptake ability, thus 
maintaining cell viability under hypoxic conditions [9;10;59;61;62]. Additionally, HIF-
1 overexpression promotes the upregulation of pro-angiogenic factors, like VEGF, 
leading to increased vascular density and tumour growth, and is also associated with 
increased metastatic potential [9;10;59;61;62]. HIF-1 was also found to induce 
resistance to cytotoxic therapy, by promoting endothelial and tumour cell survival, as 
well as impacting on resistance to oxidative stress (i.e., cellular damage due to the 
accumulation of reactive oxygen species) [9;10;59;61]. Consequently, HIF-1 
overexpression is associated with poorer survival in many tumour types [2].    
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1.4. Relative biological effects of chronic and cycling hypoxia  
The oldest model proposed to explain tumour oxygen deficiency is that of chronic 
hypoxia [19]. However, it is now widely accepted that acute changes in tumour oxygen 
delivery are of similar or perhaps even greater importance [10-12]. Examples of this 
come from different studies:  
A number of studies comprising different tumour cell lines reported the fraction of 
acutely hypoxic cells to be significantly higher than the fraction of chronically hypoxic 
cells [63-66].  
Cycling hypoxic cells were also found to have increased resistance to both 
radiotherapy [36;37;67-69] and chemotherapy [70] treatments, when compared to 
chronically hypoxic tumour regions. One of the reasons for this observation is probably 
due to the oscillatory nature of cycling hypoxia itself. Expanding on the concept 
introduced in section 1.3.1, if blood flow fluctuations are of sufficient magnitude and 
rapidity, regions of a tumour actively proliferating at one point in time can soon after 
become quiescent and hypoxic. Subsequently, fluctuating tumour perfusion may exert a 
protective effect in tumour subpopulations during chemotherapy and radiotherapy, 
leaving them ready to regrow and proliferate once adequate blood flow and nutrient 
supply is restored [51].  
Another possible factor for increased resistance to therapy is reported by Martinive et 
al. [69]. In their study, they observed that in vitro enforcement of cycles of hypoxia-
reoxygenation to vascular endothelial cells resulted in increasing accumulation of HIF-
1α after each cycle. When chronic hypoxia was enforced, subsequent reoxygenation 
rapidly degraded HIF-1α. Accumulation of HIF-1α during cycling hypoxia is possibly 
the reason why cycling, but not chronic, hypoxia was observed to promote endothelial 
cell survival and angiogenesis after radiotherapy, even if radiotherapy was administered 
in normoxic conditions. In the same study, the investigators additionally found that in 
vivo preconditioning of cycling hypoxia in tumour-bearing mice enhanced tumour 
regrowth and reduced apoptosis in endothelial and tumour cells after irradiation, relative 
to chronic hypoxic conditions. Upregulation of HIF-1 during cycling hypoxia to higher 
levels than those achieved by chronic hypoxia has also been observed in other studies 
[9;67].  
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Furthermore, cycling hypoxic cells were found to have greater influence on tumour 
progression, and higher metastatic potential, than chronically hypoxic cells [66;71;72], 
which once more is in agreement with the observations that HIF-1 (or HIF-1α) has 
higher expression during cycling hypoxia. Exposure of endothelial cells to cycling 
hypoxia was also shown to promote tumour inflammation amplification to a greater 
extent than chronic hypoxia [73].  
The ability for DNA replication in different tumour cell lines after exposure to 
chronic and cycling hypoxia was also investigated [74]. The investigators found that 
chronic hypoxia prevented initiation of DNA replication following reoxygenation. 
Conversely, cells acutely exposed to hypoxia were able to restart DNA replication, 
despite the occurrence of reoxygenation-induced DNA damage. Replication restart 
under these conditions leads to increased genomic instability, probably due to an 
accumulation of unrepaired lesions [75].  
 
1.4.1. Cycling hypoxia and glycolysis 
Glycolysis is the anaerobic cellular process by which glucose is converted into 
pyruvate and then lactic acid, generating 2 ATP of energy per glucose molecule. 
Gatenby and Gillies [76] suggested that the switch to the glycolytic pathway, a near-
universal property of primary and metastatic tumours, is an adaptation to cycling 
hypoxia, so that cells can better survive the hypoxic episodes. In fact, this theory is in 
agreement with the observations that cycling hypoxia upregulates HIF-1, and that HIF-1 
subsequently regulates the expression of all the enzymes in the glycolytic pathway as 
well as the expression of the glucose transporters GLUT1 and GLUT3 [77]. At the 
cellular level this represents a pitfall, however, as the end product of glycolysis is lactic 
acid. Consequently, increased glycolytic metabolism results in microenvironmental 
acidosis, which ultimately leads to necrosis or apoptosis. These negative consequences 
of glycolysis therefore require further cellular adaptation, inducing phenotypes that are 
resistant to acid-induced toxicity. The most likely consequence of this cycling hypoxia-
induced upregulated glycolysis is the emergence of cell populations that have both 
proliferative advantage and increased invasive potential [76]. Indeed, increased glucose 
uptake was observed to coincide with the transition of pre-malignant lesions to invasive 
cancer [78;79]. Furthermore, and similarly to cycling hypoxia, upregulated glycolysis 
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has been associated with increased occurrence of metastasis in cervical and head and 
neck cancers [80;81].  
     
1.5. Methods to detect cycling hypoxia in tumours  
Investigations on the detection of temporal fluctuations in tumour blood flow and 
tissue oxygen tension (pO2) have been done over the years with a number of different 
methods: 
Chaplin and co-workers [37] performed an in vivo study in murine SCCVII 
squamous cell carcinomas, in which they used a combination of radiation and a 
fluorescent perfusion dye (Hoechst 33342), administered either simultaneously or 20 
minutes apart, to assess the relationship between radiosensitivity and oxygenation. They 
observed that separate, but not simultaneous, administration of Hoechst 33342 and 
radiation resulted in radiation resistance of brightly stained cells. This result indicated 
that changes in tumour blood perfusion were occurring within a 20-minute interval, 
which resulted in acute radiological hypoxia. They went on to confirm this observation 
using a ‘double labelling’ fluorescence technique [24]. 
Laser-Doppler flowmetry was also applied to study tumour haemodynamic 
instabilities. More precisely, microregional fluctuations in red blood cell flux were 
observed in two murine cell lines (sarcoma F and adenocarcinoma NT), with 
periodicities of 6 to 45 minutes [82]. Encouraged by these results, the same group then 
applied this method to 3 different human tumours (breast carcinoma, metastatic 
adenocarcinoma deposits and metastatic lymph node carcinoma and lymphoma), where 
they found fluctuations with frequencies of 1 cycle/4-44 minutes [83]. 
Cárdenas-Navia and colleagues [84] used recessed-tip oxygen microelectrodes to 
directly measure tumour pO2 fluctuations, which were observed to occur between 2 and 
5 cycles/hour in fibrosarcoma and 9L glioma rat tumours. 
Braun et al. [35] combined laser-Doppler flowmetry with recessed-tip oxygen 
microelectrodes to simultaneously measure tumour blood flow and tissue pO2 in R3230 
rat mammary adenocarcinomas. Upon Fourier analysis, pO2 and blood flow showed 
dominant frequencies of oscillation at < 2 cycles/minute. 
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Dewhirst et al. [23] and Kimura et al. [25] combined intravital microscopy and 
recessed-tip oxygen microelectrodes to simultaneously measure capillary red cell flux 
and perivascular oxygenation, also in R3230 rat mammary adenocarcinomas. They 
observed that fluctuant red cell flux occurs in isolated vessels and in groups of 
contiguous vessels, with frequencies of oscillation of 1 cycle/15-60 minutes, and that 
such variations were coherent with changes in perivascular oxygenation. 
Skala et al. [85] detected blood flow fluctuations in 4T1 mouse mammary tumours, 
and found that these were correlated with haemoglobin saturation variations, by 
combining optical coherence tomography with hyperspectral imaging. 
Yasui et al. [86] used pulsed electron paramagnetic resonance imaging (EPRI) to 
directly monitor pO2 in SCCVII and HT29 mouse tumour models. They observed pO2 
fluctuations in both tumour types over a period of 28 minutes. 
Magnetic resonance imaging (MRI) was also employed in the study of cycling 
tumour hypoxia. Baudelet and colleagues used a gradient-echo (GE) technique to 
investigate spontaneous fluctuations in an MRI parameter related to tumour blood 
flow/oxygenation [34;41]. They found significant fluctuations at frequencies ranging 
from a less than 1 cycle/minute to 1 cycle/hour in syngeneic fibrosarcoma tumours in 
mice. More recently, the same group used a MRI-sensitive fluorine compound to map 
tumour tissue pO2 spontaneous fluctuations, which were observed at a rate of 1 
cycle/12-47 minutes in syngeneic transplantable mouse liver tumours [87]. 
In addition, dynamic contrast-enhanced MRI (DCE-MRI) was used to investigate 
blood flow variations in A-07 human melanoma xenografts [88]. Blood flow differences 
were found between DCE-MRI acquisitions separated by 1 hour. 
A first-pass imaging microscopy technique was also applied to the study of blood 
flow temporal patterns in A-07 human melanoma xenografts growing in window 
chambers1 [90]. This technique estimates blood flow based on the time blood takes to 
travel from the main supplying artery to a given vessel site in the tumour – blood supply 
time (BST). Tumour maps of BST revealed it to be heterogeneous across the tumour. 
Additionally, BST measurements separated by 20 minutes revealed differences in 
                                                          
1 The dorsal window chamber technique involves surgically implanting a titanium frame, a transparent 
window, and tumour cells, so as to allow microscopy imaging of the tumour. For a complete description 
see ref [89]. 
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individual vessels and in groups of vessels. Homogeneous changes in BST across the 
whole tumour were identified when there was only one supplying artery. 
Brurberg et al. [91;92] used OxyLite fibre-optic oxygen-sensing probes to investigate 
about the temporal heterogeneity in tissue pO2 in two human melanoma xenograft lines 
(A-07 and R-18). They found that pO2 fluctuated at frequencies lower than 12 
cycles/hour in R-18 tumours and lower than 20 cycles/hour in A-07 tumours. The same 
group later used OxyLite in head and neck canine tumours, where pO2 fluctuations were 
detected in untreated (1.5 – 4.3 cycles/hour) and irradiated (2.2 – 8.8 cycles/hour) 
tumours, regardless of their overall oxygenation status [93]. 
Head and neck tumours in humans were also studied using an injectable fluorine 
tracer (18F-fluoromisonidazole (FMISO)) revealed with positron emission tomography 
(PET). In a first study, the investigators found that significant restructuring of tissue 
hypoxia regions occurred across a period of 3 days [94]. In a following study, acute 
hypoxia was confirmed to occur over a 3-day interval by using a mathematical approach 
to separate the fractions of chronic and acute hypoxia [95]. However, the slow kinetics 
of PET tracer retention does not allow the mapping of the fastest modes of cycling 
hypoxia [96;97]. The estimated influence of cycling hypoxia is that of enhancing the 
retention of FMISO tracer, whereas the separation between chronic and cycling 
contributions presents a greater challenge [96]. 
 
In summary, cycling hypoxia in solid tumours is a phenomenon that results from a 
combination of structural and functional abnormalities characteristic of the tumour 
microenvironment. It has important implications regarding patient survival, as it is 
associated with disease progression and malignancy, including metastatic spread, 
alongside resistance to different forms of therapy. So far, a range of oxygen or flow 
probes, cellular biomarkers and imaging techniques have been used to study the 
dynamics and spatial distribution of cycling hypoxia in tumours, both in mouse, rat and 
canine models, with few studies applied to humans.   
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1.6. Motivation and aim of this thesis  
Although cycling tumour hypoxia has been investigated for decades [24;36;37], there 
still remains a need to counteract the pathological processes involved. The better we 
understand the cycling hypoxic processes occurring in the tumour microenvironment, 
the more likely we are of reversing its harmful effects; and it is this premise that gives 
the motivation for this thesis.  
Given this, the principal aim of this thesis is to characterise the temporal and spatial 
aspects related to cycling hypoxia in solid tumours, using a non-invasive MRI 
technique, and assess its relationship with the biological characteristics of the tumour 
microenvironment.    
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2. Magnetic resonance imaging 
Chapter one described the problem of tumour hypoxia and particularly cycling 
hypoxia, its biological effects and methods of detection. As previously mentioned, 
magnetic resonance imaging (MRI) is a useful method to detect and characterise cycling 
hypoxia in tumours. This chapter will therefore outline the basic principles of MRI, 
which will be followed by an overview of the biological characteristics that allow the 
use of MRI to non-invasively detect oscillatory patterns in blood flow and oxygenation.   
 
2.1. Basic principles of MRI  
Magnetic resonance imaging (MRI) is based on the phenomenon of ‘nuclear 
induction’ or ‘nuclear magnetic resonance absorption’ discovered by Bloch and Purcell 
in 1946. They observed that atomic nuclei which are under the influence of a constant 
magnetic field can absorb the energy of a weaker alternating magnetic field through a 
mechanism of resonance. The signal from these excited nuclei can then be detected, 
which will ultimately lead to the formation of an image. Resonance is thus key in MRI 
and this concept will be further developed in this section at a later point. Firstly 
however, in order to understand the interactions occurring in a magnetic resonance 
experiment, one should start by considering the quantum mechanical properties of 
atomic nuclei. A more complete description of MRI and nuclear magnetic resonance 
(NMR) can be found in standard textbooks [98-100].    
 
2.1.1. Angular momentum, magnetic moment and the hydrogen nucleus 
An intrinsic property of an atomic nucleus is spin or intrinsic spin angular 
momentum, 𝑱, which can be pictured as a constant rotation of the nucleus about its own 
axis. Based on quantum mechanics, in the presence of an external magnetic field, the 
angular momentum can only take 2𝐼 + 1 possible states, where 𝐼 is the spin angular 
momentum quantum number. If a nucleus has either an odd atomic weight or an even 
atomic weight, but an odd atomic number, it has a non-zero 𝐼, which means it interacts 
with an external magnetic field and can, therefore, be studied using magnetic resonance. 
The mechanism of interaction is summarised in section 2.1.2. 
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The nucleus of hydrogen, consisting of a single proton, is the most common choice 
for MRI studies due to several reasons: it has a large natural abundance; 𝐼 equal to ½; a 
large response to an applied magnetic field; and the fact that the human body is 
composed of tissues containing primarily water and fat, both of which contain 
hydrogen. 
A nucleus that is spinning and is positively charged creates a small local magnetic 
field, the magnetic moment, 𝝁: 
 𝝁 = 𝛾𝑱 = 𝛾ℏ𝐼    , Eq. 2.1 
where 𝛾 is the gyromagnetic ratio and ℏ is the Planck’s constant divided by 2𝜋. In the 
presence of an applied magnetic field, the magnetic moments align with that field and 
revolve around this direction in a motion called precession. 
  
2.1.2. Zeeman Effect, Boltzmann distribution and the Larmor frequency  
Given that 𝐼 = ½ for the proton, it results that there are only two possible states 
for 𝑱, and its projection along the orientation of the applied field can take the values 
±½. Consequently, the magnetic moments of the protons can only precess in two 
energy levels: parallel to the field (lower energy level) or antiparallel (higher energy 
level) (see figure 2.1A). Concepts of classical mechanics can now be applied to simplify 
the description of the magnetic resonance (MR) processes. This splitting of energy 
under the effect of a static magnetic field, 𝐵0, is named the Zeeman effect, and the 
energy difference between both levels is 
 ∆𝐸 = 𝛾ℏ𝐵0    . Eq. 2.2 
For a collection of protons, more will normally be in the lower energy level, where 
the exact number of protons in each level is governed by the Boltzmann distribution: 
 𝑁𝑢𝑝
𝑁𝑑𝑜𝑤𝑛
= 𝑒
−
∆𝐸
𝑘𝐵𝑇    , Eq. 2.3 
with 𝑁𝑢𝑝 and 𝑁𝑑𝑜𝑤𝑛 being the number of protons in the higher and lower energy levels, 
respectively, 𝑘𝐵 is the Boltzmann constant and 𝑇 is the absolute temperature. 
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To excite the protons from the lower to the higher energy level, photons with energy 
∆𝐸 and a specific frequency are needed. This frequency is the characteristic 
precessional frequency or Larmor frequency, 𝜔0, and is proportional to the strength of 
the magnetic field: 
 𝜔0 = 𝛾𝐵0    . Eq. 2.4 
 
2.1.3. Equilibrium magnetisation and the 𝑩𝟏 magnetic field   
The effect of a larger population of proton magnetic moments precessing in the lower 
energy level (parallel to 𝑩𝟎) is the formation of a non-zero net magnetisation, the 
equilibrium magnetisation, 𝑴𝟎, which is parallel to 𝑩𝟎 (see figure 2.1B). Considering 
that 𝑩𝟎 is oriented longitudinally (z axis), the precessional nature of magnetic moments, 
which are randomly oriented in the plane perpendicular to 𝑩𝟎 but have a constant 
longitudinal component, means that 𝑴𝟎 has constant magnitude in the longitudinal axis 
and is zero in the transverse plane (x-y plane, formed by x and y axes). Because 𝑴𝟎 
represents a large collection of nuclei, it can be treated as a macroscopic entity by 
classical mechanics. 
 
 
Figure 2.1 - Microscopic (A) and macroscopic (B) representations of a population 
of proton magnetic moments, 𝝁, in the presence of a static magnetic field, 𝑩𝟎. In 
equilibrium, the magnetic moments of protons precess out of phase about the magnetic 
field, but with a constant z component, either parallel or antiparallel to 𝑩𝟎. 
Consequently, the net magnetisation in the transverse plane is zero, as the magnetic 
moments cancel each other, whereas longitudinally a positive net magnetisation, 𝑴𝟎, 
emerges as the result of an excess of magnetic moments aligned parallel to 𝑩𝟎. Adapted 
from [98]. 
𝝁 
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For an MR signal to be generated, the orientation of 𝑴𝟎 needs first to be perturbed 
away from equilibrium towards the transverse plane. Following this perturbation, the 
resultant transverse magnetisation rotates at the Larmor frequency in the x-y plane, 
which induces a current in a receiver coil tuned to the Larmor frequency and oriented 
perpendicularly to 𝑩𝟎. This current is the source of the signal used to generate MR 
images.  
The motion of the magnetisation away from its equilibrium position is achieved by 
applying a temporary magnetic field, 𝑩𝟏, which is circularly polarised in the transverse 
plane with a frequency at (or near) the Larmor frequency. The magnetisation interacts 
with 𝑩𝟏 by resonance causing it to rotate about 𝑩𝟏 towards the transverse plane. To 
simplify the understanding of this mechanism and its effects, a rotating frame at the 
Larmor frequency and about the z axis is usually considered, thus making 𝑩𝟏 appear as 
a fixed magnetic field (see figure 2.2). In this rotating frame, the motion of 𝑴𝟎 is given 
by: 
 
(
𝑑𝑴𝟎
𝑑𝑡
)
𝑟𝑜𝑡
= 𝛾𝑴𝟎 × (𝑩𝟎 −
𝝎𝟎
𝛾
+ 𝑩𝟏) = 𝛾𝑴𝟎 × 𝑩𝟏    , 
Eq. 2.5 
where the minus sign of 𝝎𝟎 defines a clockwise rotation of the frame. The angle formed 
by 𝑴𝟎 and 𝑩𝟎 is called the flip angle, 𝛼 (see figure 2.2B). If the magnetisation vector 
ends up exactly in the transverse plane by the time 𝑩𝟏 is turned off, then 𝛼 = 90
∘ and it 
is called a 90∘ radiofrequency (RF) pulse. 
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Figure 2.2 - Mechanism of resonance absorption. A: the radiofrequency pulse 
induces a magnetic field 𝑩𝟏 perpendicular to 𝑩𝟎, which appears stationary in the 
rotating frame. B: 𝑴𝟎 precesses about 𝑩𝟏 towards the transverse plane with a flip angle, 
𝛼. Adapted from [98]. 
 
2.1.4. Relaxation   
2.1.4.1. Longitudinal relaxation (𝑇1 relaxation)    
After the 𝑩𝟏 field is turned off, and in the case of a 90
∘ pulse, the magnetisation 
vector remains rotating in the x-y plane. This is, however, a temporary state as the 
longitudinal component of the magnetisation vector, 𝑴𝒛, returns to equilibrium (𝑴𝟎). 
This recovery is named longitudinal relaxation, spin-lattice relaxation, or 𝑇1 relaxation, 
and evolves exponentially with a tissue-characteristic time constant 𝑇1: 
 𝑴𝒛(𝑡) = 𝑴𝟎(1 − 𝑒
−𝑡 𝑇1⁄ )    . Eq. 2.6 
Longitudinal relaxation reflects the transfer of excess heat, previously acquired with the 
RF excitation (𝑩𝟏 field), from the spin system into nearby atoms and molecules, 
allowing protons to return to thermal equilibrium with its surroundings. This process is 
stimulated by local magnetic fields fluctuating near the Larmor frequency, which 
originate from molecular tumbling.  
 
2.1.4.2. Transverse relaxation (𝑇2 and 𝑇2
∗ relaxation) 
In addition to longitudinal relaxation, the magnetisation that is rotating in the x-y 
plane, 𝑴𝒙𝒚, also evolves by decaying due to phenomena that disrupt the transverse 
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phase coherence of individual proton magnetic moments. Transverse relaxation, or spin-
spin relaxation, reflects the rate at which 𝑴𝒙𝒚 is lost, decaying exponentially with a 
tissue-specific time constant 𝑇2: 
 𝑴𝒙𝒚(𝑡) = 𝑴𝟎𝑒
−𝑡 𝑇2⁄     . Eq. 2.7 
Dipolar interactions between proton magnetic moments contribute to 𝑇2 relaxation. 
When two protons come close together, a slight positive or negative variation in the 
magnetic field is experienced by each of them, as the magnetic moment of the other 
proton adds or subtracts from the main field. This interaction leads to differences in 
their precessional frequencies and, consequently, loss of transverse phase coherence 
occurs, which causes a decay of 𝑴𝒙𝒚.  
Surrounding magnetic molecules also influence transverse relaxation because they 
introduce local static field disturbances. This effect can occur when, for example,  a 
water molecule is diffusing through an iron-containing media, which adds or subtracts 
from 𝑩𝟎, making the spins experience a range of 𝑩𝟎 fields and, consequently, a range of 
precessional frequencies. Consequently, this effect also causes a reduction in the 
magnitude of 𝑴𝒙𝒚 as the spins dephase relative to each other.  
In addition to these 𝑇2-only relaxation mechanisms, transverse relaxation also occurs 
accompanying 𝑇1 relaxation. This happens due to the loss of transverse phase coherence 
associated with dissipation of energy to the tissues.   
Because it depends on a combination of mechanisms, transverse relaxation evolves 
faster than longitudinal relaxation, and 𝑇2 is usually shorter than 𝑇1. Where 𝑇2-only 
effects are minimised, 𝑇2 approaches 𝑇1. 
Magnetic moments experience yet another source of dephasing, that of magnetic 
field inhomogeneities in 𝑩𝟎, either due to magnet design inaccuracies or due to the 
presence of a biological sample with non-zero magnetic susceptibility. This effect 
causes the spins to dephase actually faster than at the 𝑇2 rate, and transverse relaxation 
evolves with a shorter time constant 𝑇2
∗: 
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 1
𝑇2
∗ =
1
𝑇2
+
1
𝑇2
′    ,   
Eq. 2.8 
where 𝑇2
′ is the parameter related to magnetic field inhomogeneities in 𝑩𝟎. In reality, 
the effects of microscopic diffusion of the protons also have an effect on 𝑇2
∗ decay, and 
so a term 1 𝑇2𝑑⁄  should be included in eq. 2.8. Therefore, the signal measured in the 
receiver coil, named free induction decay (FID), decays with time constant 𝑇2
∗ (figure 
2.3). An MRI sequence conceptually similar to the one implemented in this thesis at 9.4 
T to estimate the relaxation rate 𝑅2
∗ (= 1 𝑇2
∗⁄ ) can be observed in figure 2.5, with its 
description in section 2.1.5. 
The fact that the rate of signal decay depends on the local physiological state is an 
important observation for functional studies. Particularly, the state of blood oxygenation 
influences the local magnetic field, which allows indirect measurements of local 
changes in blood oxygenation [101;102]. An explanation of how these endogenous 
magnetic properties of blood are interpreted in functional MRI is in section 2.2.    
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Figure 2.3 – Free induction decay (FID). The amplitude of the measured signal in the 
receiver coil (red curve) decays exponentially with time constant 𝑇2
∗. The magnetization 
in the x-y plane oscillates at the resonance frequency (blue curve) and becomes 
progressively smaller due to spin dephasing (represented in the circles by three 
superimposed spins (see inset)). 𝑇2
∗ inherently depends on the quality of the magnet, 
where a poor magnet generates a more inhomogeneous field than a good magnet, thus 
further shortening the FID. Adapted from [100]. 
 
2.1.5. Image formation  
In MRI, images are obtained via the implementation of pulse sequences. Pulse 
sequences consist of temporal protocols in which RF pulses and magnetic field 
gradients are applied, which allow the detection of MR signals. Magnetic field gradients 
consist of small magnetic perturbations (~1%) superimposed on the static magnetic field 
𝑩𝟎 and linearly varying in one spatial direction. They are essential in the process of 
image formation because they allow the spatial localisation of MR signals. This section 
describes the principles of a 2D pulse sequence, as implemented in this thesis. 
Comparatively, 3D or more complex sequences present slight or considerable 
differences, respectively. A 2D pulse sequence can employ three fundamental 
processes: slice selection, frequency encoding and phase encoding.  
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Slice selection consists of the application of a RF pulse of desired frequency and 
bandwidth simultaneous with a gradient, the slice selection gradient, GSS. The gradient 
causes protons to precess at different frequencies depending on their position along the 
gradient direction. Only the protons located in the slice at resonant frequency will be 
excited. This means slice position is determined by the central frequency of the pulse 
and the amplitude of GSS and slice thickness depends on the bandwidth of the RF pulse 
and the amplitude of GSS. Upon slice selection, which includes a rephrasing (negative) 
GSS lobe to realign the spins in the x-y plane, GSS is turned off. 
Within the excited slice, spatial information is further encoded by applying two 
additional gradients, orthogonal between themselves and to GSS. The frequency 
encoding gradient, GFE, is applied at the time of signal acquisition (readout), causing a 
linear variation of the precessional frequency along that spatial direction. The phase 
encoding gradient, GPE, is turned on and off before the readout starts. It has the effect of 
causing a phase shift in the precessing nuclei that is dependent on their position along 
the direction of GPE. The pulse sequence is repeated with different strengths of GPE, 
allowing all positions within the slice to have a unique combination of frequency and 
phase. For examples of basic MRI sequences see section 2.1.6. 
An alternative way of looking at this process is by considering the acquired data is 
arranged in a ‘raw data space’ two-dimensional matrix called k-space, with frequency-
encode and phase-encode directions. With each sequence repetition, a full line of k-
space is acquired in the frequency-encode direction at the time GFE is applied. Each line 
of k-space has a different position in the phase-encode direction, which results from a 
change in GPE between repetitions. K-space is thus filled line by line with each sequence 
repetition. The information in the centre of k-space contains the signal-to-noise and 
contrast information for the image, whereas the information around the outside contains 
the information about the resolution of the image, important for edge detection. A two-
dimensional image can then be obtained by applying a two-dimensional Fourier 
transform (2D FT) to k-space.   
 
2.1.6. Basic MRI sequences: spin-echo and gradient-echo  
The rate at which spins dephase in the x-y plane depends on random effects as well 
as fixed effects. 𝑇2 decay due to spin-spin interactions is a random effect, and is 
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therefore irreversible. Conversely, static 𝑩𝟎 inhomogeneities are often constant, hence 
fully reversible by application of a 180° RF ‘refocusing’ pulse.  
Spin-echo (SE) pulse sequences explore the effect of spin dephase reversibility as a 
means to retrieve the characteristic 𝑇2 of tissues. Figure 2.4 illustrates a spin-echo 
sequence, with the evolution of the magnetisation vector in the top two rows. The initial 
90° RF pulse is applied simultaneously with GSS to excite a slice of the sample, causing 
the magnetisation vector to rotate into the x-y plane. A negative lobe of GSS is applied to 
rephase the spins that started to dephase during slice selection. Spins then start to 
dephase in the transverse plane due to spin-spin interactions and off resonance effects 
(e.g. magnetic field inhomogeneities). A phase encoding gradient is applied together 
with a frequency encoding gradient, which causes further spin dephasing and describes 
a k-space trajectory from the centre of k-space towards a corner edge. A slice selective 
180° RF pulse is then applied (on the x axis) which reverses the effect of spin dephasing 
occurring due to off resonance effects, it does not reverse the random spin-spin decay, 
and describes a k-space trajectory to the opposite corner edge location. A frequency 
encoding gradient of the same polarity is applied and an echo is formed when the 
gradient moment (duration × gradient amplitude) equals that before the 180° 
‘refocusing’ pulse, at the echo time, TE. This frequency encoding gradient reverses the 
initial gradient-driven dephase and allows one line of k-space to be filled. The echo 
height depends on 𝑇2 relaxation, effectively minimising local field inhomogeneity 
effects. The time between successive excitation pulses is the repetition time, TR. The 
signal obtained by a spin-echo sequence is 𝑇2-weighted and is given by: 
 𝑆𝑆𝐸 = 𝑘𝜌 (1 − 𝑒
−𝑇𝑅 𝑇1⁄ ) 𝑒−𝑇𝐸 𝑇2⁄     ,   Eq. 2.9 
where 𝑘 contains constants and terms based on extrinsic parameters (like the number of 
signal averages and the slice thickness) and 𝜌 is the proton density of the excited 
volume. 
Conversely, gradient-echo (GE) sequences are commonly used to obtain 
measurements of 𝑇2
∗. Figure 2.5 illustrates a gradient-echo sequence with spoiler 
gradients. The slice selective excitation pulse is initially applied, which moves the 
magnetisation vector towards the x-y plane with a flip angle usually inferior to 90°. A 
negative GFE is then applied, causing rapid dephasing of the transverse magnetisation 
component. At the same time, phase encoding is performed along the remaining axis. 
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Together, GFE and GPE cause a k-space trajectory towards the corner edge of k-space. 
Next, a positive GFE is applied, acting as a spin refocusing mechanism. One line of k-
space starts then to be filled. When the positive gradient moment equals the negative 
moment an echo is produced. The height of this gradient-echo depends on 𝑇2
∗ relaxation 
because the positive gradient lobe only compensates for the previous dephasing caused 
by the negative lobe; it does not refocus the loss of precessional coherence caused by 
field inhomogeneities or spin-spin interactions. If GFE is left on, the spins get out of 
phase again. At the end of the acquisition, spoiler gradients are used to destroy any left-
over transverse signal coherence before the next RF excitation pulse is applied. The 
signal obtained by a spoiled gradient-echo sequence is 𝑇2
∗-weighted and is given by: 
 
𝑆𝐺𝐸 = 𝑘𝜌
sin 𝛼 (1 − 𝑒−𝑇𝑅 𝑇1⁄ ) 𝑒−𝑇𝐸 𝑇2
∗⁄
1 − cos 𝛼 𝑒−𝑇𝑅 𝑇1⁄
    , 
Eq. 2.10 
where 𝛼 is the flip angle. 
As noted above, single-echo GE images depend on several factors (e.g. 𝑇1, 𝑇2
∗, 
proton density) which is sometimes undesirable as it may produce confounding effects. 
Multi-echo GE sequences address this issue by implementing continuous GFE reversal, 
which produces multiple echoes at the echo times 𝑇𝐸1,  𝑇𝐸2,  𝑇𝐸3 … The height of the 
echoes depends on the parameters 𝑘 and 𝜌 as well as the 𝑇2
∗ decay, but the envelope of 
these echoes follows an exponential decay which only depends on 𝑇2
∗ relaxation, thus 
eliminating the influence of 𝑇1 and proton density: 
 𝑆𝐺𝐸
𝑚𝑢𝑙𝑡𝑖−𝑒𝑐ℎ𝑜 = 𝑘𝜌 𝑒−𝑇𝐸 𝑇2
∗⁄     . Eq. 2.11 
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Figure 2.4 – Spin-echo imaging sequence. The evolution of the magnetisation vector, 
𝑴𝟎, is represented in the first two rows. RF pulses and gradient application are shown 
in the bottom. The 90° excitation pulse is made slice selective (GSS) and rotates 𝑴𝟎 to 
the x-y plane (1). Spins start to dephase in the x-y plane (2). A 180° RF pulse is applied 
(3), which reverses the spin dephasing (4). The re-phased spins generate an echo at time 
TE (5). After TE, the spins start again to dephase (6). Adapted from [99]. 
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Figure 2.5 – Spoiled gradient-echo imaging sequence. The evolution of the 
magnetisation vector, 𝑴𝟎, is represented in the first two rows. The fact that 𝑴𝟎 is in the 
transverse plane is a simplification, given that the flip angle, α, is usually < 90° in 
gradient-echo sequences. RF pulses and gradient application are shown in the bottom. 
The excitation pulse is made slice selective (GSS) and rotates 𝑴𝟎 towards the x-y plane 
(α < 90°) (1). Negative GFE causes extra spin dephasing (2). Positive GFE reverses spin 
dephasing (3) and a gradient-echo is produced at time TE (4). Spins return to dephase 
due to the continuous effect of GFE (5). Spoiler gradients are applied before a new 
excitation pulse with the objective of dephasing the transverse magnetisation. Adapted 
from [99].   
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2.2. Gradient-echo MRI as a method of detecting variations in blood 
flow and oxygenation  
The multitude of dependencies affecting the gradient-echo signal decay allows the 
monitoring of haemodynamic changes in two ways: variations in blood oxygenation or 
in blood flow [103;104]. In the first case, blood oxygenation level-dependent (BOLD) 
contrast is commonly employed [101;102]. This method uses the endogenous magnetic 
properties of haemoglobin to estimate changes in blood oxygen saturation. 
Oxyhaemoglobin is weakly diamagnetic, which means the magnetic susceptibility of 
oxygenated blood is similar to that of surrounding tissues, therefore causing minimal 
distortion to the local magnetic field [102;105]. Conversely, deoxyhaemoglobin is 
paramagnetic, meaning the magnetic susceptibility of deoxygenated blood is 
considerably different from that of the surroundings. This difference generates local 
field inhomogeneities that are large enough to cause rapid dephasing of the local 
magnetic moments of the water protons in the blood and surrounding tissues [102;106]. 
In fact, the measure MR signal change between oxy- and deoxygenated blood is 
composed of an intravascular contribution (water molecules in the blood itself) and an 
extravascular contribution (water molecules in the tissue surrounding the vessels) [105]. 
Since the volume of a voxel is usually large when compared to individual vessels, 
especially tumour capillaries, the observed BOLD signal will be a volume-weighted 
average of intra- and extravascular water signals [105]. Although the majority of the 
water molecules reside in the extravascular compartment, the intravascular contribution 
can be quite significant, especially at lower field strengths (e.g. 1.5 T). At higher field 
strengths the intravascular contribution is decreased, however, due to the decrease of the 
intrinsic 𝑇2 and 𝑇2
∗ of deoxygenated blood [105]. A detailed review of the intra- and 
extravascular effects of water on the BOLD signal can be found in ref. [105]. 
Regardless of the field strength, increased deoxyhaemoglobin concentration impairs the 
phase coherence of the local magnetic moments, which manifests as a faster 𝑇2
∗ decay 
and results in a less intense GE signal (eq. 2.10). 
Blood flow variations also have an effect on the measured gradient-echo signal. 
Considering a vessel with static or slow flowing blood, if no complete relaxation occurs 
between excitation pulses2 (i.e., TR < T1) the longitudinal magnetisation reaches a low-
recovery equilibrium state after a few repetitions (saturation). Consequently, the GE 
                                                          
2 At 9.4 T, a GE sequence usually has TR no longer than a few hundreds of milliseconds whereas 
𝑇1 𝑏𝑙𝑜𝑜𝑑 (9.4𝑇) ~ 2430 ms [107]. 
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signal produced is lower than in the case of complete relaxation. Conversely, in the case 
of high blood flow, the water in fresh blood flowing into the imaging slice is fast 
enough not to be subject to magnetic saturation from previous RF pulses, therefore 
producing a stronger GE signal. This observation is known as the ‘in-flow effect’ 
[103;104]. Also, an increase in blood flow potentially results in an increase in the 
concentration of saturated haemoglobin [108], further intensifying the generated GE 
signal.       
As mentioned in section 2.1.6, single-echo GE signal intensity changes can be hard 
to interpret and multi-echo GE is alternatively used to isolate the 𝑇2
∗ of tissues and make 
data interpretation more straightforward. In-flow effects can additionally be minimised 
by using low flip angles. In multi-echo GE, the transverse relaxation constant  
𝑅2
∗ (= 1 𝑇2
∗⁄ ) is commonly used. It should be mentioned, however, that multi-echo GE 
can also have confounding effects, given that a change in 𝑅2
∗ can additionally reflect 
changes in blood volume, blood pH, haematocrit or in the fraction of oxygen extraction 
by the tissue [108]. Consequently, 𝑅2
∗ (or 𝑇2
∗) estimates were found not to provide a 
quantitative measurement of tumour pO2, showing only a good qualitative agreement 
[109]. The sensitivity of 𝑅2
∗ estimates to a given pO2 change was also observed to vary 
from one tumour to another [109]. 
 
2.2.1. Assessment of cycling tumour hypoxia with gradient-echo MRI 
Temporal variations in 𝑇2
∗-weighted GE images in tumour measurements have been 
suggested to be related to spontaneous fluctuations in blood flow and oxygenation, 
associated with the pathophysiology of acute hypoxia in tumours, in a study using FSa 
fibrosarcomas [34].  
Following this demonstration, the same group investigated the relationship between 
tumour vessel properties, such as maturation and functionality, and 𝑇2
∗-weighted GE 
signal fluctuations [41]. Mature vessels, coated with pericytes and smooth muscle cells, 
dilate in response to a hypercapnia challenge (elevated CO2 breathing), causing an 
increase in blood flow [110]. Conversely, immature endothelial capillaries show no 
reactivity to hypercapnia [110]. Functional blood vessels can be identified by an 
increase in haemoglobin saturation in response to hyperoxia (elevated O2 breathing), 
revealing blood is being perfused throughout these vessels [110]. Carbogen (95% O2 + 
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5% CO2), as opposed to 100% oxygen, has preferentially been used in a number of 
studies [41;104;111-113] because, in addition to high concentration of oxygen, it also 
has a high concentration of carbon dioxide. The vasodilatory effect of CO2 is expected 
to counteract the vasoconstrictory effect of oxygen, preventing vessel closure [49]. 
Results indicated the majority of spontaneous 𝑇2
∗-weighted fluctuations were in regions 
of functional and immature vasculature [41]. Vessel functionality, however, does not 
guarantee the presence of fluctuations. Also, the few regions of mature vasculature 
presented high incidence of signal fluctuations, potentially revealing the effect of 
vasomotion (i.e., temporal changes in the diameter of blood vessels) in generating 
cycling hypoxia.  
More recently, Nielsen and colleagues [114] used a ultra-high magnetic field system 
(16.4 T) to assess the occurrence of cycling hypoxia and the effect of nicotinamide 
administration, a blood flow enhancing drug, in C3H mouse mammary carcinomas. 
They implemented a multi-echo GE sequence and observed temporal variations in 𝑇2
∗ 
across a 20-minute period. However, nicotinamide did not reveal significant effects on 
these tumours. Conversely, when administered together with carbogen, nicotinamide 
was observed to reduce the percentage of the tumour experiencing 𝑇2
∗-w fluctuations in 
FSa fibrosarcomas [34]. The anticipated physiological effect of administrating 
nicotinamide is that of reducing cycling hypoxia [108], although its effect is likely to 
vary between different tumour types [115].  
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3. Experimental protocols and image analysis  
The aim of this thesis is to adapt and develop methodology to further characterise 
cycling hypoxia in tumours and assess its relationship with microenvironmental 
biological characteristics. This chapter describes the methodology implemented to that 
end and which is common to the majority of pre-clinical studies comprised in this 
thesis. Details of specific methods will be given in the corresponding chapters. All 
animal experiments were performed in accordance with the local ethical review panel, 
the UK Home Office Animals Scientific Procedures Act 1986, and United Kingdom 
Co-ordinating Committee on Cancer Research guidelines [116].     
 
3.1. Xenografts  
Two human colorectal adenocarcinoma cell lines were used: SW1222 and LS174T. 
These tumour lines were chosen for several reasons: they develop into xenografts with 
differing morphology and vascular architecture, they are readily available in the 
department and they have been well characterised due to previous work. SW1222 
tumours are well-differentiated with clearly defined glandular structures and an 
extensive and well perfused vascular network. Conversely, LS174T tumours show 
moderate-to-poor differentiation and are comparatively less well vascularised and 
perfused, with larger hypoxic and necrotic regions [117-120]. 
 
3.2. Cell culture and mouse model   
All cell work was performed at the UCL Cancer Institute. Cells of SW1222 or 
LS174T tumour lines were thawed from a stock of aliquots stored in liquid nitrogen. 
Cells were grown for 2 weeks prior to injection in complete media (Minimum Essential 
Medium Eagle with L-Glutamine (EMEM) (Lonza, Belgium) + 10% fetal bovine serum 
(Invitrogen, UK)) in a ratio 1:20 (v/v) and incubated at 37 °C and 5% CO2. Media was 
changed every 2 days. 
To prevent excessive confluence, cells were split twice per week, in which cells were 
washed with Dulbecco’s Phosphate Buffered Saline (DPBS) (Lonza, Belgium) and 
detached with trypsin-EDTA (0.05% trypsin, 0.02% EDTA in Hank’s Balanced Salt 
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Solution, Sigma-Aldrich, USA) for 7-8 minutes at 37 °C and 5% CO2. Complete media 
was then added to prevent detrimental effects of trypsin-EDTA, and cells were mixed 
with a pipette to prevent major clustering, being finally divided into new flasks 
containing complete media.  
To prepare injections, cells were washed with DPBS and detached with trypsin-
EDTA (7-8 min, 37 °C, 5% CO2). Complete media was added to annul trypsin-EDTA 
and the total volume was transferred to a falcon tube where cells were mixed to promote 
separation. The falcon tube was placed in a centrifuge for 5 minutes at 259 g (= 1200 
rpm). The resulting pellet of cells was separated from the media and re-suspended in 
DPBS. Cells were again centrifuged and the pellet re-suspended in EMEM. Cell 
concentration and viability was estimated by mixing 50 µl of the suspension with 50 µl 
of trypan blue (Life Technologies, USA) and using a haemocytometer. Final volumes of 
EMEM were calculated to obtain a concentration of 5×106 cells per 100 µl. 
To propagate tumours, 5×106 cells (SW1222 or LS174T) were injected 
subcutaneously in the flank of immunocompromised (dysfunctional thymus and T-cell 
deficient) CD1 female nude mice (6-9 weeks age, 20-30 g) and MR imaging took place 
approximately after 2 weeks of tumour growth.  
 
3.3. In vivo MRI   
3.3.1. Experimental setting  
Prior to MR imaging, anaesthesia was induced in mice by 5% isoflurane in medical 
air (78% N2 + 21% O2 + traces of Ar, CO2, H2, water vapour and others) and 
subsequently maintained in the scanner by 1.25% isoflurane in medical air, oxygen, or 
other gas mixtures, at 1 L/min., using a nose cone. The anaesthetised mice were placed 
in a purpose-built cradle and secured using adhesive tape and dental paste (CharmFlex 
Light LV, Dentkist Inc., South Korea) to minimise motion [111;121]. Warm air and 
water were used to maintain normothermia. Core temperature and respiratory rate were 
monitored using a rectal thermometer and respiratory bellows, respectively (SA 
Instruments Inc., NY, USA).   
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3.3.2. Imaging protocol  
All pre-clinical MRI data were acquired using a 9.4 T (400MHz, 1H) VNMRS 20 
cm horizontal-bore system (Agilent Technologies Inc., CA, USA) with a 39 mm 
transmit/receive birdcage coil (Rapid Biomedical, Germany). Fast spin-echo (FSE) 
images were initially acquired for anatomical reference. Dynamic gradient-echo multi-
slice (GEMS) images were subsequently acquired in order to map the temporal 
variation of the tumour relaxation rate, 𝑅2
∗. Two 60-minute spoiled GEMS scans were 
acquired for each subject. The first, a dynamic ‘resting state’ scan, was used to evaluate 
𝑅2
∗ spontaneous fluctuations at rest, i.e., with no additional external influences. The 
second, a ‘gas challenge’ scan, included 6 interleaved gas challenges: air, carbogen 
(95% O2 + 5% CO2), air, 100% O2, air, air + 5% CO2. Each gas challenge lasted 10 
minutes. Carbogen and 100% O2 challenges were aimed at studying the regional effect 
of hyperoxia on 𝑅2
∗. Hypercapnia (air +5% CO2) was used to map in-flow effects on 
signal intensity images. Imaging parameters for the FSE acquisition were: TR = 1500 
ms, effective TE = 32.9 ms, echo spacing = 8.2 ms, echo train length = 4, in-plane field 
of view 40×40 mm2, matrix size 128×128, slice thickness 1 mm, 20 slices, flip angle = 
90°. GEMS sequence parameters were: TR = 59.62 ms, 5 echoes, TE1 = 2 ms, echo 
spacing = 2 ms, in-plane field of view 20×20 mm2, matrix size 64×64, slice thickness 
1.5 mm, 5 slices, flip angle = 20°, 3.8 s/image. 
 
3.4. MRI data analysis 
Post-processing of the acquired MRI data was carried out using routines written in 
Matlab (v. 7.11, The MathWorks Inc., USA) and Interactive Data Language (IDL, v. 
8.0, Exelis Visual Information Solutions, USA). The majority of datasets presented 
time-varying susceptibility artifacts in the imaging slices positioned closer to the gut, as 
assessed by observation of dynamic signal intensity images at TE = 2 ms and TE = 6 
ms. Such imaging slices were excluded from analysis. Statistical analysis was carried 
out using GraphPad Prism (v. 6.01, GraphPad Software Inc., USA). P < 0.05 was 
considered to be significant, unless otherwise stated.  
 
50 
 
3.4.1. Relaxometry estimation and calculation of resting state and gas 
challenge maps 
Estimation of 𝑅2
∗ relaxation rate was performed on a voxel-by-voxel basis by least-
squares fitting of a single exponential decay to signal intensity curves as a function of 
echo time, as described by eq. 2.11. Tumour areas were selected by drawing regions of 
interest (ROIs) in each MRI slice. The amplitude of resting state (RS) spontaneous 
oscillations was assessed by creating voxel-wise standard deviation (SD) maps of 𝑅2
∗ 
time courses: 
 𝑅2 
∗ 𝑆𝐷 = (
1
𝑛 − 1
∑(𝑥𝑖 − ?̅?)
2
𝑛
𝑖=1
)
1
2⁄
    . Eq. 3.1 
The standard deviation calculation was considered to be an appropriate method to 
assess the resting state cycling events’ characteristics of interest in this thesis. 
Nevertheless, the effect of cycling hypoxia is effectively a frequency-specific 
characteristic, and an alternative method, named amplitude of low-frequency fluctuation 
(ALFF) [122] could have been employed instead to account for that. Also, noise is here 
considered to be characterised only by the image background, which constitutes a 
limitation if physiological noise is present, which could be best accounted for with 
fractional ALFF (fALFF) [123]. 
Gas challenge time courses were used to create voxel-wise maps of vessel 
functionality with carbogen (𝑉𝐹) [41] and with 100% O2 (𝑉𝑂) as well as of vessel 
maturation (𝑉𝐷) [41]. 𝑉𝐹 and 𝑉𝑂 maps were created from the difference between the 
mean 𝑅2
∗ values during carbogen or 100% O2 breathing and air breathing. 𝑉𝐷 maps 
were created from the difference between the mean signal intensity (SI) values during 
hypercapnia and air breathing:  
 
𝑉𝐹 = ∆𝑅2 𝐶𝑎𝑟𝑏
∗ = 𝑅2
∗(𝑐𝑎𝑟𝑏𝑜𝑔𝑒𝑛)̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅ − 𝑅2
∗(𝑎𝑖𝑟)̅̅ ̅̅ ̅̅ ̅̅ ̅̅     
𝑉𝑂 = ∆𝑅2 𝑂2
∗ = 𝑅2
∗(𝑂2)̅̅ ̅̅ ̅̅ ̅̅ ̅ − 𝑅2
∗(𝑎𝑖𝑟)̅̅ ̅̅ ̅̅ ̅̅ ̅̅    
𝑉𝐷 = ∆𝑆𝐼𝐶𝑂2 = 𝑆𝐼(𝑎𝑖𝑟 + 5% 𝐶𝑂2)
̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅ − 𝑆𝐼(𝑎𝑖𝑟)̅̅ ̅̅ ̅̅ ̅̅ ̅̅     . 
Eq. 3.2 
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The times at which 𝑅2
∗ or SI exhibited an increase or decrease as the result of changing 
the breathing gas were assessed individually for each tumour by observing the 
respective time courses. The transition phase observed after the gas change and until 
reaching a new plateau (see Figs. 4.7A and 4.10A – Chapter 4) was not included in the 
calculations of eq. 3.2. 
  
3.4.2. Noise estimation in resting state maps 
Estimates of 𝑅2
∗ will always have an associated uncertainty due to the influence of 
measurement noise [124]. The approach implemented here to account for uncertainty in 
𝑅2
∗ due to background noise was adapted from the work of Walker-Samuel et al. [124]. 
A Bayesian maximum a posteriori (MAP) approach was used, considering Rice-
distributed data, allowing a robust voxel-wise determination of the uncertainty in 𝑅2
∗ in 
all time points. In these conditions, the cost function to be maximised is the log-
likelihood, 𝑙𝑅, which reflects the probability distribution for the Rice-distributed MRI 
data : 
 𝑙𝑅(𝜃; 𝑃) = ∑ (ln 𝑃𝑖 − 2 ln 𝜎𝑅 −
𝑃𝑖
2 + 𝑆𝑖
2
2𝜎𝑅
2 + ln 𝐼0 (
𝑃𝑖𝑆𝑖
𝜎𝑅
2 ))
𝑛
𝑖=1
    , Eq. 3.3 
where θ are the parameters to be optimised (i.e., 𝑅2
∗ and 𝑆0 (signal intensity at echo-time 
= 0)), 𝑆 is the signal intensity in transverse relaxation, 𝑃 are the 𝑛 measured data points, 
𝜎𝑅
2 is the variance of the noise in the raw MR data and 𝐼0 is the zeroth-order modified 
Bessel function [124]. 
The (two-dimensional) joint posterior distribution for 𝑅2
∗ and 𝑆0 is directly 
proportional to the likelihood function: 𝑝(𝑆0, 𝑅2
∗|𝑃)  ∝ 𝐿(𝜃; 𝑃) = 𝑒𝑙(𝜃;𝑃). Estimation of 
the posterior distribution of 𝑅2
∗ is done through integration of the joint posterior 
distribution with respect to 𝑆0: 
 𝑝𝑅2∗ (𝑅2
∗|𝑃) = ∫ 𝑝(𝑆0, 𝑅2
∗|𝑃)𝑑𝑆0    . Eq. 3.4 
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The peak value and “spread” of 𝑅2
∗ are used as the point estimate and uncertainty [124]. 
A region of background noise, completely excluding tissue voxels, was selected to 
provide an estimate of 𝜎𝑅. To assess if 𝑅2
∗ spontaneous fluctuations were above the 
uncertainty associated to background noise, maps of standard deviation over the 
uncertainty were computed (SD/uncertainty). Voxels with a value of SD/uncertainty > 1 
were taken to reflect an uncertainty lower than amplitude of fluctuations and were thus 
selected for further analysis.  
 
3.4.3. Correction of gas challenge maps  
In order to identify significant effects in gas challenge maps, a voxel-wise statistical 
analysis should be performed. Calculating a statistic for each voxel results in a large 
volume, or family, of statistic values. A t-statistic is commonly employed, where each 
supra threshold voxel has an associated small probability of having survived by chance 
alone, i.e., when the null hypothesis is true. However, in a family of voxel statistics, 
these type I errors multiply, so that the number of surviving voxels when in fact there is 
no effect is larger than desired. This constitutes the multiple comparison problem [125]. 
  The Bonferroni correction could be used to circumvent this problem and set a new 
(higher) statistic threshold for the whole family of voxel statistics: the family-wise error 
rate (PFWE) [125]. Unfortunately, this method is often too conservative to be applied to 
MRI functional imaging data due to the inherent degree of spatial correlation between 
neighbouring voxels, which reduces the number of independent observations. 
Statistical parametric mapping (SPM), as implemented in the software package 
SPM8 (http://www.fil.ion.ucl.ac.uk/spm/), was used to address these issues. SPM uses 
random field theory (RFT) to find the height threshold which gives the required PFWE. 
RFT relies on the concept of the Euler characteristic (Ec) of an image, which can be 
thought as the number of clusters above a given statistic threshold [126]. At high 
thresholds, the expected Ec is considered to be a good approximation of the probability 
of observing one or more clusters at that threshold by chance alone, that is, E[Ec] ≈ 
PFWE [126]. In this thesis, the family-wise error rate was set to 0.05 (PFWE < 0.05), from 
which the associated t-values were used to threshold the gas challenge maps. A 
clustering threshold of 5 voxels was additionally employed for added robustness. The 
surviving voxels were then re-assigned their respective 𝑉𝐹, 𝑉𝑂 or 𝑉𝐷 values. 
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3.5. Histology and immunostaining 
3.5.1. Dye administration and sectioning  
After imaging, animals were allowed to recover (~ 20 min.) before an intraperitoneal 
injection (60 mg/kg) of the hypoxia marker pimonidazole (Hypoxyprobe, USA) was 
administered. Pimonidazole is an exogenous marker that acts by forming protein 
adducts in viable hypoxic cells. Twenty nine minutes after, animals received an 
intravenous injection (12.5 mg/kg) of the fluorescent perfusion marker Hoechst 33342 
(Cambridge Bioscience, UK), and were sacrificed 1 minute later. Immediately after, 
LS174T or SW1222 tumours were excised and snap frozen in isopentane (cooled with 
liquid nitrogen) and stored at -80 °C, prior to cryosectioning. Care was taken to preserve 
tumour orientation. Sections of tumour of 10 µm were cut in the same plane as the MRI 
image acquisition. 
 
3.5.2. Immunostaining 
Fluorescence distributions of vascular perfusion, vascular endothelial cells, pericytes 
and hypoxic regions were obtained. Perfused areas were directly observed via emission 
of blue fluorescence from Hoechst 33342. Endothelial cells were stained with a rat 
monoclonal antibody against CD31 (Abcam, UK), revealed with Alexa Fluor-488 (Life 
Technologies, UK). Pericytes were detected by α-smooth muscle actin (α-SMA) 
staining with a mouse monoclonal anti-α-SMA (Sigma-Aldrich, UK), revealed with 
Alexa Fluor-546 (Life Technologies, UK). Staining of hypoxic regions involved the 
detection of the in vivo administered pimonidazole with a rabbit polyclonal anti-
pimonidazole (Hypoxyprobe, USA), in turn revealed with Alexa Fluor-488 (Life 
Technologies, UK). Additionally, haematoxylin and eosin (H&E) staining was 
performed in immediately adjacent frozen sections to assess tumour morphology. 
Fluorescence images were taken on an Axio Imager microscope (Carl Zeiss, UK), 
using an AxioCam digital colour camera. Images of H&E were collected on a bright-
field Zeiss Axioskop2 microscope (Carl Zeiss, UK). Both microscopes were fitted with 
a motorized stage and used AxioVision software (v. 4.8, Carl Zeiss, UK).  
Quantification of immunofluorescence was performed in Matlab software (v. 7.11, 
The MathWorks, Inc., USA). ROIs were drawn around the total area of the tumour and 
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images were thresholded to exclude background fluorescence signal. Tumour coverage 
of each of the fluorescent markers was calculated as the ratio between fluorescent pixels 
and the total number of pixels within the ROI. Additionally, the percentage of 
capillaries covered with pericytes was calculated as the ratio between co-localised α-
SMA and CD31 fluorescent pixels and the total number of CD31 fluorescent pixels to 
assess vascular maturation. 
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4. Characterisation of spontaneous temporal fluctuations in 
tumour 𝑹𝟐
∗  and relationship with gas challenge 
responsiveness  
The first study in this thesis investigates the spontaneous oscillatory characteristics of 
blood oxygenation estimates in SW1222 and LS174T tumours. This chapter first 
describes a longitudinal study on the dynamics of tumour 𝑅2
∗ fluctuations at rest, 
complemented by its relationship with vascular properties inferred from applied gas 
challenges. Histological assessment of both tumour lines then follows. Finally, the 
evolution of systemic blood oxygenation, pH, metabolites and dissolved gases as a 
function of the steps in the experimental protocol is assessed. 
 
4.1. Introduction  
The realisation of the potential to reverse the deleterious effects of tumour cycling 
hypoxia necessarily needs the prior understanding of the hypoxia-related dynamic 
processes occurring in the tumour microenvironment, which can only be achieved 
through dedicated research. Cycling hypoxia was described several decades ago 
[24;36;37], although the pathological sources that result in its manifestation still lack 
effective treatment strategies. 
The protocol of the study described in this chapter was adapted from previous studies 
[34;41]. However, here it was performed longitudinally and in the SW1222 and LS174T 
colorectal tumour lines for the first time. Briefly, gradient-echo MRI sequences have 
been used to estimate variations in blood oxygenation and flow due to the endogenous 
magnetic properties of haemoglobin and in-flow effects. Additionally, gas mixtures 
with elevated concentrations of oxygen and/or carbon dioxide (relative to medical air) 
were used to infer information about tumour vascular functionality and maturation. 
Please see section 2.2 for a more in depth review. 
The initial aim of this study was to investigate the feasibility of using a dynamic GE-
MRI sequence to map spontaneous fluctuations in blood oxygenation in SW1222 and 
LS174T tumours. Comparison of tumour and muscle frequencies of 𝑅2
∗ oscillation was 
attempted in order to infer about systemic influences in the tumour. Longitudinal scans 
were aimed at assessing the evolution of spontaneous fluctuations (dynamics and 
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distribution) and gas challenge responsiveness with the growing tumour. Moreover, this 
study aimed to assess if tumour 𝑅2
∗ spontaneous fluctuations were related to vascular 
properties, assessed with vasoactive gas challenges, and to histological markers of 
structure and vascular function and maturation. Finally, the relationship between 
breathing of air, or other gas mixtures, and variations in systemic blood oxygen 
saturation, pH, metabolites and dissolved gases was investigated. 
This study was conducted in an exploratory fashion, with basis on the aims described 
above, and where interpretation of the results was predominantly derived from their 
observation, rather than confirming or rejecting a set of pre-defined hypotheses. 
 
4.2. Materials and methods 
4.2.1. Cell culture and imaging protocol 
Cells of SW1222 or LS174T tumour lines were grown and injected as described in 
section 3.2. The relatively rapid growth rate of these tumours (doubling time is 3 to 4 
days), combined with the fact that this was a longitudinal study (8 days length), led MR 
imaging to be initiated at 10 days post injection, instead of the usual 2 weeks in this 
thesis, to prevent overly large tumours at the end of the study. Each SW1222 (n = 8) or 
LS174T (n = 8) tumour bearing mouse underwent a 60-minute resting state scan 
followed by a 60-minute gas challenge scan, as described in section 3.3. One mouse 
bearing a SW1222 tumour died in the scanner at day 4 but this animal’s previous 
datasets were considered for analysis. 
 
4.2.2. Analysis of resting state maps 
4.2.2.1. Percentage and amplitude of resting state fluctuations   
Resting state maps were calculated and thresholded following the procedures 
detailed in section 3.4. For each tumour, quantification of resting state maps was 
performed for both the percentage of voxels exhibiting 𝑅2
∗ fluctuations with amplitudes 
above the uncertainty associated to background noise (standard deviation/uncertainty > 
1) and the mean standard deviation (SD) of 𝑅2
∗ fluctuations corresponding to those voxel 
locations. A two-way ANOVA followed by Holm-Šídák’s multiple comparisons test 
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was used to assess significance between days of study in the same tumour line and 
between tumour lines in the same day of the longitudinal study [127]. 
 
4.2.2.2. Frequency analysis   
Frequencies of 𝑅2
∗ oscillation of supra-threshold voxels (SD/uncertainty > 1) were 
assessed with the Lomb method (also known as Lomb-Scargle, Gauss-Vaníček or 
Least-Squares spectrum) [128;129]. The Lomb method computes the Lomb normalised 
periodogram (spectral power as a function of angular frequency) of a dataset, ℎ, 
containing 𝑁 data points sampled at times 𝑡𝑗 using the relation 
 
𝑃𝑁(𝜔) =
1
2𝜎2
(
[∑ (ℎ𝑗 − ℎ̅𝑗 ) cos 𝜔(𝑡𝑗 − 𝜏)]
2
∑ cos2 𝜔 (𝑡𝑗 − 𝜏)𝑗
+
[∑ (ℎ𝑗 − ℎ̅) sin 𝜔(𝑡𝑗 − 𝜏)𝑗 ]
2
∑ sin2 𝜔(𝑗 𝑡𝑗 − 𝜏)
)    , 
Eq. 4.1 
where 𝜔 is the angular frequency, 𝜎2 and ℎ̅ are the variance and mean of the data, 
respectively, and 𝜏 is an offset constant that allows eq. 4.1 to be invariant to time 
translation and is defined by [128;129]: 
 tan 2𝜔𝜏 =
∑ sin 2𝜔𝑡𝑗𝑗
∑ cos 2𝜔𝑡𝑗𝑗
    . Eq. 4.2 
One of the advantages of the Lomb method over other methods of frequency analysis 
(e.g. fast Fourier transform (FFT)) is the possibility to easily calculate the statistical 
significance associated with the power of each frequency. In this context, the null 
hypothesis is that the data values are independent Gaussian random values. A useful 
result for the statistical analysis is that the probability distribution of the power at a 
given frequency is exponentially distributed [129]. Considering 𝑍 = 𝑃𝑁(𝜔), if 𝑀 
independent frequencies are considered, the probability of obtaining a significant 
frequency peak, given the null hypothesis is [128;129]: 
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 𝑃(𝑍 > 𝑧) = 1 − (1 − 𝑒−𝑧)𝑀    . Eq. 4.3 
The Lomb method has another important advantage relative to FFT methods. If 𝑇 is 
the span of the input data (𝑇 = max(𝑡𝑗) − min(𝑡𝑗)), the sampling frequencies in an 
FFT are integer multiples of 1 𝑇⁄ . The Lomb method, however, has the ability to (over-) 
sample more finely than at 1 𝑇⁄  in order to more accurately identify any frequency peak. 
This oversampling parameter is typically ≥ 4, and was set to 4 in this study, which 
means the number of frequency points obtained were 4 times the amount that would 
have been obtained with an FFT method, in the same range of frequencies. 
For each tumour, the Lomb method was applied to individual voxel 𝑅2
∗ time courses 
and the resulting spectra were combined into a single average frequency spectrum. The 
spectral mean and standard deviation of the cohort of SW1222 or LS174T tumours was 
then computed, independently for each day of study. 
To compare tumour and muscle frequencies of 𝑅2
∗ oscillation, a second cohort of 
SW1222 (n = 5) or LS174T (n = 3) tumours were used. MR imaging was performed in 
an orientation encompassing the tumour and the hind leg muscle of the mouse. Imaging 
and map thresholding were performed as before.   
In order to attempt to further resolve frequency peaks, a third group of mice were 
injected with SW1222 (n = 5) or LS174T (n = 6) tumour cells and imaged at rest 
(resting state) for 3 hours. With the exception of the length of scan, the imaging 
parameters were kept constant and the post processing analysis was performed as 
before.  
 
4.2.3. Analysis of gas challenge maps 
Gas challenge maps were calculated and thresholded as detailed in section 3.4. For 
each tumour, quantification of 𝑉𝐹, 𝑉𝑂 and 𝑉𝐷 maps was performed for both the 
percentage of voxels exhibiting a significant ∆𝑅2
∗ or ∆𝑆𝐼 (positive or negative) and the 
corresponding mean magnitude values of those voxel locations (absolute values of ∆𝑅2
∗ 
or ∆𝑆𝐼 were used to directly compare positive and negative magnitudes). Three different 
types of group-wise statistical assessments were performed in each of these two 
quantities:  
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- Between positive and negative ∆𝑅2
∗ or ∆𝑆𝐼 (e.g. SW1222 −∆𝑅2
∗ day 0 vs. SW1222 
+∆𝑅2
∗ day 0), to infer the functionality or maturation state of the perfused vasculature 
in that tumour type; 
 
- Between different tumour types (e.g. SW1222 −∆𝑅2
∗ day 0 vs. LS174T −∆𝑅2
∗ day 0), 
in which the primary goal was to identify differences in functional or mature 
vasculature between tumour types, assessed by considering −∆𝑅2
∗ or +∆𝑆𝐼 
responses. Additionally, it aimed to study the relative occurrence of +∆𝑅2
∗ or −∆𝑆𝐼  
responses in each tumour type; 
 
- Between 2 different days of the longitudinal study, consecutive or not (e.g. SW1222 
−∆𝑅2
∗ day 0 vs. SW1222 −∆𝑅2
∗ day 2), aiming to assess the evolution of the response 
(positive or negative) with the growing tumour. 
Differences between groups were assessed with a two-way ANOVA followed by 
Holm-Šídák’s multiple comparisons test. Maps without supra-threshold voxels were 
defined as having 0% responsive voxels and were considered for analysis of percentage 
responsiveness. Consequently, in such cases, the ∆𝑅2
∗ or ∆𝑆𝐼 response was inexistent, 
and was therefore not considered for analysis of magnitude response. 
     
4.2.4. Relationship between resting state and gas challenge maps 
Resting state 𝑅2
∗ standard deviation maps were correlated with 𝑉𝐹, 𝑉𝑂 and 𝑉𝐷 gas 
challenge maps, on a voxel-by-voxel basis, in order to investigate the relationship 
between resting state fluctuations and vascular properties in SW1222 and LS174T 
tumours. The values of individual voxels surviving the thresholds in both maps were 
plotted against each other. One plot was created for each tumour line, each gas 
challenge and each day of the longitudinal study. In each plot, voxels of all respective 
tumours were grouped. Pearson’s linear correlation was then used to assess the strength 
and significance of the relationships. 
 
4.2.5. Histological assessment 
To compare tumour spontaneous fluctuations with histological markers, a fourth 
cohort of SW1222 (n = 5) or LS174T (n = 5) tumours were imaged at rest. MR imaging 
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and post processing were performed as previously described. Upon MR imaging, 
histology was performed following the protocol detailed in section 3.5. Histology could 
not be performed on one LS174T tumour due to sample degradation following excision. 
 
4.2.6. Analysis of oxygenation and pH of systemic blood 
This part of the experimental protocol was performed in collaboration with Dr. 
Richard Ong (UCL Department of Neuroscience, Physiology and Pharmacology). 
Blood samples and pulse oximetry readings were taken to investigate the systemic 
effects of the MR imaging protocol on blood pH, blood metabolites, dissolved gases and 
blood oxygen saturation. MRI experimental conditions were reproduced outside of the 
scanner regarding anaesthesia and normothermia. The resting state and gas challenge 
protocols were also reproduced as described in section 3.3. Some gas challenge 
breathing phases lasted a few minutes longer than the proposed 10 minutes due to small 
delays in changing the gas mixtures. CD1 mice (n = 6, 7 weeks age, 23-27 g) were used 
instead of CD1 nude mice. Both mouse strains were assumed to exhibit comparable 
physiological responses to the applied changes. The right common carotid artery was 
cannulated for arterial blood sampling and arterial blood pressure monitoring. Blood 
samples were taken at the end of the resting state period and during the course of the gas 
challenge period to measure pH, metabolites, dissolved gases and oxygen saturation. 
Simultaneously, arterial haemoglobin saturation was continuously measured using a 
MouseOx pulse oximeter sensor (Starr Life Sciences Corp., USA) clamped to the right 
thigh of the animal.   
 
4.3. Results 
4.3.1. Spontaneous fluctuations at rest  
Figure 4.1 shows, in an example LS174T tumour slice, resting state 𝑅2
∗ time courses 
at all voxel locations (Fig. 4.1A) and the corresponding, noise thresholded, standard 
deviation (SD) map (Fig. 4.1B). Resting state SD maps reflect the degree of 𝑅2
∗ 
amplitude of variations with time at each voxel location. Clear temporal variations in 𝑅2
∗ 
can be observed, which are heterogeneously distributed within the tumour. 
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Throughout the longitudinal study, the percentage of voxels spontaneously 
fluctuating above the noise uncertainty did not significantly change in either tumour line 
(Fig. 4.2). Between tumour lines, a significant difference was observed at day 4, with 
LS174T tumours revealing higher percentages of spontaneous fluctuations.   
 
 
 
 
 
Figure 4.1 – Dynamic 𝑹𝟐
∗  estimates, at rest, in an example LS174T tumour 
xenograft. A: 60-minute 𝑅2
∗ voxel time courses. B: Corresponding standard deviation 
(SD) map of the 𝑅2
∗ time courses, thresholded to the voxel locations exhibiting 
fluctuations with amplitudes above the uncertainty associated to background noise. SD 
values reflect the amplitude of 𝑅2
∗ fluctuations. 
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Figure 4.2 – Evolution of the percentage of the tumour volume experiencing 𝑹𝟐
∗  
fluctuations with the tumour growth. Bars represent mean ± SD. A significant 
difference between tumour lines was identified at day 4 (two-way ANOVA followed by 
Holm-Šídák’s multiple comparisons test). *, P < 0.05. 
 
Figure 4.3 illustrates the longitudinal evolution of 𝑆𝐷(𝑅2
∗) mean values. As opposed 
to figure 4.2, no significant differences between tumour lines were observed, although a 
decrease in the amplitude of 𝑅2
∗ fluctuations was detected between days 0 and 8 in 
LS174T tumours. Together, these observations suggest that the percentage of the 
tumour experiencing spontaneous fluctuations is not coupled with the amplitude of such 
fluctuations. Additionally, spontaneous fluctuations in SW1222 tumours appear not to 
depend on the size/stage of the tumour, whereas in LS174T tumours the amplitude of 
fluctuations was observed to evolve with time. 
Figure 4.4 shows the result of a simulation performed to compare the performance of 
two different methods of frequency analysis: the Lomb method and fast Fourier 
transform (FFT). A signal composed of six sinusoids at different frequencies and with 
different amplitudes of oscillation was generated (see Figure 4.4), to which normally 
distributed random noise was added (noise amplitude = 2 a.u.). With the exception of 
the lowest frequency (2×10-4 Hz), the Lomb method accurately identified all frequency 
peaks, all being significant (P < 0.01). 
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Figure 4.3 – Evolution of the mean standard deviation (SD) of 𝑹𝟐
∗  fluctuations with 
the tumour growth. Bars represent mean ± SD. A significant difference was found 
between days 0 and 8 in LS174T tumours (two-way ANOVA followed by Holm-
Šídák’s multiple comparisons test). *, P < 0.05.  
 
Conversely, the FFT algorithm was considerably less accurate in its estimations, and 
failed to identify some peaks. The Lomb method also performed better in preserving the 
inter-peak ratio, meaning it better reflects the true relative amplitudes of the individual 
sinusoids. Given its superior performance, the Lomb method was chosen to analyse the 
frequencies of spontaneous 𝑅2
∗ oscillations. 
 
 
Figure 4.4 - Comparison between FFT (magenta) and the Lomb method (blue) in 
identifying the oscillatory frequencies of a generated signal. Grey vertical dashed 
lines represent the generated frequencies. The Lomb method performed better in 
identifying the frequency peaks of oscillation relative to FFT.      
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Figure 4.5 illustrates the dominant (peak) frequencies of 𝑅2
∗ oscillation for all study 
days and for both tumour lines. Although some variations in the frequency power were 
observed longitudinally and between tumour types, the dominant frequencies were 
usually contained in similar [flow – fhigh] low-frequency bands. Frequency peaks were 
found between flow = 2.1×10
-4 Hz (≈ 0.76 cycles/hour) and fhigh = 1.8×10-3 Hz to  
2.3×10-3 Hz (= 6.48 to 8.28 cycles/hour) throughout the study days and between tumour 
types. However, on two occasions, fhigh was higher: at day 4 in LS174T tumours (fhigh = 
3.5×10-3 Hz = 12.6 cycles/hour) and at day 8 in SW1222 tumours (fhigh = 2.7×10
-3 Hz = 
9.72 cycles/hour). These results suggest that, in LS174T tumours, the range of dominant 
frequencies of oscillation is not related to the tumour stage, at least in the time scale 
studied here. In SW1222 tumours, the same is true until day 6, although at a later stage 
(day 8) higher frequency peaks were observed.  
Comparison between frequencies of 𝑅2
∗ oscillation between tumour and muscle was 
equally attempted. Unfortunately, the percentage of muscle voxels exhibiting 𝑅2
∗ 
dynamic variations above the noise uncertainty was too low for a comparison to be 
possible (mean percentage = 0.5%). This is indicative of the low amplitude fluctuations 
in muscle tissue. 
Figure 4.6 shows the frequency spectra for the 3 hour-long resting state scans. 
SW1222 tumours revealed dominant frequencies between 7×10-5 Hz and 1.9×10-3 Hz  
(≈ 0.25 to 6.84 cycles/hour). LS174T tumour frequency peaks ranged from 7×10-5 Hz to  
1.8×10-3 Hz (≈ 0.25 to 6.48 cycles/hour). Scanning for longer periods revealed slower 
oscillating patterns in both tumour types (≈ 0.25 cycles/hour), whereas the higher 
frequency peaks are in the range previously observed in figure 4.5.  
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Figure 4.5 – Frequencies of 𝑹𝟐
∗  oscillation at rest for SW1222 and LS174T 
tumours. Mean (black line) and standard deviation (shaded area) of power spectra are 
shown. Dominant frequencies were usually between flow = 2.1×10
-4 Hz and fhigh = 1.8 to 
2.3×10-3 Hz, although at day 4 (LS174T) and day 8 (SW1222) fhigh was 3.5×10
-3 Hz and 
2.7×10-3 Hz, respectively.  
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Figure 4.6 – Frequencies of 𝑹𝟐
∗  oscillation at rest for SW1222 (n=5) and LS174T 
(n=6) tumours during 3-hour long acquisitions. Mean (black line) and standard 
deviation (shaded area) of power spectra are shown. Inset graphs show magnifications 
of the shaded rectangles. SW1222 tumour dominant frequencies were observed in the 
low-frequency band of 7×10-5 Hz to 1.9×10-3 Hz. In LS174T tumours, dominant 
frequencies were registered between 7×10-5 Hz and 1.8×10-3 Hz. 
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4.3.2. Response to hyperoxia challenges 
A typical gas challenge voxel time course is shown in figure 4.7A. Hyperoxia 
(breathing of carbogen or 100% O2) has the effect of decreasing the relative 
concentration of paramagnetic deoxyhaemoglobin in the blood of perfused vessels, 
therefore reducing the relaxation rate 𝑅2
∗.  This negative ∆𝑅2
∗ (−∆𝑅2
∗) response is the 
expected effect of switching from air to carbogen or oxygen, which is shown in blue in 
figure 4.7B. However, positive responses (+∆𝑅2
∗) can also occur due to not yet fully 
understood reasons (Fig. 4.7B, red/orange voxels), and a number of possible 
mechanisms will be debated in Discussion section 4.4.2.  
 
Figure 4.7 – Hyperoxia gas challenge in an example LS174T tumour. A: Single 
voxel 𝑅2
∗ time course depicting the variation in 𝑅2
∗ as a response to the breathing gas. 𝑅2
∗ 
estimates were not used for hypercapnia assessment. B: Gas challenge spatial maps of 
vessel functionality with carbogen (𝑉𝐹) or 100% O2 (𝑉𝑂) in a single slice, calculated 
from the difference in 𝑅2
∗ between the hyper-oxygenated gas and air. Maps were 
thresholded to PFWE < 0.05. Voxels surviving the threshold are coloured. 
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As for the resting state analysis, the percentage of tumour responsive voxels (−∆𝑅2
∗ 
or +∆𝑅2
∗) was assessed for gas challenge data. Figure 4.8A shows the results for 
carbogen breathing. Negative ∆𝑅2
∗ responses were more common than positive ∆𝑅2
∗ 
responses in SW1222 tumours in days 4, 6 and 8. In LS174T tumours, no differences 
between negative and positive ∆𝑅2
∗ prevalence were found. Between tumour types, 
−∆𝑅2
∗ responses were predominant in SW1222 tumours on days 4 and 8. SW1222 
tumours also showed an increase in the occurrence of −∆𝑅2
∗ responses between early 
time points (days 0 and 2) and a late time point (day 8). Figure 4.8B shows the results 
for 100% O2 breathing. Here, −∆𝑅2
∗ responses were more common within SW1222 
tumours at day 8. No further significant differences were observed.  
Figure 4.9 shows the mean magnitude of ∆𝑅2
∗ responses to hyperoxia. Carbogen 
breathing caused stronger −∆𝑅2
∗ responses relative to +∆𝑅2
∗ responses in SW1222 
tumours at day 8. No differences were observed between tumour types or study days 
(Fig. 4.9A). Conversely, the 100% O2 challenge revealed a reduction in the magnitude 
of +∆𝑅2
∗ responses between day 2 and later time points (days 6 and 8) in SW1222 
tumours (Fig. 4.9B). 
Overall, results show −∆𝑅2
∗ responses to hyperoxia to be more common and stronger 
than +∆𝑅2
∗ responses, but only in SW1222 tumours. Negative ∆𝑅2
∗ responses were also 
more prevalent in SW1222 tumours relative to LS174T tumours. The longitudinal 
assessment revealed the tumour development to favour the occurrence of −∆𝑅2
∗ 
responses and to decrease the strength of +∆𝑅2
∗ responses in SW1222 tumours.  
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Figure 4.8 – Evolution of the percentage of the tumour volume responsive to 
carbogen (A) and 100% oxygen (B) gas challenges with the tumour growth. Boxes 
define the interquartile range, whiskers the 10th and 90th percentile, and central lines the 
median. Panel A shows three different types of statistical significance: between −∆𝑅2
∗ 
and +∆𝑅2
∗ responses within SW1222 tumours at days 4, 6 and 8; between tumour types 
regarding the −∆𝑅2
∗ response at days 4 and 8; between days of study regarding the 
−∆𝑅2
∗ response within SW1222 tumours (day 0 vs. day 8 and day 2 vs. day 8). Panel B 
shows a significant difference between −∆𝑅2
∗ and +∆𝑅2
∗ responses within SW1222 
tumours at day 8. Significance was tested with a two-way ANOVA followed by Holm-
Šídák’s multiple comparisons test. *, P < 0.05. **, P < 0.01. ***, P < 0.001. ****, P < 
0.0001. 
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Figure 4.9 - Evolution of the magnitude of tumour response (|∆𝑹𝟐
∗ |) to carbogen (A) 
and 100% oxygen (B) gas challenges with the tumour growth. A significant 
difference between −∆𝑅2
∗ and +∆𝑅2
∗ responses to carbogen was observed within 
SW1222 tumours at day 8 (panel A). Between days of study, significant differences 
were observed in the +∆𝑅2
∗ response to 100% oxygen within SW1222 tumours (panel 
B, day 2 vs. day 6 and day 2 vs. day 8). Significance was tested with a two-way 
ANOVA followed by Holm-Šídák’s multiple comparisons test. *, P < 0.05. 
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4.3.3. Response to hypercapnia challenge  
Figure 4.10A shows a single voxel time course depicting increased signal intensity 
(SI) upon changing from breathing air to air + 5% CO2 (hypercapnia) due to in-flow 
effects. Figure 4.10B shows the corresponding spatial map exhibiting clusters with a 
similar response. This +∆𝑆𝐼 response is the expected effect of a hypercapnia challenge 
in mature vessels. However, and similarly to hyperoxia, responses with opposite-to-
expected signal change also occur (−∆𝑆𝐼), which may be due, at least in part, to similar 
mechanisms (see Discussion section 4.4.2).    
 
Figure 4.10 – Hypercapnia gas challenge in an example LS174T tumour. A: Single 
voxel SI time course depicting the variation in SI (or not) as a response to the breathing 
gas. SI measurements were used exclusively to assess hypercapnia response. B: Gas 
challenge spatial map of vessel maturation (𝑉𝐷) in a single slice, calculated from the 
difference in SI between hypercapnia and air. Coloured voxels survived PFWE < 0.05. 
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Figure 4.11 shows the percentage of tumour responsive voxels to hypercapnia. 
SW1222 tumours showed, in day 4, higher percentages of +∆𝑆𝐼 responses relative to 
−∆𝑆𝐼 responses and to LS174T tumours. No longitudinal differences were observed. 
Additionally, figure 4.12 did not reveal significant effects of any kind in the mean 
magnitude of ∆𝑆𝐼 responses. 
 
Figure 4.11 – Evolution of the percentage of the tumour volume responsive to the 
hypercapnia challenge with the tumour growth. At day 4, SW1222 tumours revealed 
a significant difference between positive and negative responses. Also at day 4, the 
percentage of voxels with positive response was significantly different between tumour 
types (two-way ANOVA followed by Holm-Šídák’s multiple comparisons test).  
*, P < 0.05; **, P < 0.01. 
 
Figure 4.12 - Evolution of the magnitude of tumour response (|ΔSI|) to the 
hypercapnia challenge with the tumour growth. No significant differences were 
observed between days of study, tumour type or response signal within the same tumour 
type (two-way ANOVA followed by Holm-Šídák’s multiple comparisons test). 
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4.3.4. Relationship between spontaneous fluctuations and gas challenge 
responsiveness 
Correlation between resting state 𝑅2
∗ SD and carbogen ∆𝑅2
∗ magnitude responses is 
exemplified in figure 4.13 for SW1222 and LS174T tumours at day 0. Table 4.1 extends 
the same analysis to all study days. Generally, correlations were significant although 
with weak correlation coefficients. A similar result was observed for the correlations 
between resting state 𝑅2
∗ SD and 100% oxygen ∆𝑅2
∗ (table 4.2). This suggests a weak 
association between spontaneous fluctuations and vessel functionality, although it might 
still be influenced by any remaining uncertainty not accounted for in the map 
thresholding process. 
Although still not very strong, more suggestive correlations were found in a few 
instances. In LS174T tumours, −∆𝑅2
∗ responses to carbogen breathing in day 0 and to 
100% O2 breathing in day 2 revealed stronger associations: r
2 = 0.53 and  
r2 = 0.44, respectively. Interestingly, +∆𝑅2
∗ responses to carbogen in day 2 (in LS174T 
tumours) and to 100% O2 in day 0 (in SW1222 tumours) also revealed higher 
correlation coefficients: r2 = 0.54 and r2 = 0.42, respectively. Additionally, the existence 
of longitudinal trends was investigated, i.e., from day 0 to day 8 within the same tumour 
line and response type (positive or negative). No longitudinal trends were observed in 
carbogen or 100% O2 breathing. 
 
 
Figure 4.13 – Voxel-wise correlation between resting state 𝑹𝟐
∗  standard deviation 
(SD) and carbogen ∆𝑹𝟐
∗ , at day 0, in SW1222 (left) and LS174T (right) tumours. 
Dots represent individual tumour voxels. ****, P < 0.0001 (Pearson’s linear 
correlation). 
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Table 4.1 – Pearson’s linear correlation (r2, P-value) between resting state 𝑹𝟐
∗  
standard deviation and carbogen ∆𝑹𝟐
∗  in SW1222 and LS174T tumours. Significant 
correlations are common, although generally with weak correlation coefficients.  
****, P < 0.0001.   
r2 
SW1222 LS174T 
−∆𝑹𝟐
∗  +∆𝑹𝟐
∗  −∆𝑹𝟐
∗  +∆𝑹𝟐
∗  
Day 0 
0.15 
 **** 
0.17 
**** 
0.53 
**** 
0.19 
**** 
Day 2 
0.16 
**** 
0.22 
**** 
0.28 
**** 
0.54 
**** 
Day 4 
0.35 
**** 
0.21 
**** 
0.32 
**** 
0.33 
**** 
Day 6 
0.29 
**** 
0.38 
**** 
0.22 
**** 
0.16 
**** 
Day 8 
0.24 
**** 
0.23 
**** 
0.36 
**** 
0.12 
**** 
 
 
Table 4.2 – Pearson’s linear correlation (r2, P-value) between resting state 𝑹𝟐
∗  
standard deviation and 100% O2 ∆𝑹𝟐
∗  in SW1222 and LS174T tumours. Mostly 
significant correlations were observed, although weak correlation coefficients are 
common. ns, P > 0.05 (non-significant). *, P < 0.05. **, P < 0.01. ****, P < 0.0001.   
r2 
SW1222 LS174T 
−∆𝑹𝟐
∗  +∆𝑹𝟐
∗  −∆𝑹𝟐
∗  +∆𝑹𝟐
∗  
Day 0 
0.11 
**** 
0.42 
**** 
0.15 
**** 
0.06 
**** 
Day 2 
0.25 
**** 
0.36 
**** 
0.44 
**** 
0.22 
**** 
Day 4 
0.36 
**** 
0.07 
**** 
0.16 
**** 
0.23 
**** 
Day 6 
0.17 
**** 
8×10-8 
ns 
0.37 
**** 
0.27 
**** 
Day 8 
0.19 
**** 
0.08 
* 
0.16 
**** 
0.21 
**** 
 
 
Table 4.3 shows the results of the correlation between resting state 𝑅2
∗ SD and 
hypercapnia ∆𝑆𝐼 magnitude responses. A great number of poor correlations were 
observed, with some even lacking statistical significance. Of all, only −𝛥𝑆𝐼 responses 
in SW1222 tumours at day 2 approached a noticeable degree of association with the SD 
of spontaneous fluctuations (r2 = 0.51). Longitudinal trends alongside the study days 
were also investigated, although no trends were observed. 
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Table 4.3 – Pearson’s linear correlation (r2, P-value) between resting state 𝑹𝟐
∗  
standard deviation and hypercapnia ∆𝑺𝑰 in SW1222 and LS174T tumours. 
Significant and non-significant correlations were observed, mostly with weak 
correlation coefficients. ns, P > 0.05 (non-significant). *, P < 0.05. **, P < 0.01.  
***, P < 0.001. ****, P < 0.0001.   
r2 
SW1222 LS174T 
−∆𝑺𝑰 +∆𝑺𝑰 −∆𝑺𝑰 +∆𝑺𝑰 
Day 0 
0.04 
* 
0.003 
ns 
6×10-4 
ns 
0.13 
**** 
Day 2 
0.51 
*** 
0.05 
** 
0.009 
ns 
0.05 
**** 
Day 4 
0.18 
**** 
0.009 
ns 
0.02 
ns 
0.19 
*** 
Day 6 
0.17 
**** 
0.002 
ns 
8×10-4 
ns 
0.03 
* 
Day 8 
0.06 
* 
0.11 
**** 
0.006 
ns 
0.007 
ns 
 
 
4.3.5. Histological markers and their relationship with spontaneous 
fluctuations 
Fluorescently labelled tumour sections revealed significant differences between 
tumour types, with SW1222 tumours showing a more extensive vascular network (from 
endothelial cell staining), which was better perfused and less hypoxic than in LS174T 
tumours (Figs. 4.14A, 4.15A and 4.15B). These observations are in agreement with 
previous studies by El-Emir et al. [117] and Pedley et al. [120]. Furthermore, visual 
inspection of H&E sections confirmed the different morphology of each tumour line, 
with SW1222 tumours showing better differentiation into glandular structures, which is 
in agreement with previous literature (Fig. 4.15C) [119]. The percentage of pericyte 
coverage in the tumours, alongside the degree of pericyte attachment to tumour blood 
vessels (% mature vessels), was not significantly different between tumour types (Fig. 
4.14A and B). 
In tumour sub-regions with high 𝑅2
∗ SD, tissues were well perfused and viable (non-
necrotic) in all SW1222 (n = 5) and LS174T (n = 4) tumours (examples in Fig. 4.15B, C 
and D). Mature and immature blood vessels were homogeneously distributed in both 
tumour types, suggesting spontaneous fluctuations in these tumours can occur 
regardless of the presence of pericyte coverage of the tumour vessels. 
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Figure 4.14 – Quantitative fluorescence histology in SW1222 (n = 5) and LS174T  
(n = 4) tumour xenografts. A: Percentage tumour coverage of endothelial cells, 
pericytes, perfusion and hypoxia. B: Percentage of blood vessels covered with 
pericytes. Bars represent mean ± SD. SW1222 tumours have significantly higher 
vascular density and are better perfused and less hypoxic than LS174T tumours (Mann-
Whitney U-test). No difference was found in the percentage of pericytes or in its 
coverage of blood vessels between both tumour types (Mann-Whitney U-test). *, P < 
0.05. 
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Figure 4.15 – Histology in example SW1222 and LS174T tumour xenografts and comparison with MRI data. A: Double staining with CD31 
(endothelial cells, green) and α-SMA (mature vessels, red). Insets show blood vessels covered with pericytes (yellow). B: Double staining with 
Hoechst 33342 (perfusion, blue) and pimonidazole (hypoxia, green). C: Morphology (H&E) showing moderate-to-well differentiated tissue into 
glandular structures in the SW1222 tumour and poorly differentiated tissue in the LS174T tumour. D: Corresponding resting state maps of 𝑅2
∗ SD. 
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4.3.6. Oxygenation and pH of systemic blood 
Alternate breathing of different gas mixtures can cause blood pH variations. This 
effect can further influence the oxygenation status of the blood due to the Bohr effect, 
which states that haemoglobin’s oxygen binding affinity is inversely related to acidity 
[130]. Therefore, blood pH can also affect 𝑅2
∗ estimations. Blood sampling allowed the 
measurement of pH, dissolved gases, oxygen saturation and some metabolites. 
Figure 4.16A shows the pH variation throughout the experimental protocol. At the 
end of the resting state period, pH values were within the reference range (7.350 – 
7.450). Carbogen (70 – 85 min., ΔpH = -0.11) and hypercapnia (130 – 140 min.,  
ΔpH = -0.16) caused pH decreases relative to the resting state pH, due to increased CO2 
content (5% in both, see figure 4.16B). This mechanism is shown in equations 4.4 and 
4.5, where the concentration of hydrogen ions ([H+]) depends on the concentration of 
dissolved CO2. Higher [H
+] causes pH decrease: 
 
𝐶𝑂2 + 𝐻2𝑂 ⇌ 𝐻2𝐶𝑂3 ⇌ 𝐻𝐶𝑂3
− + 𝐻+    , 
𝑝𝐻 = − log[𝐻+]    , 
Eq. 4.4 
Eq. 4.5 
where H2CO3 is carbonic acid and HCO3
- is the bicarbonate ion, which is alkalotic, and 
its concentration throughout the protocol is shown in figure 4.16C. Conversely, the 
second air breathing phase (85 – 100 min., ΔpH = +0.11) caused blood alkalosis, which 
was then inverted with 100% O2 breathing (100 – 115 min., ΔpH = +0.04). 
Figure 4.16D shows similar blood saturation (O2sat) levels between pulse oximetry 
and blood sampling, with a mean discrepancy of 1.1% between them. The trend of both 
measurements also follows the same pattern along the different time points, meaning the 
relative differences are maintained approximately constant. Hyperoxia challenges 
(carbogen and 100% O2) naturally caused the greatest O2sat values. Conversely, 
hypercapnia registered the lowest O2sat, probably due to the Bohr effect. 
 
 
 
79 
 
 
Figure 4.16 – Blood gas analysis and pulse oximetry. A: pH variation with the 
different breathing gas mixtures. B: CO2 partial pressure. C: Bicarbonate ion 
concentration. D: Comparison between blood sample and pulse oximetry readings 
regarding systemic oxygen blood saturation. Blood samples were taken at the end of the 
gas breathing periods, immediately before changing the breathing gas mixture. Solid 
lines connect the mean values at each time point.  
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4.4. Discussion 
4.4.1. Detection of spontaneous fluctuations at rest  
Spontaneous fluctuations in 𝑅2
∗ above noise uncertainty were observed in 60-minute 
dynamic MRI scans in SW1222 or LS174T colorectal tumour xenografts. The presence 
of fluctuations was confirmed by the identification of frequency peaks in power spectra. 
Fluctuating frequencies were usually found between flow = 0.76 cycles/hour and fhigh = 
6.48 to 8.28 cycles/hour between tumour types and study days. These oscillatory 
periods are in a similar interval to those observed by several groups in a range of mouse 
[34;82;87], rat [23;25;84], canine [93], human xenograft [91;92] and human [83] 
tumours. In two occasions, however, peaks of higher frequency were detected: 12.6 
cycles/hour in LS174T tumours at day 4, and 9.72 cycles/hour in SW1222 tumours at 
day 8. Frequencies of this periodicity are not uncommon [34;82;83;92], but represent a 
deviation from the observed range in these tumours and can possibly reflect an 
alteration of the microenvironmental processes governing tumour blood flow variations.   
Also at day 4, LS174T tumours presented a higher percentage of fluctuating voxels 
relative to SW1222 tumours. Additionally, the amplitude of fluctuations significantly 
decreased between days 0 and 8 in LS174T tumours. These differences were probably 
not due to the experimental setup or the quality of the data, which were identical 
throughout the study. Regarding the observation at day 4, it should be stressed that it 
occurred only between tumour types, and was not a longitudinal effect in either 
SW1222 or LS174T tumours. One possible explanation for the observation of such 
difference relies on the markedly different phenotype of these tumours, specifically their 
vascular properties, in which perfusion status may vary in different ways. Another 
reason might be due to the statistical test itself, where a small relative variation in the 
percentage of oscillating voxels between tumour types resulted in a significant result, 
even if there was not a longitudinal variation in each individual tumour line. 
Conversely, the variation between days 0 and 8 in LS174T tumours suggests that 
longitudinal effects can occur in these tumours. This result may be a confounder in 
interpreting variations in spontaneous fluctuations in the case of studies aimed at 
targeting the tumour vasculature, if the study length is 8 days or more.    
In addition to the 60-minute scans, three-hour long resting state scans were also 
undertaken to resolve low-frequency peaks in the frequency spectra. These longer 
scanning times enabled lower frequency oscillations of 0.25 cycles/hour (or higher) to 
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be detected. Fluctuating periods in this range have not yet been specifically reported in 
tumours, possibly because continuous acquisition protocols do not usually exceed 80 
minutes. This result is indicative of the potential of long scanning sessions in 
uncovering slower periodicities of oscillation, as an alternative to increased sampling 
frequency. 
Muscle 𝑅2
∗ dynamic variations did not generally present high enough amplitude to 
overcome the background noise uncertainty threshold, which is indicative of the 
comparatively larger amplitude fluctuations in tumours. Braun et al. [35] made a similar 
observation between tumour and muscle pO2 using recessed-tip oxygen 
microelectrodes. Muscle fluctuations were previously observed in 𝑇2
∗-weighted 
gradient-echo images [34], and so it is conceivable that 𝑅2
∗ variations might also be 
occurring, although not entirely detectable with the sequence implemented here. Low 
amplitude fluctuations in the muscle could suggest the influence of systemic variations 
in the tumour is minor, however, this is a rather simplistic approach, and more studies in 
this regard are needed before a conclusion can be made. 
Tumour regions of high resting state 𝑅2
∗ amplitude variation were located in 
vascularly perfused and viable areas in both tumour types, as assessed by CD31, 
Hoechst 33342 and H&E immunoreactivity. A similar observation was made by 
Baudelet et al. [34;41] in 𝑇2
∗-weighted images of fibrosarcomas. This result is as would 
be expected, given there will only be dynamic changes in blood flow, and consequently 
oxygenation, in blood vessels that are perfused, even if this perfusion occurs in a 
transient fashion, as it is characteristic of solid tumours.  
Following a qualitative assessment, some evidence was found for a longitudinal re-
distribution of local high amplitude 𝑅2
∗ oscillations, especially in SW1222 tumours, 
which represents an important observation in further characterising the evolution of the 
tumour microenvironment. Still, an accurate assessment of such evolution would have 
to include a computational registration step to insure the same tumour regions were 
being compared between different days.  
In SW1222 tumours, given the small percentage of hypoxic areas, the observed 𝑅2
∗ 
fluctuations might not correspond to cycling hypoxia, but possibly to an oscillation in 
the blood oxygenation which is regularly above 10 mmHg. In fact, spontaneous 
fluctuations in pO2 were previously observed to occur in syngeneic mouse liver tumours 
regardless of the basal oxygenation state [87]. If true, delivery of systemically applied 
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therapies would still be hindered due to the oscillatory behaviour, but radiotherapeutic 
treatments would potentially be more effective than in LS174T tumours.  
No clear spatial relationship was observed between the amplitude of spontaneous 
fluctuations and vessel maturation/immaturity. Pericyte coverage was not preferentially 
located in specific tumour sub-regions, suggesting it is not essential nor it impairs 
spontaneous fluctuations. Therefore, vasomotion of mature vessels could be partially 
responsible for generating dynamic changes in blood flow and oxygenation in these 
tumours. In fact, Baudelet et al. [41] reported that the majority of fluctuating tumour 
areas was immature, but that mature regions also presented high incidence of 
fluctuations. Previously, also Dewhirst et al. [23] found a relationship between 
vasomotion and flow oscillations in rat mammary tumours. Spontaneous fluctuations in 
blood flow and oxygenation in SW1222 and LS174T tumours are thus potentially 
induced by a combination of structural vascular abnormalities and muscularly-induced 
vascular contraction and dilation cycles. 
 
4.4.2. Tumour response to hyperoxia 
Vasoactive gas challenges have been used in numerous tumour studies because they 
enable inferences to be drawn about vascular properties [41;49;110;131-136] and about 
the possible outcome of antitumour treatment strategies [49;110;137-139]. One aim of 
this longitudinal hyperoxic challenge (carbogen or 100% oxygen) was to infer the 
evolution of tumour vascular function within the growing tumour, by assessing the 
strength and prevalence of 𝑅2
∗ decrease responses (−∆𝑅2
∗). Discrimination between 
tumour types was also sought, as well as between types of response (−∆𝑅2
∗ vs. +∆𝑅2
∗) 
to infer about the functionality state of the perfused vasculature. 
Negative −∆𝑅2
∗ responses to hyperoxia, the anticipated response type due to decrease 
of paramagnetic deoxyhaemoglobin concentration, were observed in SW1222 and 
LS174T tumours, indicating regions of functional vasculature. Conversely, other 
tumour areas presented 𝑅2
∗ step increase responses (+∆𝑅2
∗). Despite having been 
reported before [49;104;111;112;131;140-142], the mechanisms behind this 
contradictory response are not yet fully understood. In the case of carbogen breathing, 
which improves both blood flow and oxygenation, several mechanisms can be 
occurring. Two possible effects are vascular steal from the surrounding vasculature or 
83 
 
intratumoral vascular steal [49;104;108;111;112;131;140-142]. These effects consist of 
an increase in blood flow in the host vasculature or in a localised tumour region, 
respectively, due to CO2-induced vasodilation. This causes blood to be diverted from 
tumour regions that have no compensatory vasoactive mechanisms [104], leading to a 
decrease in oxygenation in those areas and consequent 𝑅2
∗ increase. In addition, a 
vasoactive challenge that improves blood flow is likely to be associated with a blood 
volume increase [108]. If this effect occurs in the feeding arterioles containing partially 
desaturated blood, the net effect could be of an increase in deoxyhaemoglobin 
concentration. Moreover, especially in hypoxic tumours, increased blood flow may not 
decrease the blood desaturation if the fraction of oxygen extraction increases. 
Consequently, even under improved oxygen delivery, it is the balance between changes 
in blood flow, blood volume and oxygen utilisation that will decide which way the 𝑅2
∗ 
shifts [108].  
Robinson et al. [104] suggested that 𝑇2
∗-weighted GE decreases upon carbogen 
breathing (reflecting a similar effect to 𝑅2
∗ increases) could also be due to a decrease in 
perfusion, resulting from the oxygen-induced vasoconstriction, should the CO2-induced 
vasodilation not be of sufficient magnitude to overcome the oxygen effect. If this is the 
case, it makes sense that vasoconstriction could also occur with 100% O2 breathing, 
where vascular dilation will not happen and the accumulation of deoxyhaemoglobin in 
the affected regions will be even greater.  
Growth of SW1222 tumours favoured an increase in −∆𝑅2
∗ percentage 
responsiveness to carbogen. This behaviour occurred potentially due to the well-known 
fact that tumours need to recruit blood vessels from the surrounding vasculature to 
promote growth [143]. Increased blood supply from such feeding vessels alongside 
tumour growth would be expected to gradually increase tumour susceptibility to 
systemic variations. Additionally, the magnitude of +∆𝑅2
∗ responses to 100% O2 
decreased with the study days. In this regard, and as previously mentioned in section 
2.2, the relationship between 𝑅2
∗ variation and tumour pO2 change was found not to be 
reproducible, and so a direct comparison between tumours requires caution [109], which 
represents a limitation of the current study. Nevertheless, this observation suggests 
tumour growth promoted gradually weaker steal effects, possibly through decreased 
vasoconstriction, although the reasons behind this effect merit further investigation.  
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Between tumour types, SW1222 tumours showed higher prevalence of −∆𝑅2
∗ 
response to carbogen at days 4 and 8. This effect was also anticipated due to the 
previously known vascular differences between SW1222 and LS174T tumours [117-
120] which were confirmed in the histological analysis performed here. SW1222 
tumours have higher vascular density and are better perfused, which leads to higher 
functional fractions. Under a carbogen challenge, SW1222 tumours could potentially 
respond better to radiation therapy, due to larger oxygenated tumour volume, as well as 
to systemically applied therapies (e.g. chemotherapy), due to better delivery, relative to 
LS174T tumours, although therapy response also depends on the sensitivity of the 
targeted cell line.  
Relative to the response type, −∆𝑅2
∗ responses were significantly more prevalent 
than +∆𝑅2
∗ responses to carbogen (days 4, 6 and 8) and 100% O2 (day 8) breathing in 
SW1222 tumours. This result suggests the majority of perfused vessels are experiencing 
increased oxygenation, being therefore functional. Negative ∆𝑅2
∗ responses were also 
stronger (higher magnitude) than positive ∆𝑅2
∗ responses to carbogen (day 8) in 
SW1222 tumours, which, although not quantitatively related to tumour pO2, is further 
informative about the state of functional vasculature in these tumours. 
The lack of any longitudinal effects or response type differences in LS174T tumours 
is probably the result of the relatively low vascular density and poor perfusion alongside 
large hypoxic areas in these tumours [112]. Such microenvironmental characteristics 
potentially impair the effect of the hyperoxic gas challenges, rendering it too small to be 
reliably detected. 
The observations from the longitudinal vasoactive hyperoxia gas challenges indicate 
that the size/stage of the tumour development influences its vascular response, so one 
must take that into account when performing studies of this nature. 
On a technical note, it is worth to acknowledge that some 𝑅2
∗ values in the time series 
of some voxels are possible to have been influenced by poor goodness of fit, arising 
mostly from the lower signal intensity at later echo times against the background noise 
and consequent greater measurement uncertainty. However, the majority of such 
inaccuracies are expected to have been filtered out by applying the MAP thresholding, 
in resting state maps, or the family-wise clustered SPM thresholding, in gas challenge 
maps. 
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4.4.3. Tumour response to hypercapnia 
The longitudinal hypercapnia challenge (air + 5% CO2) aimed to infer the evolution 
of tumour vessel maturation by assessing the strength and prevalence of signal intensity 
increase responses (+∆𝑆𝐼). Differences between response type (+∆𝑆𝐼 vs. −∆𝑆𝐼) were 
additionally studied to assess the maturation state of the perfused vasculature. 
Differences in mature vasculature between tumour types were also investigated.   
Longitudinal effects were not observed in SW1222 or LS174T tumours, suggesting 
no tumour growth-associated evolution of the mature vasculature. This result indicates 
the 100% O2-induced decrease in +∆𝑅2
∗ magnitude (discussed in section 4.4.2.) was 
probably not due to a decrease in vascular maturation. 
Between tumour types, +∆𝑆𝐼 responses were significantly more prevalent in 
SW1222 tumours at day 4. This result could indicate the vasculature of SW1222 
tumours was more mature than in LS174T tumours. However, the histological analysis 
of the percentage of mature vessels revealed similar values between tumour types. 
Consequently, this predominance of +∆𝑆𝐼 response in SW1222 tumours is probably 
due to their higher vascular density and perfusion. 
The percentage of +∆𝑆𝐼 responses was higher than their negative counterpart in 
SW1222 tumours at day 4, which suggests most perfused vessels are mature in his 
tumour type. LS174T tumours did not discriminate between response types, and so the 
percentage of mature perfused vessels is possibly similar to the percentage of immature 
perfused vessels.  
 
4.4.4. Spontaneous fluctuations versus gas challenge responsiveness 
The possibility that the amplitudes of 𝑅2
∗ spontaneous fluctuations and gas challenge-
responsive areas (hyperoxia and hypercapnia) were well correlated was not generally 
confirmed. Suggestive correlations only occurred in a few occasions at days 0 and 2, 
and even these were not especially strong.  
It must be true that spontaneous fluctuations, as well as gas challenge responses, can 
only occur in perfused blood vessels. Related to this is the good spatial agreement 
between the histological perfusion marker Hoechst 33342 and 𝑅2
∗ SD high amplitude 
variations. So why were the amplitudes of spontaneous fluctuations and gas challenge 
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responses not strongly correlated? First of all, the relationship between the amplitudes 
of both measurements is not necessarily the same as the relationship between their 
spatial distributions. Additionally, while a tumour region is fluctuating at a given 
moment, it might not be at a future time point [34]. This behaviour can cause an 
apparent reduction in the fluctuating amplitude, whereas the vasculature might still be 
well perfused and strongly responsive to the gas challenge. The opposite may also 
happen, where a high spontaneous 𝑅2
∗ amplitude variation occurred in a region weakly 
responsive to the gas challenge, due to a decrease in perfusion at the time of the gas 
challenge. Another potential confounder is the fact that well-perfused and highly oxic 
tumour areas would not show a significant 𝑅2
∗ change because haemoglobin is already 
largely saturated [49]. This could have occurred, particularly in SW1222 tumours, 
further impairing the correlations between resting state and hyperoxia amplitudes. 
Finally, a degree of uncertainty might still be present in each of the 𝑅2
∗ estimates, which 
can manifest as additional scatter in the voxel-wise correlation plots and reduce the 
correlation coefficient. 
In the hypercapnia challenge, one must additionally take into account the fact that 
around 50% of the vasculature was immature. This means perfused vessels can be either 
mature or immature, further diminishing the likelihood of a strong correlation.  
 
4.4.5. Influence of blood pH on 𝑹𝟐
∗  measurements  
Spontaneous fluctuations in tumour and muscle tissues were probably not influenced 
by the pH of blood, given that no deviations from the reference range were observed at 
60 minutes post-anaesthesia induction.  
During the gas challenge experiment, pH oscillations under and above the resting 
state pH were observed. Carbogen breathing caused a pH decrease due to increased 
carbon dioxide in the blood. This effect triggered a compensatory acid-base homeostasis 
mechanism, in which the concentration of metabolic HCO3
- ([HCO3
-]) alkalotic ion also 
increased.  
Upon changing to the second air breathing phase, CO2 tension in the blood decreased 
to its initial value. However, a further increase in [HCO3
-] was observed, causing the 
highest registered pH. It should be mentioned this effect was observed in one animal 
and, given the impossibility to repeat the experiment (due to faulty equipment and lack 
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of assistant personnel), it is unclear whether this is a reproducible phenomenon. 
Nevertheless, observation of 𝑅2
∗ time courses revealed similar 𝑅2
∗ values between 
baseline and upon the second air breathing phase, suggesting either the Bohr effect did 
not significantly affect 𝑅2
∗ estimates or the blood alkalosis at the second air breathing 
phase is uncommon. 
The 100% oxygen breathing phase caused a [HCO3
-] decrease due to the continued 
absence of perturbations to the CO2 tension. This caused pH values to return closer to 
the resting state pH. Finally, hypercapnia caused the lowest pH due to the combined 
effect of increased CO2 and low concentration of HCO3
-.        
Variations in pH between carbogen and air breathing were previously reported [108], 
and were suggested to be a possible confounder to 𝑅2
∗ response, although its effect is 
unclear [144]. In this study, if the Bohr effect had had an influence on the hyperoxia 
response, carbogen breathing would have been expected to show weaker responses 
and/or lower percentage responsiveness relative to 100% O2 breathing. It is not obvious 
that such difference occurred in either tumour type, although carbogen and 100% O2 
responses were not statistically compared. Still, this observation is further suggestive of 
the minimal influence of the Bohr effect on the tumour response. Perhaps the fact that 
carbogen improves blood flow, in addition to oxygenation, in functional and mature 
blood vessels, counteracted the pH effect [135]. 
 
4.5. Conclusions 
This study demonstrated the feasibility of using gradient-echo MR sequences to 
estimate the occurrence of spontaneous fluctuations in blood oxygenation in colorectal 
carcinomas. In particular, it showed that the percentage of the tumour experiencing 
spontaneous fluctuations is independent of the tumour size, and that the amplitude of 
such fluctuations may be influenced by the tumour stage, depending on the tumour type.  
The frequencies of oscillatory behaviour were additionally found to be influenced by the 
stage of tumour development. 
Vasoactive challenges revealed that the percentage of the tumour responsive to 
carbogen breathing increases with the tumour growth, which suggests systemic 
influences in tumours become increasingly more important. However, this occurs only 
88 
 
if the tumour is well perfused. Consequently, the better perfused tumours also have 
higher response prevalence.  
Comparison of magnitude variations between gas challenge responses and 
spontaneous fluctuations did not reveal strong correlations, indicating one cannot use 
vasoactive protocols to infer about the amplitudes of fluctuation. However, a good 
spatial agreement was found between high amplitude fluctuations and histological 
markers of viable tissue and vascular perfusion, confirming spontaneous fluctuations 
occur preferentially in perfused areas.  
Breathing of gas mixtures of high oxygen and/or carbon dioxide concentration was 
shown to affect systemic blood oxygen saturation and systemic blood pH. Still, the pH 
effect probably had minimal repercussions in the studied tumours given that both the 
prevalence and response amplitude were similar between different breathing gases. 
Conversely, continuous air breathing showed no pH drifts from the reference range, and 
so the occurrence of tumour spontaneous fluctuations was probably not influenced in 
this way.  
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5. Influence of systemic variations on cycling hypoxia 
patterns in tumours    
The experimental results shown in Chapter 4, together with earlier studies (described 
in section 2.2.1), support of the use of gradient-echo MRI to study several aspects of 
blood oxygen fluctuations in tumours. However, the influence of systemic variations in 
cycling hypoxia patterns in tumours has not yet been directly investigated. This chapter 
addresses this issue by comparing spontaneous 𝑅2
∗ fluctuations in tumours with systemic 
measurements of blood oxygen saturation, in which two different approaches were 
considered. Part of the work comprised in this chapter was used to write a paper entitled 
‘Decomposition of spontaneous fluctuations in tumour oxygenation using BOLD MRI 
and independent component analysis’, which was accepted for publication in the British 
Journal of Cancer [145].   
 
5.1. Introduction  
The initial approach to the above-described problem consisted of a correlation 
assessment between tumour 𝑅2
∗ dynamics and systemic pulse oximetry recordings. This 
method allows the mapping of the tumour regions mostly influenced by systemic blood 
oxygen variations, thereby enabling fluctuations caused specifically by tumour 
pathophysiology to be identified.  
Although useful for a fast initial assessment, this initial “direct correlation” approach 
requires a given tumour imaging voxel to be fluctuating either due to systemic or 
tumour-specific influences, when it is likely that most oscillating voxels display a 
combination of both processes. To overcome this limitation, a novel methodological 
approach based on independent component analysis (ICA) was developed. ICA is a 
computational blind source separation technique that has been used in BOLD studies of 
the brain, which allows a signal to be decomposed into its constituent components [146-
148]. In the brain, ICA has been applied to identify spatially coherent fluctuations in 
blood oxygenation that are associated with regions that are functionally connected. By 
analogy, ICA is here proposed as a method to identify regional connectivity within 
tumours, albeit reflecting different biological mechanisms to those in brain, alongside 
the ability to study such signals in isolation. Each isolated tumour signal can thus be 
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compared with pulse oximetry to discriminate between systemically-driven and tumour-
specific 𝑅2
∗ fluctuations and account for both effects in the same imaging voxel. 
Therefore, this study aimed to investigate whether tumour spontaneous fluctuations 
included contributions from systemic variations in blood oxygenation in SW1222 and 
LS174T tumours, alongside tumour-specific sources. To this end, direct correlation and 
ICA decomposition approaches were applied.  
The hypotheses for this study were: 
 Tumour cycling hypoxia events are the result of a combination of systemic and 
tumour-specific effects; 
 
 The estimates of the ICA approach better reflect the relative influence of 
systemic and tumour-specific sources of fluctuation. 
In addition, this study aims to assess whether the separation of the 𝑅2
∗ patterns based 
on their source of fluctuation allows relationships with tumour pathophysiology to be 
uncovered. 
 
5.2. Materials and methods 
5.2.1. Animal models and imaging protocol 
SW1222 (n = 5) or LS174T (n = 5) tumour xenografts were grown as previously 
described. Each tumour was scanned at rest at two weeks after inoculation, following 
the procedure described in section 3.3. Tumour volumes ranged from 135 mm3 to 670 
mm3. The cohort of tumours used in this study is the same as the one used in Chapter 4 
to assess histological distributions, although this chapter describes distinct post-
processing strategies from those previously implemented.  
 
5.2.2. In vivo pulse oximetry 
Concurrently with the MRI acquisition, pulse oximetry recordings were obtained 
with a sensor clamped to the thigh of the animal (MouseOx, Starr Life Sciences Corp., 
USA), which allowed the direct measurement of systemic arterial oxyhaemoglobin 
91 
 
saturation – O2sat. Systemic and tumour vasculature were modelled as shown in figure 
5.1, wherein the tumour is influenced by both systemic and local changes in 
oxygenation.  
 
 
Figure 5.1 – Schematic diagram of the systemic influence on the tumour 
oxygenation. 
 
5.2.3. Tumour MRI data analysis and relationship with systemic blood 
oxygenation 
Tumour maps of resting state 𝑅2
∗ estimates were calculated as described in section 
3.4. Specific post-processing methods for each adopted approach (direct correlation or 
ICA) are described next. 
 
5.2.3.1. Direct correlation approach   
As with the analysis described in Chapter 4, only tumour imaging voxels exhibiting 
amplitude 𝑅2
∗ oscillations above the uncertainty associated with background noise were 
considered for analysis. Pearson’s correlation between each voxel’s 𝑅2
∗ time course and 
the systemic O2sat trace was then performed. If the correlation was significant (P < 
0.01), the corresponding 𝑅2
∗ oscillatory behaviour was considered to be mostly due to 
systemic blood oxygen variations, and was represented in a voxel-wise matrix – 𝑅2 𝑠𝑦𝑠
∗ . 
Conversely, poorer correlations (P > 0.01) were ascribed to local, tumour-specific, 
events, where 𝑅2
∗ time courses were represented in a separate matrix – 𝑅2 𝑡𝑠
∗ . A summary 
of the data acquisition and post-processing is shown in figure 5.2A. Measurements of 
systemic arterial blood pressure were equally taken, concomitantly with O2sat and MRI, 
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although issues with probe malfunction meant not enough numbers were obtained to 
perform a reliable statistical analysis, and so these measurements were not included in 
this thesis.  
The percentage of oscillating voxels and their mean 𝑅2
∗ standard deviation (SD) were 
computed separately for systemic and tumour-specific oscillations. Wilcoxon matched-
pairs tests were used to compare between systemic and tumour-specific distributions 
within the same tumour line. Mann-Whitney U-tests were used to assess differences 
between tumour types. 
  
5.2.3.2. Model for MRI data decomposition – ICA approach    
A timeline of the data acquisition and post-processing procedures for the ICA 
approach is shown in figure 5.2B. Tumour 𝑅2
∗ time courses were first processed using 
principal component analysis (PCA), a computational technique that allows the 
extraction of the highest variance components in the data, and which is usually applied 
to highly dimensional datasets. In PCA, the variance in the data is associated to 
eigenvectors in a decreasing rank-order fashion, so that the first eigenvector has the 
largest variance, the second eigenvector has the second largest variance, and so on 
[149]. This ordered process results in the last eigenvectors having very little variance, 
being thus ascribed to background noise [149]. Dimensionality reduction of the 𝑅2
∗ data 
was then performed. This was achieved by selecting all the eigenvectors up to the 
‘shoulder’ of the PCA decomposition curve (see Fig. 5.2C) as well as the eigenvectors 
after that point which were associated with a time course exhibiting a dominant 
frequency peak. At this intermediate stage, power spectra were observed using the Fast 
Fourier Transform (FFT) method, instead of the Lomb method, due to its substantially 
faster computational time and because the main concern was to observe whether any 
frequency peaks were present, regardless of how accurate these were being represented. 
On average, 89 out of 944 eigenvectors per dataset were chosen (𝑛 = 10). This pre-
processing procedure was performed for two reasons: (i) it allowed the subsequent ICA 
decomposition of the data to be simplified, because the great majority of the variance is 
concentrated on a reduced number of eigenvectors, meaning all the data can be 
explained in fewer components, and (ii) by doing so, some of the background noise is 
expected to be filtered out, which also facilitates the ICA decomposition [149]. 
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Spatial ICA was then applied to this dimensionally reduced data (FastICA v2.5 
[150]), allowing the linear superposition of signals that compose the 𝑅2
∗ dynamics to be 
separated into independent processes (or components). Each independent component 
has a (previously unknown) unique time course and an associated spatial map. Each 
component map quantifies how much each voxel’s 𝑅2
∗ behaviour is explained by the 
corresponding component time course. Due to their independence from one another, 
each independent component can be studied individually. The decomposition process 
was modelled as: 
 𝑋 = 𝑀𝑆    , Eq. 5.1 
where 𝑋 is the voxel-wise matrix of 𝑅2
∗ time courses, which was transformed into a 2D 
matrix (time points × number of voxels); 𝑀 is the “mixing” matrix (time points × 
number of components), which contains each (data-driven) component time course in a 
separate column, and has a corresponding spatial representation in the rows of matrix 𝑆 
(number of components × number of voxels) [148]. 
Separation between systemic and tumour-specific influences on tumour 𝑅2
∗ 
fluctuations was undertaken by correlating each independent component time course 
with the systemic O2sat time course (Pearson’s linear correlation). A significant 
correlation (P < 0.01) suggested that the current independent component represented 
systemic blood oxygenation dynamics. Conversely, if the correlation was less 
significant (P > 0.01), the time course of the independent component, its FFT power 
spectrum and its spatial map were studied in order to assess if it was a component 
modelling tumour-specific dynamics. Two selection criteria were adopted: (i) if the 
frequency spectrum presented a peak at a defined frequency, this was enough evidence 
of cycling behaviour, or (ii) if the independent component spatial maps, which were 
normalised and thresholded by z-value (|z-score| ≥ 2.2) [148], presented clustering 
regions (minimum of 5 voxels), this meant that those regions shared a degree of 
similarity in their 𝑅2
∗ dynamics. To improve the robustness of the second selection 
criteria, only the components that exhibited spatial clustering regions associated with 
non noise-like (distinctive) temporal features were selected, in order to prevent noisy 
independent components from being considered (see Fig. 5.2D). When observed, 
regional clustering was often present across several imaging slices, as demonstrated by 
the 3D representation in figure 5.2D, suggesting temporally coherent 𝑅2
∗ patterns over a 
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tumour volume. Any remaining components (i.e., ones with poor correlation and that 
did not exhibit a frequency peak or spatial clustering effects), were considered to be 
modelling any background noise not previously filtered by PCA and were not 
considered for further analysis.  
 
 
Figure 5.2 – Data acquisition and post-processing for the direct correlation 
approach and the ICA approach. A, B: Timeline of data acquisition and post-
processing methods for each approach. C: PCA decomposition curve showing the 
relative variance associated to each eigenvector. Eigenvectors to the left of the 
‘shoulder’ of the curve have high variance. D: Time course and 3D spatial map of one 
independent component in an example SW1222 tumour. Adapted from [145]. 
 
The next step consisted of combining the component time courses matrix with the 
component spatial maps matrix to recover the 𝑅2
∗ data, although now separated into 
systemic and tumour-specific influences, in a process which is the reverse of the ICA 
decomposition: 
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𝑅2 𝐼𝐶𝐴 𝑠𝑦𝑠
∗ = 𝑀𝑠𝑦𝑠𝑆𝑠𝑦𝑠 
𝑅2 𝐼𝐶𝐴 𝑡𝑠
∗ = 𝑀𝑡𝑠𝑆𝑡𝑠    , 
Eq. 5.2 
where 𝑅2 𝐼𝐶𝐴 𝑠𝑦𝑠
∗  and 𝑅2 𝐼𝐶𝐴 𝑡𝑠
∗  are the voxel-wise matrices of systemic and tumour-
specific 𝑅2
∗ time courses, respectively.  
Lastly, to threshold 𝑅2 𝐼𝐶𝐴 𝑠𝑦𝑠
∗ , a final correlation between the systemic O2sat and the 
time courses of individual voxels of 𝑅2 𝐼𝐶𝐴 𝑠𝑦𝑠
∗  was computed (Pearson’s linear 
correlation). Only the most significant correlations (P < 0.01) were selected to represent 
systemically oscillating tumour regions. A similar procedure was employed to detect the 
most tumour-specific fluctuating areas, where only non-significant correlations (P > 
0.05) between the systemic O2sat and the dynamics of 𝑅2 𝐼𝐶𝐴 𝑡𝑠
∗  were considered. As in 
the direct correlation approach, Wilcoxon matched-pairs tests were used to compare 
between systemic and tumour-specific distributions within the same tumour line. Mann-
Whitney U-tests were used to assess differences between tumour types. 
 
5.2.4. Frequency analysis of thresholded 𝑹𝟐
∗  maps and O2sat curves 
Time courses of thresholded systemic or tumour-specific 𝑅2
∗ maps, following the 
direct correlation or the ICA approach, were analysed in the frequency domain, for both 
tumour lines. Similarly to Chapter 4, the Lomb method was applied to individual 𝑅2
∗ 
time courses and subsequently combined into a single averaged spectrum. The spectral 
mean and standard deviation of the tumour cohort was then computed. The Lomb 
method was equally applied to O2sat curves, where the mean and standard deviation of 
the cohort of mice bearing SW1222 or LS174T tumours was computed. Dominant 
frequencies of 𝑅2
∗ or O2sat oscillation were assessed based on spectral power (peak 
height).   
 
5.2.5. Histological assessment and whole-tumour statistical relationships  
Histology was performed following MRI imaging as described in section 3.5. Fast 
spin-echo anatomical images were used to measure tumour volumes. Statistical 
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correlations between distributions of histological, 𝑅2
∗ or tumour volume measurements 
required the use of non-parametric Spearman’s rho test due to small sample numbers.  
P < 0.05 was considered to be significant.  
 
5.3. Results 
5.3.1. Relationships between sources of 𝑹𝟐
∗  oscillation and between tumour 
lines   
Figure 5.3 shows an example SW1222 tumour, in which 𝑅2
∗ time courses were found 
to be significantly correlated with systemic blood oxygenation variations (P < 0.01, 
Pearson’s correlation) using either the direct correlation approach (𝑅2 𝑠𝑦𝑠
∗ ) or the ICA 
approach (𝑅2 𝐼𝐶𝐴 𝑠𝑦𝑠
∗ ). Additionally, both approaches revealed 𝑅2
∗ temporal patterns that 
were not correlated with systemic blood oxygen variations (P > 0.05, Pearson’s 
correlation), which were considered to be specific to the tumour microenvironment 
(𝑅2 𝑡𝑠
∗  or 𝑅2 𝐼𝐶𝐴 𝑡𝑠
∗ ). Using the direct correlation approach, these two sources of 
oscillation were identified in separate tumour regions. However, the ICA approach 
demonstrated the ability to identify systemic and tumour-specific 𝑅2
∗ oscillations in the 
same voxel, not being necessarily from discrete regions in the tumour. Both oscillatory 
sources were observed in all SW1222 (n = 5) and LS174T (n = 5) tumours using either 
approach.  
The percentage of voxels exhibiting systemic or tumour-specific fluctuations in each 
tumour line is represented in figure 5.4A (direct correlation approach) and figure 5.4C 
(ICA approach). The majority (or all – Fig. 5.4A, SW1222) of SW1222 and LS174T 
tumours showed a greater occurrence of tumour-specific fluctuations than systemic 
fluctuations, although the difference was not statistically significant (P > 0.05, 
Wilcoxon matched-pairs test). 
The mean standard deviation of 𝑅2
∗ fluctuations is plotted in figure 5.4B (direct 
correlation approach) and 5.4D (ICA approach). No significant differences were 
observed between systemic and tumour-specific fluctuations or between tumour lines. 
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Figure 5.3 - Systemic and tumour-specific influences on tumour 𝑹𝟐
∗  spontaneous 
fluctuations in an example SW1222 tumour, following the direct correlation or the 
ICA approach. A, C: Voxel-wise standard deviation (SD) maps of the 𝑅2
∗ fluctuations 
due to systemic (direct correlation: 𝑅2 𝑠𝑦𝑠
∗ ; ICA: 𝑅2 𝐼𝐶𝐴 𝑠𝑦𝑠
∗ ) or tumour-specific (direct 
correlation: 𝑅2 𝑡𝑠
∗ ; ICA: 𝑅2 𝐼𝐶𝐴 𝑡𝑠
∗ ) influences. High SD in different regions between maps 
distinguishes the tumour areas most affected by either source. With ICA decomposition, 
colocalised voxels between both maps reflect the simultaneous influence of systemic 
and tumour-specific events in those tumour regions. B: Correspondence between the 𝑅2
∗ 
time course from a single voxel (red), oscillating above noise uncertainty, and the O2sat 
curve (blue). D: Correspondence between the 𝑅2
∗ time course from a single voxel (red), 
after ICA separation, and the O2sat curve (blue). 𝑅2
∗ and O2sat were measured 
simultaneously. Adapted from [145].  
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Figure 5.4 – Relative influence of systemic (Sys) and tumour-specific (T-sp) 
fluctuations in SW1222 and LS174T tumours, following the direct correlation or 
the ICA approach. A, C: Percentage of systemic and tumour-specific oscillating 
voxels. B, D: Mean standard deviation (SD) of 𝑅2
∗ fluctuations. In both tumour lines, 
fluctuations due to tumour-specific influence showed higher prevalence in the majority 
of tumours, relative to systemic fluctuations (panels A and C), although these 
differences were not statistically significant (Wilcoxon matched-pairs test). No 
significant differences were found in the SD of 𝑅2
∗ fluctuations (panels B and D). 
Adapted from [145].  
   
All LS174T tumours exhibited large systemic fluctuations in the tumour periphery 
(Fig. 5.5), which can more easily be appreciated in the 𝑅2
∗ SD maps of the ICA 
approach, whereas tumour-specific fluctuations were observed in both the centre and the 
periphery. Conversely, systemic and tumour-specific fluctuations were distributed 
throughout SW1222 tumours.  
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Figure 5.5 – Spatial distribution of high amplitude systemic 𝑹𝟐
∗  fluctuations, 
following the direct correlation (𝑹𝟐 𝒔𝒚𝒔
∗ ) or the ICA approach (𝑹𝟐 𝑰𝑪𝑨 𝒔𝒚𝒔
∗ ). High 
amplitude systemic fluctuations are located in the tumour periphery, which is more 
apparent in the ICA approach maps. Conversely, SW1222 fluctuations (systemic and 
tumour-specific), and LS174T tumour-specific fluctuations, displayed no obvious 
spatial patterning. Adapted from [145]. 
 
Figure 5.6 shows the frequencies of 𝑅2
∗ fluctuations, organised by tumour line and 
fluctuating source, for both approaches3. Dominant frequencies were assessed from the 
peak height of frequency spectra. The range of dominant frequencies (in cycles/hour) in 
each plot is shown in bold. The lowest frequency peaks, observed at 0.75 cycles/hour or 
1.00 cycle/hour, are at similar frequencies to those observed in Chapter 4 for a 60 
minute-long acquisition. Conversely, highest frequencies of oscillation are commonly 
different to those previously detected, especially for the ICA approach, where these are 
either above (systemic: SW1222) or below (systemic: LS174T and tumour-specific: 
both tumour lines). 
Between direct correlation and ICA approaches, the range of dominant frequencies in 
LS174T tumours is comparable. In SW1222 tumours, however, some differences were 
                                                          
3 The results of the frequency analysis here presented (using the Lomb method) differ from those 
published in the British Journal of Cancer paper (where FFT was employed) [145]. Here, the Lomb 
method revealed an advantage relative to FFT due to the oversampling capacity, which allowed a better 
differentiation between frequency peaks. 
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observed. Specifically, a broad peak at 7.75-8.00 cycles/hour was detected in tumour-
specific oscillations when using the direct correlation approach (see green arrow), but 
not when ICA decomposition was employed. Upon analysis of the spectra of SW1222 
systemic oscillations, peaks at similar frequencies to the one mentioned above were 
observed in both the direct correlation (peak at 7.5 cycles/hour) and ICA (broad peak at 
7.5-7.75 cycles/hour) approaches (see red arrows). This observation suggests the 𝑅2
∗ 
fluctuations identified as tumour-specific in the direct correlation approach are 
additionally being partially influenced by systemic influences, which provides further 
evidence of the simultaneous influence of systemic and local fluctuating mechanisms in 
a given tumour region. The ICA decomposition additionally revealed the ability to 
detect complex fluctuating modes, where 6 distinct peaks were observed in the spectrum 
of SW1222 systemic oscillations against the 5 peaks in the equivalent spectrum of the 
direct correlation approach. 
Within the spectra of the ICA approach, systemic influences revealed differences in 
the range of oscillatory frequencies between both tumour lines, with SW1222 tumours 
presenting peaks at higher frequencies. The same was not observed in tumour-specific 
influences, where the dominant frequency range was comparable between SW1222 and 
LS174T tumour types. Between sources of fluctuation, systemic influences showed 
broader dominant frequency ranges, with peaks at higher frequencies, in both tumour 
lines, which is in agreement with the fact that systemic O2sat curves exhibit a relatively 
broad range of frequencies in both SW1222 and LS174T tumour-bearing mice (see Fig. 
5.7). 
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Figure 5.6 – Frequency analysis of tumour 𝑹𝟐
∗  oscillations, for the direct 
correlation or the ICA approach, organised by tumour line and systemic or 
tumour-specific influence. Mean (black line) and standard deviation (shaded area) of 
power spectra are shown. The range of dominant frequency peaks is shown in bold. 
Green and red arrows show frequency peaks at similar frequencies between plots, 
suggesting systemic influences are present in tumour-specific oscillations in the direct 
correlation approach only. Different tumour types were observed to exhibit dominant 
oscillatory frequencies across different ranges. Systemic and tumour-specific sources 
also revealed different ranges of oscillatory frequency. 
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Figure 5.7 – Frequency analysis of the O2sat curves in SW1222 or LS174T tumour-
bearing mice. Mean (black line) and standard deviation (shaded area) of power spectra 
are shown. The range of dominant frequency peaks is shown in bold.  
 
5.3.2. Physiological basis of tumour fluctuations   
The percentage of each tumour that exhibited 𝑅2
∗ fluctuations due to systemic 
influences was significantly correlated with the tumour volume when using the ICA 
approach (Fig. 5.8C, systemic) but not with the direct correlation approach (Fig. 5.8A, 
systemic). There was no significant correlation between tumour volume and the 
percentage of each tumour exhibiting tumour-specific fluctuations in either approach 
(Fig. 5.8A, C, tumour-specific).  
Comparison of histological measures with MRI data revealed a significant inverse 
correlation between the percentage of mature vessels (assessed by co-localisation of α-
SMA and CD31 immunostaining) and the magnitude of tumour-specific, but not 
systemic, fluctuations when using either approach (Fig. 5.8 B, D). No correlation was 
found between the percentage of mature vessels in each tumour and the size of the 
tumour. 
Focusing on the results from the ICA approach, qualitative observations revealed 
that, in tumour sub-regions with high systemic or tumour-specific 𝑅2
∗ variation, tissues 
were well perfused and viable (non-necrotic) in 4 SW1222 (n = 5) and 3 LS174T (n = 4) 
tumours. This result is slightly different from that observed in Chapter 4 in the same 
tumour cohort, where all tumours presented high 𝑅2
∗ SD associated with well perfused 
and viable tissue. 
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Figure 5.8 – Relationship between tumour size, 𝑹𝟐
∗  fluctuations and mature 
vasculature, for the direct correlation or the ICA approach. Significance was tested 
with Spearman’s rho correlation test. A, C: Influence of tumour size on the occurrence 
of systemic or tumour-specific 𝑅2
∗ fluctuations. Direct correlation did not reveal any 
significant relationships (P > 0.05). Conversely, ICA decomposition showed the 
percentage of systemically oscillating voxels is directly related to the size of SW1222 
and LS174T tumours (P = 0.02), but no relationship was found with tumour-specific 
oscillations (P = 0.30). B, D: Both approaches revealed the percentage of mature 
vessels is inversely related to the mean standard deviation (SD) of tumour-specific, but 
not systemic, 𝑅2
∗ fluctuations (P = 0.04 for both approaches). Adapted from [145].    
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5.4. Discussion 
5.4.1. Discrimination between the sources of 𝑹𝟐
∗  fluctuation in tumours and 
between tumour types   
In this study, two different approaches were employed for characterising individual 
contributions to cycling hypoxia in tumours. Specifically, each approach was designed 
to separate systemic from tumour-specific sources of 𝑅2
∗ variation in individual tumours. 
The first – direct correlation approach – involved the correlation of tumour 𝑅2
∗ time 
courses with systemic blood oxygen saturation (O2sat) readings. The second – ICA 
approach – involved the decomposition of tumour 𝑅2
∗ signals into its constituent 
components, using independent component analysis, and posterior separation into 
systemic or local influences based on the O2sat curve, alongside noise filtration. Each 
approach allowed the identification of the areas mostly affected by either mechanism in 
individual tumours. Low-frequency fluctuations in oxygen tension and blood flow were 
previously observed in both tumour and muscle by Braun and collaborators [35], using 
recessed-tip oxygen microelectrodes and laser-Doppler flow probes. Despite having 
observed greater low-frequency activity and greater magnitude changes in tumours, this 
provided an early suggestion for systemic influences. Baudelet and colleagues [34] also 
reported a similar observation when comparing 𝑇2
∗-weighted gradient-echo fluctuations 
between tumour and contralateral muscle. They additionally looked at whether muscle 
and tumour time series were correlated, and concluded that systemic changes did not 
affect the tumour microenvironment because no significant results were obtained. 
Although the direct correlation approach presented here is conceptually similar to their 
study, the ICA approach is more refined, as it isolates high-variance data and separates 
the multitude of processes contributing to 𝑅2
∗ fluctuations prior to any time series 
correlation. Moreover, ICA decomposition provides the unique advantage of being able 
to identify tumour regions that are simultaneously suffering from systemic and tumour-
specific effects, which would be otherwise impossible. These features meant the results 
between both approaches differed in occasions, as observed in the previous section, 
with the measurements obtained with the ICA approach being generally considered 
more reliable. For this reason, interpretation of the results obtained will mainly focus on 
the ICA approach data.  
Systemically-driven, high amplitude fluctuations were observed to be preferentially 
located in the tumour periphery in LS174T tumours, whereas in SW1222 tumours there 
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was no preferential location. This observation is potentially due to the less extensive 
vascular network evident in LS174T tumours, compared with SW1222 tumours. Fewer 
blood vessels can lead to impaired perfusion which, in combination with the higher 
microvascular density in the LS174T tumour periphery, potentially reduces the 
influence of systemic variations in the central area of the tumour. A similar observation 
was reported in an MRI study of A-07 melanoma xenografts, where blood flow 
fluctuations occurred preferentially in the tumour periphery, in which case the authors 
considered vasomotor activity in the supplying vasculature as a probable cause of 
fluctuations [88]. Conversely, SW1222 tumours have a vascular tree closer to that of 
normal tissues, leading to greater perfusion throughout the tumour (and less hypoxia), 
and potentially allowing the transmission of systemic variations from the tumour edge 
towards its core more effectively.   
The range of dominant oscillatory frequencies of 𝑅2
∗ estimates varied between 
tumour lines and between sources of fluctuation. Considering the systemic fluctuations, 
SW1222 tumours exhibited a wider range of frequencies relative to LS174T tumours. 
This result is unlikely to be due to differences in the O2sat fluctuations between mice 
bearing one or the other tumour type because LS174T tumour-bearing mice actually 
presented a wider range of frequency peaks than SW1222 tumour-bearing mice. This 
result is again probably due to the significantly denser and better perfused vasculature 
of SW1222 tumours, which renders these tumours more susceptible to systemic 
influences relative to LS174T tumours, as was demonstrated in Chapter 4 with the 
systemically applied carbogen and hypercapnia challenges. Conversely, tumour-specific 
fluctuations of both tumour types have comparable frequencies of fluctuation. Between 
sources of fluctuation, broader ranges of frequency peaks were observed in systemic 
fluctuations in both tumour types. Considering that (i) O2sat fluctuations experience a 
relatively broad range of frequencies and (ii) tumour-specific 𝑅2
∗ fluctuations have a 
relatively narrow frequency span, then systemic 𝑅2
∗ fluctuations would indeed be 
expected in a wider range relative to tumour-specific 𝑅2
∗ fluctuations. Interestingly, the 
higher frequencies of O2sat oscillations seem to have been attenuated in tumours. 
Tumour and normal vasculatures present marked structural and functional differences, 
and so it is conceivable that not all dynamic properties of systemic oxygenation will 
influence the tumour regions suffering from such effects. 
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5.4.2. Relationships between 𝑹𝟐
∗  fluctuations and pathophysiological 
measurements in tumours 
Systemic and tumour-specific sources of 𝑅2
∗ oscillations were further assessed by 
comparing the percentage of oscillating voxels with the tumour size. The occurrence of 
systemic, but not tumour-specific, 𝑅2
∗ oscillations was found to be directly related to the 
size of tumours in both SW1222 and LS174T xenografts. Related to this, Chaplin et al. 
[37] had already reported a relationship between the occurrence of cycling hypoxia and 
the size of SCCVII tumours. In their study, they injected (i.v.) the fluorescent perfusion 
marker Hoechst 33342 twenty minutes before applying 10 Gy of radiation to tumours. 
Subsequently, a large differential survival between well perfused cells and poorly 
perfused cells was observed in small tumours (≤ 200 mg). However, this differential 
decreased as the tumour size increased, which they inferred was due to a higher 
occurrence of cycling hypoxia in larger tumours, therefore acting as a protective 
mechanism against radiation. They suggested this relationship should depend on tumour 
type or site of implantation. Still, given the results presented here, one possible 
alternative is that, as tumours develop and acquire increased blood supply from the 
surrounding vasculature, the influence of systemic blood flow variations in the tumour 
becomes increasingly prevalent. Such effect can potentially occur by (i) an increase in 
the number of systemic feeding vessels accompanying tumour growth or (ii) an increase 
in the diameter of those vessels. In fact, results of Chapter 4 support this hypothesis, 
given that tumour growth favoured an increase in the percentage responsiveness to 
carbogen breathing. Nevertheless, the evolution of the tumour feeding vasculature does 
not seem to have yet been directly investigated and a study of this nature would provide 
valuable information about the systemic influences on tumour cycling hypoxia.  
Oscillations in 𝑅2
∗ estimates additionally revealed a link to tumour biology. The 
amplitude of tumour-specific fluctuations was found to be inversely correlated to the 
degree of vessel maturation in SW1222 and LS174T tumours, but no similar 
relationship was found with systemic fluctuations. This illustrates another key benefit of 
the methods developed in this study, in that isolation of tumour-specific fluctuations 
from those occurring due to systemic influence allows a clear insight into tumour 
pathophysiology. Interpretation of this finding relies on the role of mural cells in the 
structural support of blood vessels: mature vessels have increased integrity and stability 
[151], thus being less susceptible to mechanical stress-related microenvironmental 
factors responsible for cycling hypoxia, such as raised interstitial fluid pressure [31]. 
107 
 
This interpretation is in agreement with a previous electron paramagnetic resonance 
imaging study of two carcinoma models, which suggested an inverse relationship 
between the maturity of the tumour microvascular network and the amplitude of tissue 
pO2 fluctuations [86]. A similar conclusion was reported in a related study of melanoma 
and cervical carcinoma xenografts, where the presence of connective tissue embedding 
the tumour microvessels was associated with stabilisation of blood flow and tissue pO2 
fluctuations [152]. Moreover, T2
*-weighted MRI estimates of pO2 and blood flow in 
syngeneic fibrosarcoma-II tumours previously showed that signal fluctuations occur 
predominantly in regions of immature vasculature [41]. 
Moreover, no correlations were observed between the percentage of oscillating 
voxels (systemic or tumour-specific) and the percentage of mature vessels. This result is 
in agreement with the suggestion from Chapter 4 which stated that spontaneous 
fluctuations should occur regardless of the presence of muscle cell coverage, due to the 
homogeneous distribution of mature and immature blood vessels.  
 
5.4.3. Limitations of the method 
The approaches used in this study suffer from a number of limitations. In addition to 
the previously mentioned confounding effects associated to estimating blood oxygen 
variations with gradient-echo MRI [108], both approaches, as implemented here, did not 
consider any possible lag between the O2sat variations and tumour 𝑅2
∗ fluctuations. 
However, the circulation time in mice is of the order of the temporal resolution of the 
gradient-echo acquisition used in this study, so such effects can be assumed to be 
negligible. Additionally, systemic influences in the tumour microenvironment can come 
from different sources, such as pulsatile flow and blood pressure, in addition to blood 
oxygenation, which prevents the realisation of a ‘complete picture’ of the systemic 
physiological sources of the oscillations in the tumour. Still, this limitation can be 
overcome, at least partially, by simultaneous measurements of these systemic 
properties, concomitantly with MR imaging. 
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5.5. Conclusions 
This study demonstrated a non-invasive and, particularly with the ICA approach, 
novel method to directly identify systemic influences on tumour cycling hypoxia 
patterns and separate these from tumour-specific effects. Due to its further refinement, 
the ICA approach is additionally considered a more accurate estimate of the relative 
influence of each source of 𝑅2
∗ fluctuation in tumours, which is reflected in the results of 
this study.  
This method has the potential to be easily translatable to the clinic, where tumour 
cycling hypoxia is still poorly characterised, with only a few published studies to date 
[83;94] (see Chapter 7 for an implementation of ICA in a clinical context). Although the 
systemic blood oxygenation might not suffer from such dramatic temporal variations in 
humans, the fact that other systemic effects are possibly influencing the tumour 
microenvironment is advantageous and can be incorporated in the method. If applied in 
the clinical setting, the ICA approach or its future versions would help predict the 
temporal and spatial delivery of systemically applied therapies, such as chemotherapy or 
radioimmunotherapy, in individual patients, and consequently help tailor a more 
effective delivery regime. Additionally, separating the sources of fluctuations occurring 
in tumours could potentially provide an insight into tumour pathophysiology in a 
clinical context, given the relationships found with vascular characteristics in this study. 
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6. Effect of imatinib therapy on 𝑹𝟐
∗  spontaneous fluctuations 
and gas challenge responsiveness in tumours    
Chapters four and five were aimed to investigate the microenvironmental 
characteristics of tumour cycling hypoxia and its physiological basis. The current 
chapter builds on this knowledge to assess the effect of the agent imatinib mesylate, 
which has shown to have antiangiogenic properties, on tumour spontaneous 𝑅2
∗ 
fluctuations and systemically applied vasoactive gas challenges. These measurements 
are complemented by a comprehensive range of histological markers.  
 
6.1. Introduction  
The antitumour therapy protocol employed in this study used imatinib mesylate 
(Novartis Pharma GmbH, Germany), a form of targeted therapy originally developed to 
treat chronic myeloid leukaemia [153], which was then applied to treat other tumour 
types such as gastrointestinal stromal tumours [154-156] or other forms of leukaemia, 
amongst others [157;158]. Imatinib mesylate is a tyrosine-kinase inhibitor of the 
receptor of platelet-derived growth factor (PDGF) [153;159;160]. PDGF is a protein 
that has an important role in the angiogenic process [161-164] and, accordingly, 
imatinib has previously been observed to reduce the microvascular density in clinical 
and pre-clinical tumours, including LS174T colorectal tumour xenografts [165-168]. 
Additionally, imatinib therapy was shown to decrease the intratumoral interstitial fluid 
pressure (IFP) in human xenograft models of lung (A549) and colorectal (LS174T) 
carcinoma [166;169]. Given these effects, imatinib therapy could potentially be 
promoting the normalisation of the vasculature in LS174T tumour models. The 
“vascular normalisation” hypothesis was popularised by Jain in 2001 [170], but was 
first proposed by Le Serve and Hellmann in 1972 [171]. It posits that antiangiogenic 
agents can prune some vessels whilst promoting an improvement of the integrity and 
function of the remaining vasculature towards a state more closely resembling normal 
vessels [170]. This effect was later supported in a number of studies using inhibitors of 
vascular endothelial growth factor (VEGF) or its receptor (VEGFR), where IFP 
reduction and improvements in perfusion, oxygenation and delivery of drugs or other 
molecules were observed [172-176]. Structural and functional vascular improvement is 
consequently associated with increased vascular coverage of perivascular cells 
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(comprised of pericytes and vascular smooth muscle cells) [174-177]; however, 
imatinib treatment has shown to reduce the pericyte coverage in different tumour 
models [178;179], given that PDGF also regulates the recruitment of such cells 
[180;181]. Still, this consequence is potentially tumour-type dependent, as no such 
effect was observed in a study with LS174T tumours [165]. 
Given the effects of imatinib therapy on LS174T tumours, a hypothesis of vascular 
normalisation can be formulated. The anticipated implications of a normalised 
vasculature are: 
 To reduce the amplitude and prevalence of tumour 𝑅2
∗ spontaneous 
fluctuations, which are characteristic of the highly permeable tumour vessels 
and elevated IFP microenvironment;  
 To increase the responsiveness to gas challenges. Improvements in the 
tumour uptake of chemotherapeutic and radioimmunotherapeutic agents 
upon treatment with imatinib, including LS174T tumours, provide additional 
support for this hypothesis [165;168;169;182;183].  
Further to these specific hypotheses, this study aims to investigate whether imatinib 
treatment caused an effect on tumour perfusion, hypoxia, vascular density or vascular 
maturation, as measured with histological markers. 
 
6.2. Materials and methods 
6.2.1. Animal models and in vivo MRI  
Cells of the LS174T colorectal tumour line were cultured and injected as previously 
described (see section 3.2). After approximately 2 weeks of tumour growth, baseline 
MRI scans were performed (day 0). Three sets of data were acquired. The first 
acquisition was a 60-minute dynamic GEMS ‘resting state’ scan aimed at evaluating 𝑅2
∗ 
spontaneous fluctuations at rest. The second acquisition was a 40-minute dynamic 
GEMS ‘gas challenge’ scan, during which different gas mixtures were administered in 
10-minute intervals: air, carbogen, air, air + 5% CO2 (hypercapnia). Changes in signal 
intensity (SI) and 𝑅2
∗ relative to air-breathing phases were measured. GEMS sequence 
parameters were the same as described in section 3.3. The final acquisition was a Look-
Locker segmented Inversion Recovery sequence, from which two 𝑅1(= 1 𝑇1⁄ )  maps 
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were calculated, one during air breathing and another during carbogen breathing. Look-
Locker sequence parameters: TR = 10 s, 50 TIs, TI spacing = 110 ms, TRRF = 2.3 ms, 
TE = 1.18 ms, in-plane field of view 20×20 mm2, matrix size 128×128, slice thickness 
1.5 mm, 5 slices, flip angle = 8°. This MRI protocol was repeated at days 3 and 5 of the 
study. 𝑅1 data was obtained in collaboration with Rajiv Ramasawmy (UCL Centre for 
Advanced Biomedical Imaging). 
 
6.2.2. Therapy protocol  
Imatinib was administered by oral gavage (100 mg × kg-1 × day-1, non-fractioned 
dose) immediately after the baseline scans and then each day for five consecutive days 
(n = 10). Animals in the control group were treated with saline (n = 9). Daily calliper 
measurements were taken to assess tumour growth rate. Tumour volume (𝑉) was 
determined by the equation: 𝑉 = (𝜋 6⁄ ) × 𝑙𝑜𝑛𝑔𝑒𝑟 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 × (𝑠ℎ𝑜𝑟𝑡𝑒𝑟 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟)2 
[169]. In the treated group, one tumour was not imaged, and was instead used for 
tumour growth assessment and histology. Another tumour in the treated group ulcerated 
at day 3 and this mouse had to be euthanised. 
 
6.2.3. MRI data analysis  
Four different spatial maps were calculated: (i) standard deviation maps of 
spontaneous 𝑅2
∗ fluctuations (𝑅2
∗ SD maps); (ii) 𝑅2
∗ maps of the difference between 
carbogen and air breathing (Δ𝑅2
∗); (iii) 𝑅1 maps of the difference between carbogen and 
air breathing (∆𝑅1); (iv) signal intensity (SI) maps of the difference between 
hypercapnia and air breathing (ΔSI). 
Maps of 𝑅2
∗ SD were acquired in order to estimate the percentage of voxels 
fluctuating above the background noise uncertainty and their respective amplitude. To 
this end, the MAP algorithm was employed to threshold the maps. The example curves 
represented in figure 6.1A show, as would be expected, that original 𝑅2
∗ time courses 
have a similar profile to PCA/ICA-filtered 𝑅2
∗ time courses, although with higher 
variability. Nevertheless, relative differences between different regions within a given 
tumour are similar between MAP-thresholded and PCA/ICA-filtered maps (see the 
similarity between both maps in figure 6.1B). MAP thresholded maps were thus used 
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for assessment of the amplitude of fluctuations and percentage of fluctuating voxels, 
which would not be possible with the PCA/ICA maps because these show all voxels, 
regardless of their fluctuating profile (see figure 6.1B). 
 
 
Figure 6.1 – MAP thresholding and PCA/ICA filtering on an imatinib-treated 
tumour at day 5. A: Original (blue) and PCA/ICA noise filtered (red) 𝑅2
∗ time courses 
in 3 example, representative, voxels. Filtered 𝑅2
∗ curves show less variability than 
original 𝑅2
∗, although both curves follow a similar behaviour. B: Corresponding 
standard deviation (SD) maps. Original 𝑅2
∗ (MAP thresholding map) shows slightly 
larger SD values relative to PCA/ICA filtering. Still, relative differences are kept 
throughout the tumour, which can be observed by comparing both maps.    
 
Maps of Δ𝑅2
∗ between carbogen and air breathing were calculated and thresholded as 
detailed in section 3.4, with the aim of estimating blood oxygenation changes. Similarly 
to the analysis described in Chapter 4, quantification of the maps was performed for 
both the percentage of voxels exhibiting a significant Δ𝑅2
∗ (positive or negative) and the 
corresponding mean magnitude values of these voxel locations.  
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Maps of ∆𝑅1 between carbogen and air breathing were calculated to estimate tissue 
oxygenation changes. Paramagnetic dissolved molecular oxygen accelerates 𝑇1 
relaxation through dipole-dipole interactions between the water protons and the 
molecular oxygen [105]. A paramagnetic molecule tumbling in solution creates a 
fluctuating magnetic field [184], therefore causing a faster 𝑇1 recovery (i.e., shorter 𝑇1) 
by increasing the likelihood of the tumbling frequency to match the precessional 
frequency of an excited proton (i.e., the Larmor frequency). The closer the tumbling rate 
is to the Larmor frequency, the more efficient the molecule is in promoting relaxation 
[184]. Voxel-wise ∆𝑅1 maps were calculated as: 
 
∆𝑅1 =
1
𝑇1 𝐶𝑎𝑟𝑏
−
1
𝑇1 𝐴𝑖𝑟
    , Eq. 6.1 
which means an increase in tissue oxygenation upon carbogen breathing is expected to 
cause a positive ∆𝑅1. Maps of ∆𝑅1 were not thresholded because a statistical analysis 
could not be performed due to the fact that 𝑇1 measurements are not dynamic (only one 
time point). This issue could be overcome by performing repeated measurements under 
identical conditions, although this is time consuming and not suitable to have been 
implemented in the current study. The percentage of positive or negative carbogen-
responsive voxels and its mean ∆𝑅1 value were computed for all treated tumours (n = 8) 
and 3 control tumours. 
The matrix size of ∆𝑅1 maps was additionally reduced to 64×64 in order to perform a 
correlation analysis with Δ𝑅2
∗ maps. This was aimed at assessing the relationship 
between tissue oxygenation and blood oxygenation estimates in treated tumours. The 
magnitude values of individual voxels in both maps were plotted against each other 
(only supra-threshold voxels in Δ𝑅2
∗ maps were considered). One plot was created for 
each day of MRI scanning. In each plot, voxels of all respective tumours were grouped 
(n = 8).  
Maps of ΔSI between hypercapnia and air breathing were calculated and thresholded 
as detailed in section 3.4, being aimed at estimating blood flow variations. As before, 
the percentage of voxels exhibiting positive or negative ΔSI responses and their 
respective mean magnitude values were computed. 
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6.2.4. Histological assessment  
Histology was performed as previously described for H&E and fluorescence 
distributions of vascular perfusion (Hoechst 33342 – blue), pericytes (α-SMA – red) and 
hypoxia (pimonidazole – green). Also as before, vascular endothelial cells were stained 
with a rat monoclonal antibody against CD31 (Abcam, UK), but now revealed with 
either Alexa Fluor-488 (Life Technologies, UK) or Alexa Fluor-568 (Life 
Technologies, UK), green or red fluorophores, respectively. Pericytes were also 
identified using a rabbit polyclonal anti-NG2 antibody (Millipore, UK), which was 
revealed with Alexa Fluor-488 (Life Technologies, UK). Tumour coverage of pericytes 
stained with anti-NG2 was performed as for the rest of the fluorescent markers. The 
percentage of capillaries covered with pericytes (α-SMA or NG2) was also calculated 
following the procedure described in section 3.5.  
Seven treated tumours were histologically assessed. Histology was not performed on 
the imaged tumours of the control group because a similar analysis had been performed 
previously (see Chapter 4). However, pericyte staining with the anti-NG2 antibody had 
not been carried out and, given this necessity, a new cohort of LS174T tumours (n = 6) 
was set up, in which pericyte quantification was performed in this way. From these, one 
mouse was additionally injected with Hoechst 33342 and pimonidazole before being 
sacrificed. Together with earlier fluorescence distribution assessments, the sample size 
of each marker in the control group was: Hoechst 33342 (n = 5), pimonidazole (n = 5), 
CD31 (n = 10), α-SMA (n = 10), NG2 (n = 6), α-SMA coverage of blood vessels (n = 
10) and NG2 coverage of blood vessels (n = 6). 
 
6.2.5. Statistical analysis  
Differences in the growth rate between treated and control tumours (assessed with 
MRI or calliper measurements) were assessed with a Mann-Whitney U-test in each 
individual day. The same test was used for assessing differences between treated and 
control tumours regarding quantitative distributions of histological fluorescence 
markers.  
In order to assess the effect the administration of imatinib had on tumour MRI 
estimates, the longitudinal evolution of individual tumours (i.e., throughout the study 
days) was observed. Tumours in the control group were studied to assess if similar 
115 
 
effects occurred without administrating the drug. A one-way ANOVA followed by 
Holm-Šídák’s multiple comparisons test was used to assess significant differences 
between days 0, 3 and 5 in treated tumours. The same test was used separately in the 
control group. This was performed for 𝑅2
∗ spontaneous fluctuations, 𝑅2
∗ response to 
carbogen, 𝑅1 response to carbogen and SI response to hypercapnia. Voxel-wise 
correlation between Δ𝑅2
∗ and ∆𝑅1 responses to carbogen breathing was assessed with 
Pearson’s linear correlation. 
 
6.3. Results 
6.3.1. Imatinib therapy did not impact on tumour growth rate or on 
spontaneous 𝑹𝟐
∗  fluctuations 
Administration of imatinib mesylate did not affect tumour growth, as assessed by 
MRI or calliper measurements (Fig. 6.2). A similar observation was previously 
reported, in which imatinib, on its own, did not significantly delay the growth of 
LS174T tumours [169]. 
 
Figure 6.2 – Tumour growth in treated (imatinib) and control (saline) tumours 
assessed with MRI (left) and calliper (right) measurements. Imatinib or saline was 
first administered immediately after the baseline scan. No significant differences in 
growth rate between both groups were identified (Mann-Whitney U-test). Data are mean 
± SD. 
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Imatinib therapy did not cause a significant change in the prevalence or amplitude of 
spontaneous 𝑅2
∗ fluctuations throughout the duration of the study (Fig. 6.3). Upon MRI 
scanning, one control tumour was found to present substantial time-varying 
susceptibility artifacts. This tumour was not considered in dynamic MRI-related 
assessments. 
 
 
Figure 6.3 – Percentage of the tumour voxels experiencing spontaneous 𝑹𝟐
∗  
oscillations (A) and corresponding mean standard deviation (SD) of such 
variations (B). No significant differences were found in the treated (imatinib, n = 8) or 
control (saline, n = 8) groups throughout the study days (one-way ANOVA followed by 
Holm-Šídák’s multiple comparisons test).   
 
6.3.2. Imatinib therapy promoted gas challenge response heterogeneity  
Figure 6.4 illustrates the tumour 𝑅2
∗ response to the carbogen challenge. Data from 
day 3 was omitted only for illustration purposes, but an alternative illustration 
containing data from the 3 scanning days is shown in the supplementary data (Fig. 
S6.4). The percentage of voxels exhibiting positive (+Δ𝑅2
∗) or negative (−Δ𝑅2
∗) 
responses did not change significantly throughout the study days, both in treated or 
control groups (Fig. 6.4B). The magnitude of 𝑅2
∗ responses was also not significantly 
different between different days (Fig. 6.4C). However, an interesting effect was 
observed in the treated group between days 0 and 5, in which positive responses showed 
larger magnitudes at day 5 and negative responses presented larger negative magnitudes 
in the same day (Fig. 6.4C). This observation led to the investigation of the 
heterogeneity in the tumour response. The standard deviation (SD) of all supra-
threshold Δ𝑅2
∗ magnitude values was computed, and a significant increase in the 
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response heterogeneity was observed in the treated group, but not in the control group, 
between days 0 and 5 (Fig. 6.4D). This result can be qualitatively appreciated in figure 
6.4A. 
 
 
Figure 6.4 – Tumour 𝑹𝟐
∗  response to the carbogen challenge at baseline (day 0) and 
day 5. Significance between days of study in treated (imatinib, n = 8) or control (saline, 
n = 8) groups was tested with a one-way ANOVA followed by Holm-Šídák’s multiple 
comparisons test. A: Representative example dataset of the effect of imatinib therapy: 
increase in the heterogeneity of carbogen response between days 0 and 5. B: Percentage 
of tumour voxels showing a positive (+∆𝑅2
∗) or negative (−∆𝑅2
∗) response to carbogen.  
C: Corresponding mean ∆𝑅2
∗ values for each treated or control tumour. D: Standard 
deviation of the magnitude values represented in C, depicting a significant increase in 
the heterogeneity of the carbogen response between days 0 and 5 in the treated group, 
but not in the control group. *, P < 0.05. 
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Figure 6.5 shows the tumour 𝑅1 response to the carbogen challenge. The percentage 
of positive (+∆𝑅1) or negative (−∆𝑅1) responsive voxels was not significantly different 
between study days, both in treated or control groups (Fig. 6.5A). The corresponding 
∆𝑅1 magnitudes were also not significantly different throughout the study (Fig. 6.5B). 
 
 
Figure 6.5 – Tumour 𝑹𝟏 response to the carbogen challenge at days 0, 3 and 5 in 
treated (imatinib, n = 8) and control (saline, n = 3) groups. A: Percentage of tumour 
voxels showing a positive (+∆𝑅1) or negative (−∆𝑅1) response. B: Corresponding 
mean ∆𝑅1 values for each treated or control tumour. No significant differences were 
observed throughout the study days in the treated or control groups (one-way ANOVA 
followed by Holm-Šídák’s multiple comparisons test). 
 
Correlation between 𝑅2
∗ and 𝑅1 responses to carbogen is represented in figure 6.6. 
This relationship was not significant at days 0 and 3. Day 5 revealed a significant 
correlation between both parameters, although with a weak correlation coefficient  
(R=-0.11). Still, this trend showed the anticipated relationship, in which a relatively low 
Δ𝑅2
∗ (high blood oxygenation) corresponds to a relatively high ∆𝑅1 (high tissue 
oxygenation).   
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Figure 6.6 – Voxel-wise correlation between 𝚫𝑹𝟐
∗  and ∆𝑹𝟏 responses to carbogen 
breathing in treated tumours (n = 8) at days 0, 3 and 5 of the therapy study. Dots 
represent individual tumour voxels. Correlation coefficients (R) and significance (P-
values) were obtained using Pearson’s linear correlation. 
 
Figure 6.7 shows the tumour SI response to the hypercapnia challenge. The 
percentage of responsive voxels (+ΔSI or –ΔSI) and their corresponding magnitude ΔSI 
were not significantly different between study days in treated or control groups (Fig. 
6.7A and B). However, similarly to figure 6.4, a “mirrored” longitudinal evolution 
between +ΔSI and –ΔSI magnitude responses was observed in the treated group (Fig. 
6.7B). Thus, the standard deviation of ΔSI magnitude values was calculated to assess 
the response heterogeneity to hypercapnia (Fig. 6.7C). No significant differences were 
observed, although there was a decrease in heterogeneity in 5 treated tumours between 
days 0 and 3 (no change in 3 tumours) and an increase in heterogeneity in 7 treated 
tumours between days 3 and 5 (decrease in 1 tumour). 
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Figure 6.7 – Tumour signal intensity (SI) response to air + 5% CO2 breathing 
challenge (hypercapnia) at days 0 (baseline), 3 and 5. A: Percentage of tumour 
voxels showing a positive (+ΔSI) or negative (-ΔSI) response to hypercapnia. B: 
Corresponding mean ΔSI values for each treated or control tumour. C: Standard 
deviation of the magnitude values represented in B. No significant differences were 
observed throughout the study days in the treated or control groups (one-way ANOVA 
followed by Holm-Šídák’s multiple comparisons test). 
 
6.3.3. Imatinib therapy did not normalise the tumour vasculature 
Pericytes express a number of markers of differentiation and, consequently, no single 
marker has the ability to identify all pericytes [185]. In this study, two of these markers 
were used: α-smooth muscle actin (α-SMA) and NG2 chondroitin sulfate proteoglycan. 
The expression of α-SMA occurs in most perivascular cells (composed of pericytes and 
vascular smooth muscle cells), whereas NG2 is expressed on arteriolar perivascular 
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cells and capillary pericytes but not on venular pericytes [185;186]. Since the 
vasculature of LS174T tumours is predominantly composed of capillaries, both 
antibodies exclusively stain pericytes in this tumour type. Moreover, the expression of 
α-SMA is possibly dependent on endothelial release of transforming growth factor-β 
(TGF-β), whereas differentiation into NG2-positive pericytes is independent of TGF-β 
[187].  
Administration of imatinib caused a decrease in the percentage of capillaries covered 
with NG2-stained pericytes, relative to control tumours (Fig. 6.8A and B and Fig. 6.9B). 
However, the percentage of capillaries covered with α-SMA-stained pericytes was 
similar between treated and control groups (Fig. 6.8A and B and Fig. 6.9B). This NG2-
selective effect of imatinib could be due to the different factors involved in the 
expression of both pericyte populations. No significant differences were observed 
between treated and control tumours concerning the percentage tumour coverage of 
perfusion, hypoxia, vascular endothelial cells or pericytes (α-SMA or NG2) (Fig. 6.9A). 
These results combined indicate vascular normalisation did not occur with imatinib 
therapy. 
Structurally, imatinib-treated tumours presented hyperdilated blood vessels (see Fig. 
6.8A), which is potentially due to a loss of structural support given the decreased 
pericyte coverage (NG2). Enlarged blood vessels like these were not very commonly 
found in untreated LS174T tumours (see Fig. 6.8B), and when they were the dilation 
was not so apparent.  
A qualitative analysis of the tumour morphology revealed that treated tumours 
presented larger areas of small, round and sparsely distributed nuclei, relative to control 
tumours (see Fig. 6.8C for examples of treated tumours). Cells of this morphological 
aspect were additionally experiencing nuclei fragmentation (Fig. 6.8C, red arrows). 
These observations combined suggest cells are possibly undergoing imatinib-induced 
apoptosis. However, an unequivocal conclusion cannot be drawn without a specific 
marker of apoptosis, such as caspase-3. Conversely, viable tumour cells are more 
densely arranged and have larger and non-spherical nuclei, being commonly located 
near the tumour edges or around the blood vessels (Fig. 6.8C).    
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Figure 6.8 – Histology in treated (A, C) and control tumours (B). A, B: 
Fluorescence microscopy showing enlarged capillaries in treated but not in control 
tumours. C: H&E showing regions of necrosis, small and sparse round nuclei 
(possibly revealing apoptosis) and viable tissue around capillaries (yellow arrow) 
or the tumour edge. Red arrows indicate nuclear fragmentation.   
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Figure 6.9 – Quantitative fluorescence histology in control and treated LS174T 
tumours. A: Percentage tumour coverage of perfusion, hypoxia, endothelial cells and 
pericytes stained with either anti-α-SMA or anti-NG2 antibodies. B: Percentage of 
blood vessels covered with pericytes. Bars represent mean ± SD. Imatinib treatment 
caused a significant decrease in the capillary coverage of pericytes stained with anti-
NG2 but not with anti α-SMA. Significance between distributions of treated and control 
tumours was assessed with a Mann-Whitney U-test. **, P < 0.01.  
 
 
6.4. Discussion 
The antitumour drug imatinib mesylate was used in this study to assess its influence 
on tumour 𝑅2
∗ spontaneous fluctuations and responsiveness to vasoactive gas challenges. 
Between LS174T and SW1222 tumour xenografts, the former was chosen because 
imatinib therapy previously caused an increase in antibody uptake in LS174T but not in 
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SW1222 tumours [165]. In the same study, the authors additionally reported that 
imatinib promoted pericyte detachment from endothelial cells (ECs) only in SW1222 
tumours. Decreased vessel maturation opposes to the proposed hypothesis of vascular 
normalisation, therefore not a desirable effect in the context of this study. Moreover, 
LS174T tumours present moderate to poor differentiation and are less vascularised and 
perfused than SW1222 tumours, thus could be considered as having a priori a greater 
potential for an increase in the efficiency of its vascular network upon therapy. 
 
6.4.1. Effect of imatinib therapy on the vascular and cellular 
characteristics of LS174T tumours  
Quantification of histological distributions revealed that the regime of drug 
administration used (100 mg × kg-1, once per day during 5 consecutive days) did not 
promote normalisation of the tumour microvasculature. Vascular pruning did not occur 
and perfusion and hypoxia were not different from control tumours. This result could 
possibly be due to the relatively short therapy window (5 days vs. 7 days in previous 
studies [165;169]) and/or the fact that therapy was not fractioned (half-life of imatinib is 
approx. 4 hours in mice [188], meaning a fractioned dose is more effective [169]). In 
accordance with this previous knowledge, the planned length of this study was 9 days, 
although issues with ulceration in some tumours caused the experiment to be shortened. 
Also, fractioned dose proved to be challenging to implement due to the length of the 
MRI scans. 
Contrary to what was previously reported for LS174T tumours, the vascular 
coverage of pericytes (expressing NG2) decreased upon therapy, which is in agreement 
with the observation that imatinib inhibits the PDGF pathway in this tumour line [169], 
further disproving the normalisation hypothesis. Differing observations regarding the 
effect of imatinib on LS174T vessel maturation could be due to differences in the 
employed quantification methods: in the present study the percentage of pericyte 
coverage was calculated, whereas Rajkumar et al. [165] calculated the Pearson’s 
correlation between the colocalisation of endothelial and pericyte marker staining. 
Disruption of the pericyte-EC contact resulted in blood vessel hyperdilation. This effect 
was previously observed with an inhibitor of PDGF receptor (PDGFR), where the 
authors concluded that tumour pericytes, albeit less abundant or more loosely attached 
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relative to normal vasculature, still have an important role in maintaining vascular 
integrity and function [187]. 
Decreased pericyte coverage is likely to increase leakage into the extravascular space 
[189] and, consequently, increase the interstitial fluid pressure (IFP). However, PDGF is 
a critical regulator of IFP [182;183;190] and imatinib-mediated inhibition of its receptor 
was shown to decrease IFP and hypoxia in LS174T tumours [169]. The fact that this 
study did not reveal changes in the percentage of hypoxia staining upon treatment 
possibly results from these two antagonistic effects cancelling each other. 
A previous study has also shown that absence of vascular normalisation occurred in 
other tumour models with a number of angiostatic compounds [191]. Normalisation is 
therefore dependent on the combination of compound + tumour type. Consequently, it is 
also worth to keep in mind that imatinib might not be a drug that straightforwardly 
promotes vascular normalisation, at least in LS174T tumours. 
The observed effects of imatinib therapy on the tumour cellular characteristics are 
more challenging to interpret. Histological sections of H&E revealed what can possibly 
be an increase in apoptosis observed across large areas of the tumour. Imatinib is a 
PDGFR inhibitor that targets the tumour vasculature and, accordingly, inhibition of 
PDGFR was previously observed to increase endothelial cell apoptosis [187]. Still, the 
majority of the observed non-viable cells distributed in the tumour stroma are unlikely 
to be of vascular nature. So why were non-endothelial cells affected? Imatinib 
additionally targets tyrosine kinases involved in signal transduction pathways, like Bcr-
Abl and c-kit receptor [153], and it was previously shown that imatinib-mediated 
inhibition of the c-kit pathway induced apoptosis in a human colon adenocarcinoma cell 
line (LS180) [192]. Given that LS174T tumours are also a c-kit-positive human colon 
adenocarcinoma cell line [193], it is conceivable that imatinib could have had a similar 
apoptotic effect in the current study. 
 
6.4.2. Effect of imatinib therapy on spontaneous 𝑹𝟐
∗  fluctuations 
Imatinib therapy did not affect the percentage of oscillating voxels or the amplitude 
of 𝑅2
∗ fluctuations. Baranowska-Kortylewicz et al. [169] showed that imatinib can 
decrease IFP through blockade of PDGFR. In such circumstances, the amplitude and/or 
prevalence of 𝑅2
∗ variations are expected to decrease due to their dependence on raised 
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IFP. However, as mentioned above, it is not obvious that imatinib caused IFP decrease 
in the current study, due to the pericyte-EC dissociation and likely increase in vessel 
permeability. If IFP remained unchanged with therapy, it provides an explanation for 
the lack of therapeutic effect in 𝑅2
∗ fluctuations. 
Additionally, the fact that spontaneous 𝑅2
∗ fluctuations were not affected despite the 
decrease in vessel maturation combined with the result of Chapter 5 of an inverse 
relationship between the amplitude of tumour-specific fluctuations and vessel 
maturation, suggests that vasomotion of mature vessels has little effect in generating 
flow/oxygen fluctuations in LS174T tumours. Perhaps the pericyte-EC contact is strong 
enough to regulate the vascular structure but still excessively loose in order to exert 
vasoconstrictive effects. Blood flow/oxygen spontaneous fluctuation independence from 
vasomotion could thus help explain the absence of therapeutic effect. 
 
6.4.3. Effect of imatinib therapy on the tumour response to applied gases 
Administration of imatinib revealed interesting results regarding the gas challenge 
responses, although of no straightforward interpretation, and drew attention to the 
importance of localised, rather than generalised, effects. 
An increase in the heterogeneity of ∆𝑅2
∗ upon carbogen breathing was observed at 5 
days following treatment. Relying on histological observations, vessel hyperdilation 
could be thought of leading to increased blood volume, which could increase the 
tumour’s capacity for oxygen transport, resulting in a greater negative ∆𝑅2
∗. In turn, 
stronger responses to the challenge increase the potential for vascular steal effects from 
the nearby vasculature, causing a greater positive ∆𝑅2
∗. A combination of these effects 
could therefore explain the increased heterogeneity in the 𝑅2
∗ response to carbogen. 
A decrease in the heterogeneity of the ΔSI response to hypercapnia at day 3 was also 
observed, albeit non-significant. Imatinib reduced the vascular coverage of pericytes, 
potentially causing a smaller positive ΔSI via loss of muscle tone. This weaker response 
has the potential consequence of decreasing the amplitude of negative ΔSI responses 
due to vascular steal effects. These two effects combined provide an explanation for the 
reduced heterogeneity in ΔSI at day 3. The early effect of imatinib on the hypercapnia 
response was reversed at day 5, which could be related to previous reports of 
“windows” of therapeutic efficacy in the first few days of treatment with antiangiogenic 
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drugs, after which the tumour recovers to the initial state (see a review on ref. [194]). 
Two factors could be casing the window’s closure: excessively high or prolonged 
dosing or emergence of drug resistance [194].   
Imatinib did not cause a significant change in the 𝑅1 response to the carbogen 
challenge throughout the study. Additionally, correlation between carbogen ∆𝑅2
∗ and 
∆𝑅1 revealed non-significant or weak relationships. Similarly to the data presented in 
Chapter 4, these results might be due to uncertainty in the measurement estimates, 
possibly because of background noise, which causes additional scatter. Concerning the 
𝑅1 data in particular, uncertainty could also be due to sub-optimal imaging parameters. 
O’Connor et al. [195] performed a conceptually similar experiment, in which they 
compared 𝑅2
∗ and 𝑅1 responses to carbogen and oxygen inhalation in patients. They 
observed significant 𝑅1 increases with the gas challenge in a number of organs, 
indicating 𝑅1 mapping can be used to monitor the molecular oxygen status. Of note, 
oxygen dissolved in blood plasma, apart from that in tissue fluid, also influences the 𝑅1 
relaxation rate. Still, ∆𝑅1 response upon a hyperoxic gas challenge is dependent on 
several physiological processes, like arterial blood flow, arterial blood volume and 
tissue metabolism [195], which can further influence measurement uncertainty in 
tumours due to their inherent heterogeneous microenvironment. Furthermore, tumour 
areas responsive to carbogen could have also varied between 𝑅2
∗ and 𝑅1 acquisitions due 
to variations in the perfusion status, providing an additional explanation for the poor 
correlation results.   
 
6.5. Conclusions 
This study aimed to assess the effect of the antitumour therapy imatinib mesylate on 
the LS174T tumour spontaneous 𝑅2
∗ fluctuations and responsiveness to vasoactive gas 
challenges. It was additionally hypothesised that imatinib could potentially promote a 
“vascular normalisation” effect, similarly to what has been observed with other 
antiangiogenic drugs. The results revealed that imatinib, as administered here, does not 
promote the normalisation of the vasculature in LS174T tumours. Consequently, the 
amplitude and prevalence of 𝑅2
∗ fluctuations remained unchanged.  Also, responsiveness 
to gas challenges did not reveal a generalised effect, rather emphasized the importance 
of local effects which influenced response heterogeneity. 
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Despite the results of this study, previous reports suggest that imatinib is a drug with 
great potential. If the therapy protocol can be fractioned and of greater duration, it is 
possible that it can have a more desirable effect towards an evolution of the tumour 
microenvironment that can decrease spontaneous oxygen fluctuations and better 
respond to secondary therapies.    
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7. Resting state 𝑹𝟐
∗  as a biomarker for prostate tumours: a 
clinical study    
The dynamic gradient-echo MRI (GE-MRI) sequence used in Chapters 4 to 6 was 
adapted to a translational study, where 𝑅2
∗ fluctuations were investigated as a method of 
discriminating early-stage prostate tumours from healthy tissue. The realisation of the 
potential of this MRI technique in the characterisation of the preclinical tumour 
microenvironment led to the assessment of its suitability in identifying tumours in the 
prostate in the clinical setting. This study was carried out in collaboration with Dr. 
Shonit Punwani, Dr. Catherine Morgan and Nicola Stevens (University College 
Hospital), where I contributed to the design of the study and performed the post-
processing of the MR data, including the implementation of independent component 
analysis for the first time in prostate studies.  
 
7.1. Introduction  
Prostate cancer is the most common and the second most deadly cancer among UK 
men [196]. Prostate biopsy guided by ultrasound remains the gold standard for 
diagnosing prostate cancer [197]. Although providing histopathological evidence, this 
technique suffers from a number of limitations. Perhaps the greatest drawback is due to 
the fact that prostate cancer is generally multifocal, whereas only a small portion of the 
prostate is sampled, which does not guarantee confirmation of tumour disease and 
causes large cancers to be under-evaluated [197;198]. In fact, prostate biopsy mainly 
samples the most posterior 18 mm of the gland, and it usually fails to include the 
anterior part, where about 20% of cancers develop [197;199]. Conversely, the fact that 
prostate biopsies are usually directed in a “blind fashion” causes millimetre-sized cancer 
foci to be detected, which do not usually represent clinically significant cancers [197].  
To overcome the limitations imposed by blind biopsies, multiparametric MRI of the 
prostate has become an important tool in the diagnosis, evaluation and treatment 
planning of prostate cancer [197]. In any given patient, a T2-weighted morphological 
sequence, a diffusion imaging sequence, and a dynamic contrast-enhanced (DCE) T1-
weighted sequence are commonly used to characterise different aspects of the tumours 
[197;200]. Spectroscopy sequences may also be employed [197;200]. The combination 
of T2-w, diffusion and perfusion imaging led to a diagnostic precision between 85% and 
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87% in a number of studies (see a review in ref. [197]). However encouraging, these 
results indicate there is still room for improvement. The current study describes an 
attempt to improve on early detection of prostate tumours using dynamic GE-MRI 𝑅2
∗ 
measurements. The evidence that tumours exhibit 𝑅2
∗ temporal fluctuations, combined 
with the dynamic and non-invasive characteristics of this imaging protocol, justifies 
undertaking an assessment of its diagnostic performance.  
Early tumour detection is fundamental to improve disease survival, and so the aim of 
this study was to investigate whether tumour 𝑅2
∗ spontaneous fluctuations occur in a 
clinical setting. If true, the potential of such fluctuating behaviour to be a biomarker of 
malignancy can be assessed. 
 
7.2. Materials and methods 
7.2.1. Patient cohort   
Patients with elevated levels of prostate-specific antigen (PSA) serum are at risk of 
developing prostate cancer [198;200]. Accordingly, the cohort of this study was 
composed of 20 male patients (mean age 65.85, range 58-79 years) with PSA 
concentration usually above 4.00 ng/ml (mean 7.03, range 1.40-15.00 ng/ml). Patients 2 
and 3 presented low PSA levels (2.00 and 1.40 ng/ml, respectively) but were still 
approved for this study by the medical staff. A table with each patient’s information is 
shown in supplementary data (Table S7.1). Twenty two patients were initially 
scheduled, although patients 5 and 18 did not proceed with the template biopsy and 
were therefore excluded from analysis. Patients were informed of the study and signed 
consent was given prior to their enrolment. 
 
7.2.2. MRI imaging protocol  
Multiparametric MRI of the prostate was performed on a Philips Achieva 3.0 T 60 
cm horizontal-bore system (Philips Medical Systems, Best, The Netherlands). 
Anatomical T2-weighted images were obtained, alongside maps of apparent diffusion 
coefficient (ADC) (Fig. 7.1A, B) and DCE, for tumour localisation. Before DCE 
acquisition, a 15-minute dynamic GE-MRI sequence was also obtained to assess 𝑅2
∗ 
temporal variations. GE sequence parameters were: TR = 200 ms, 5 echoes, TE1 = 20 
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ms, echo spacing = 3.5 ms, in-plane field of view 256×256 mm2, matrix size 128×128, 
slice thickness 2 mm, spacing between slices = 5.39 mm, 5 slices, flip angle = 20°, 22.5 
s/image. 
 
7.2.3. MRI data analysis  
Regions of healthy prostate (n = 24 regions) and prostate tumour (n = 16 regions) 
were selected upon analysis of multiparametric MRI data by an experienced radiologist. 
Tumour lesions were subsequently confirmed with a biopsy. Maps of 𝑅2
∗ SD were 
calculated as described in section 3.4, where healthy and tumour regions were then 
reproduced. 
Occurrence of rectal peristaltic movements, which can produce motion artifacts, was 
assessed by observing cine images of raw 𝑇2
∗-w data (Fig. 7.1C, a). Independent 
component analysis (ICA) was then implemented as a strategy to eliminate such 
artifacts. ICA was applied to the whole prostate volume. Differences in MR acquisition 
parameters between pre-clinical and clinical data meant some adaptations had to be 
performed to the ICA decomposition procedure described in Chapter 5. Dimensionality 
reduction with PCA was not employed in the prostate data because even the last 
principal components showed relevant information. This resulted from the small 
number of time points (40 vs. 944 in the pre-clinical datasets), which meant only 40 
principal components could be generated. Few data time points also made it harder to 
judge the nature (noisy/non-noisy) of each independent component. This, associated to 
the fact that healthy prostate regions do not necessarily experience blood 
flow/oxygenation fluctuations, prompted the decision to eliminate only those 
independent components that were suspect of modelling artifacts. This was performed 
based on the presence of spikes in their time courses. Figure 7.1C, b shows an example 
of one such artifactual independent component and its spatial map, showing a clustering 
effect in the same region of the motion artifact (previously observed in Fig. 7.1C, a). 
This artifact is clearly visible in the original 𝑅2
∗ SD map (Fig. 7.1C, c), but not in the 
ICA-filtered 𝑅2
∗ SD map (Fig. 7.1C, c). The effect of removing artifactual components is 
also obvious upon observation of individual 𝑅2
∗ voxel time courses (Fig. 7.1 C, c), 
where the spike at the time of motion (time-point 32) was eliminated. On average, 27.45 
out of 40 independent components were chosen. 
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Figure 7.1 – Post-processing strategy. Identification of healthy and early-stage tumour 
regions in the prostate was carried out by observation of T2-weighted images (A) and 
ADC maps (B), and posteriorly confirmed with a biopsy. C: Detection and elimination 
of motion artifacts. a: Prostate motion was observed in cine images of raw data (see 
yellow arrows). b: Time course and respective spatial map of one example independent 
component (IC #9), found to be modelling motion of the prostate: a peak above the 
time-course baseline and corresponding spatial clustering were observed. c: Elimination 
of such ICs resulted in decreased artifactual 𝑅2
∗ temporal variation. Original (green) and 
ICA-filtered (red) 𝑅2
∗ time courses of the voxel identified by the arrowheads are shown.   
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Mean 𝑅2
∗ SD values were calculated for each tumour region and its corresponding 
healthy region (n = 16) to assess if there was a significant difference in the amplitude of 
𝑅2
∗ fluctuations between them. Healthy prostate regions that did not have corresponding 
tumour lesions were not considered in this assessment, in order to exploit the paired 
nature of the statistical test used. Statistical differences were assessed with the 
Wilcoxon matched-pairs tests. 
𝑅2
∗ time courses of healthy (n = 24) or tumour (n = 16) regions were also assessed in 
the frequency domain using the Lomb method. As before, for each dataset, spectra of 
individual voxels were combined into a single averaged spectrum. The spectral mean 
and standard deviation of the cohort was then computed. 
 
7.3. Results and Discussion  
Figure 7.2 shows the difference between 𝑅2
∗ SD values of healthy and prostate 
tumour regions, which was not significant. Observation of individual independent 
component spatial maps also did not reveal any clustering effect in the selected regions 
of interest. The power spectra of 𝑅2
∗ time courses was also similar between healthy and 
tumour areas (Fig. 7.3).  
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Figure 7.2 – Mean standard deviation (SD) of 𝑹𝟐
∗  time-courses in healthy and 
tumour regions of the prostate (n = 16). No significant differences were observed 
(Wilcoxon matched-pairs test). 
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  These observations indicate that dynamic 𝑅2
∗ measurements of the prostate, as 
implemented here, are not sensitive enough to detect early-stage tumours of the prostate, 
and are therefore not yet suitable to be used as a biomarker of tumour disease in the 
clinic. Reasons for this lack of differentiation might include the fact that cycling 
hypoxia has been identified in advanced stages of tumour progression; hence, it might 
not yet be present in the early stages of tumour development. In addition, studies on 
cycling tumour hypoxia in humans are still scarce, which means the clinical reality of 
this problem might present considerable differences in relation to the pre-clinical 
situation. Consequently, as the MRI protocol implemented here was directly adapted 
from the pre-clinical protocol, it is possible that the parameters used in this study were 
sub-optimal in the detection of 𝑅2
∗ prostate tumour spontaneous fluctuations. One 
limitation of this study was that drawing of regions of interest on maps of 𝑅2
∗ SD 
possibly suffered from lack of accuracy. This could be overcome by co-registering T2-w 
images, ADC maps and DCE maps to 𝑅2
∗ SD maps. Other limitations consisted of 
involuntary motion artifacts due to rectal peristalsis and low sampling rate or 
insufficient scan length. These could be addressed by considering a clinical situation in 
which the tumours do not suffer from such neighbouring motion (e.g. brain), and also 
by increasing the number of acquisition points, mainly by increasing the sampling rate 
Figure 7.3 – Frequencies of 𝑹𝟐
∗  variation in healthy (n = 24) and tumour (n = 16) 
regions. Mean (black line) and standard deviation (shaded area) of power spectra are 
shown. Spectra do not reveal differences between the 𝑅2
∗ dynamics of healthy and 
tumour regions. 
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to allow clinical practice feasible, aiming to help to improve the distinction between 
oscillatory and noise-modelling independent components. 
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8. Conclusions and future directions 
Hypoxia, either chronic or cycling, has been found to occur in solid tumours, causing 
resistance to treatment and is also associated with tumour progression and development 
of metastatic disease. However, between both types of hypoxia, several comparative 
studies found the cycling form to be more severe and the one that appears to be present 
to a greater extent in tumours. For these reasons, and due to its oscillatory nature, which 
makes it more easily measurable with MRI, cycling hypoxia was made the focus of this 
research, while looking for associations between these transient patterns and tumour 
pathophysiology. 
Two studies by Baudelet et al. [34;41] provided the starting point for this thesis. The 
initial approach, here implemented in Chapter 4, consisted in adapting their ‘resting 
state’ and ‘gas challenge’ protocols to subcutaneous colorectal tumour xenografts. A 
major difference was the use of 𝑅2
∗ estimates instead of signal intensity recordings from 
𝑇2
∗-weighted images. 𝑅2
∗ transverse relaxation rates directly depend only on the 
oxygenation of the blood and not on blood flow, therefore helping in the interpretation 
of the data. Spontaneous 𝑅2
∗ fluctuations were detected in SW1222 and LS174T 
tumours, suggesting the occurrence of cycling levels of oxygenation. The longitudinal 
imaging protocol revealed that some aspects of spontaneous fluctuations depend on the 
stage of the tumour development, such as their oscillatory frequencies, whilst others do 
not, such as their prevalence. The vasoactive carbogen challenge differentiated between 
well and poorly perfused tumour types, which is in agreement with histological 
distributions, and where perfusion status revealed to be a determining factor in the 
evolution of the carbogen response with the growing tumour. Gas challenge responses 
that were opposite to those expected were also observed. These effects are challenging 
to interpret and are probably the result of the chaotic nature of the tumour 
microenvironment. This chaotic nature constitutes an inherent limitation in tumour 
studies, being a major source of temporal and spatial variability, which would have also 
impaired the correlation assessments between spontaneous 𝑅2
∗ fluctuations and gas 
challenge responses. Another limitation relates to spatial co-registration issues between 
histological images and MRI maps due to the considerable difference in resolution, 
which prevented the quantification of the relationships between their spatial 
distributions.  
137 
 
Potential future steps to overcome some of these limitations or explore further 
relationships consist of: implementation of a quantitative MR sequence sensitive to 
blood flow to shed new light on the gas challenge response heterogeneity, pulse 
sequence modifications to increase measurement accuracy, assessment of the 
relationship between glucose consumption/lactate production and cycling hypoxia, and 
assessment of the influence of the tumour site on the structural and functional properties 
of the tumour. 
Several studies hypothesised that tumour gas challenge responses revealing opposite 
variations to the a priori assumptions could be due to ‘vascular steal’ effects. These 
effects consist in a diversion of blood flow from a given tumour region due to increased 
blood flow in adjacent regions or in the feeding vasculature. Arterial spin labelling 
(ASL) is an established non-invasive quantitative MR technique that allows the 
estimation of blood flow and, if applied to tumours, could potentially identify the areas 
more susceptible of suffering from steal effects. In fact, efforts at our laboratory (the 
UCL Centre for Advanced Biomedical Imaging (CABI)) already allowed perfusion 
measurements in colorectal tumour liver metastasis, and discrimination relative to the 
surrounding liver tissue [201]. Ultimately, these maps would be compared with maps of 
𝑅2
∗ to investigate the relationship between tumour regions presenting opposite 𝑅2
∗ 
response and blood flow redistribution. 
   One additional source of measurement variability is its associated uncertainty. 
Although resting state and gas challenge maps were thresholded, there might have 
remained some residual uncertainty that could have affected the 𝑅2
∗ estimates. One way 
to decrease measurement uncertainty under noise is to increase the sampling rate (i.e., 
oversample) by decreasing the repetition time (TR). This would probably improve 𝑅2
∗ 
estimation performance and could have a measurable effect in improving the 
correlations between spontaneous 𝑅2
∗ fluctuations and gas challenge responses. 
An interesting study would be to explore the hypothesis of Gatenby and Gillies [76], 
that the tumour switch to the glycolytic pathway is an adaptive response to cycling 
hypoxia. A non-invasive MR method was recently developed at our laboratory which 
allows the imaging of glucose uptake in vivo in tumours, named glucoCEST [202]. A 
protocol which included glucoCEST and dynamic gradient-echo measurements would 
allow the assessment of the relationship between glucose uptake and the occurrence of  
𝑅2
∗ spontaneous fluctuations in tumours. Alternatively, monitoring the production of 
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lactate with proton MR spectroscopy, both with single-voxel and multi-voxel techniques 
(e.g., chemical shift imaging (CSI)), would allow the assessment of the evolution of the 
tumour glycolytic activity [203]. A second alternative would consist of using a recent 
technique, dynamic nuclear polarisation (DNP), which can increase the sensitivity of the 
MR spectroscopy experiment by 10000 fold, and can assess the tumour metabolism by 
mapping the flux of hyperpolarised 13C between pyruvate and lactate [204]. 
Finally, an appropriate alternative tumour site of implantation would probably more 
accurately mimic the clinical reality. Subcutaneous tumours are a good initial approach 
because of their reproducibility and relatively simple induction protocol. However, it 
was shown that the tumour site of implantation affects the vascular properties of the 
tumour [205]. Orthotopic tumour models are considered more clinically relevant and 
better predictive of therapeutic efficacy than subcutaneous xenograft models. In 
orthotopic tumours, the cancerous cells are implanted directly in the organ of origin, so 
that the tumour microenvironment more closely resembles the original clinical situation.   
Chapter 5 described a study aimed to investigate if tumour spontaneous 𝑅2
∗ 
fluctuations were influenced by blood oxygen variations in the systemic vasculature. It 
comprised the implementation of independent component analysis (ICA), a 
computational blind source separation technique extensively used in brain studies, 
which was here adapted to tumour data for the first time. Together with concomitant 
measures of systemic blood oxygenation, ICA applied to 𝑅2
∗ tumour maps allowed the 
identification of temporal variations that were due to systemic influence, as well as 
tumour-specific fluctuations. Importantly, ICA provided the ability to identify tumour 
regions that were simultaneously suffering from systemic and tumour-specific effects, 
which is a major advantage in relation to direct correlation approaches. Here, it is 
important to acknowledge that correlation analyses can represent a rather simplistic 
approach, and the analysis of multi-echo GE data in this study would merit the 
(alternative) implementation of a model-based strategy, such as with a General Linear 
Model (GLM), either on its own or in combination with ICA. Separation between 
systemic and tumour-specific sources of 𝑅2
∗ fluctuation revealed links to tumour 
pathophysiology, namely the tumour size and vascular maturation. The method here 
described has the potential to be adapted to the human condition, where it could help 
predict the delivery of systemically applied therapies in individual patients, and 
therefore help planning the delivery regime accordingly. Limitations of this study 
include the non-modelling of any possible lag between the systemic and tumour 
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recordings, which could have impaired the correlations. Also, tumours possibly suffer 
from a number of systemic influences, and so only by simultaneous measurement of all 
these systemic variations it would be possible to thoroughly assess the systemic 
influence in the tumour oxygen fluctuating patterns. 
Future work regarding the study presented in Chapter 5 includes a longitudinal study 
to assess the evolution of the systemic influence and the evolution of tumour feeding 
vasculature with the growing tumour.  
Following on the result of Chapter 4 that SW1222 tumours show more widespread 
response to carbogen breathing with the growing tumour, suggesting increased 
susceptibility to systemic variations, and on the result of Chapter 5 that revealed a link 
between tumour size and systemically-driven fluctuations, it would be interesting to 
apply the ICA method to a longitudinal study. Simultaneous acquisition of systemic 
physiological parameters and tumour ‘resting state’ 𝑅2
∗ in a longitudinal fashion would 
allow to confirm if the percentage of the tumour oscillating due to systemic effects does 
in fact increase with the tumour size. 
Related to the above suggestion, a longitudinal study on the evolution of the tumour 
supplying vasculature would provide valuable insights on the influence of systemic 
sources of cycling hypoxia in the tumour, which could be through an increase in the 
number of systemic feeding vessels, an increase in the calibre of such vessels, or both. 
ASL measurements could additionally be taken to quantify the evolution of blood flow 
entering the tumour.  
Chapter 6 described a therapy study, with the agent imatinib, conducted under the 
hypothesis of “vascular normalisation”, i.e., decrease in the tumour vascular density 
alongside structural and functional improvement of the remaining capillaries. 
Histological assessment revealed that imatinib therapy did not promote normalisation of 
the vasculature. Consequently, the prevalence or amplitude of tumour 𝑅2
∗ spontaneous 
fluctuations were not affected by the drug. Similarly, the whole-tumour responsiveness 
to gas challenges did not improve. However, imatinib promoted increased heterogeneity 
in the 𝑅2
∗ response to carbogen breathing, which draws attention to the importance of 
considering regional effects. A correlation between blood oxygenation (𝑅2
∗ estimates) 
and tissue oxygenation (𝑅1 estimates) was also attempted. However, no significant 
associations were observed, which could once again be due to measurement uncertainty, 
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particularly in 𝑅1 estimates. Limitations include the short length of the study, the non-
fractioned drug administration regime, and the uncertainty in measurement estimates. 
Future steps to the work presented in Chapter 6 comprise alterations to the therapy 
regime, employment of alternative methods to estimate tumour tissue oxygenation, or 
the use of alternative therapies.  
A longer lasting regime, possibly 9 or 10 days, in which lower doses of the drug are 
administered at more regular intervals, so as to allow continued exposure, would help to 
provide a more accurate estimate of the efficacy of imatinib. Examples of the 
advantages of a fractioned regime come from different studies [169;173]. This could 
offer a method to investigate ‘windows’ in which to apply secondary antitumour 
therapies. 
𝑅1 estimates were found to be relatively  insensitive to tissue oxygenation variations. 
Alternative methods to measure tissue pO2 could thus be pursued. In particular, electron 
parametric resonance imaging (EPRI) looks very promising in providing non-invasive 
dynamic measurements of tumour pO2 [12;86;206]. Together with a gradient-echo 
sequence, EPRI could be used to assess the relationship between variations in tumour 
pO2 and 𝑅2
∗. In fact, EPRI has already revealed to be sensitive enough to distinguish 
between tumour regions of chronic and cycling hypoxia [12;86]. 
Alternative therapies could equally be used to promote vascular normalisation and 
assess its effect of spontaneous 𝑅2
∗ fluctuations and gas challenge responsiveness. 
Inhibitors of a receptor of vascular endothelial growth factor (VEGF) or multi-tyrosine 
kinase inhibitors, such as sunitinib, have been shown to promote vascular normalisation 
[173;207]. Sunitinib, in particular, was also shown to suppress tumour pO2 fluctuations 
during the vascular normalisation window [207].  
Chapter 7 described a pilot clinical study where the feasibility of using spontaneous 
𝑅2
∗ fluctuations as a biomarker of prostate tumour was assessed. Healthy and tumour 
prostate regions did not reveal significant or discernible differences in the amplitude or 
frequency of fluctuations. Few acquisition time points and the fact that the prostate 
suffers from artifactual motion due to rectal peristalsis constitute limitations of this 
study. 
A similar protocol could be applied to a cohort of patients with brain tumours, where 
motion and susceptibility artifacts should be less limiting. A faster acquisition rate or a 
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longer imaging protocol would allow more dynamic data points, which would be 
advantageous in identifying oscillatory patterns and noisy components.    
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Figure S6.4 – Treated (imatinib) and 
control (saline) tumour response to 
carbogen at days 0 (baseline), 3 and 5. 
Significance between days of study was 
tested with a one-way ANOVA followed 
by Holm-Šídák’s multiple comparisons 
test. A: Percentage of tumour voxels 
showing a positive (+Δ𝑅2
∗) or negative 
(−Δ𝑅2
∗) response to carbogen. B: 
Corresponding mean Δ𝑅2
∗ values for 
each treated or control tumour. C: 
Standard deviation of the magnitude 
values represented in B, depicting a 
significant increase in the heterogeneity 
of the carbogen response between days 0 
and 5 in the treated group, but not in the 
control group.     
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Table S7.1 – Age, PSA level and biopsy results for the cohort of patients. 
Patient # Age 
PSA 
(ng/ml) 
Prostate biopsy 
Site 
Gleason 
score 
1 66 5.26 left mid anterior base 3+3 
2 60 2.00 
mid apex 3+3 
right medial anterior apex 3+3 
left lateral 3+3 
right lateral 3+3 
right para posterior apex 3+3 
right medial posterior apex 3+3 
3 58 1.40 
left para anterior apex 3+3 
right medial anterior base 3+3 
4 74 9.30 left medial posterior apex 3+3 
6 65 6.60 
left parasagittal anterior apex 3+4 
left parasagittal anterior base 3+4 
right parasagittal anterior 
apex 
3+3 
right medial anterior apex 3+3 
right lateral 3+3 
right parasagittal posterior 
apex 
3+3 
right medial posterior apex 3+3 
right medial posterior base 3+3 
7 73 12.10 No tumour 
8 63 11.00 
left para anterior apex 3+3 
right para anterior apex 3+3 
mid base 3+3 
left lateral 3+3 
right lateral 3+3 
left para posterior apex 3+3 
left medial posterior apex 3+3 
left medial posterior base 3+3 
right medial posterior base 3+3 
9 79 11.80 
left para anterior apex 3+3 
mid apex 3+3 
left mid anterior apex 3+3 
right lateral 4+3 
right para posterior apex 3+3 
right medial posterior apex 4+3 
right medial posterior base 3+3 
10 71 5.54 
left para anterior apex 3+3 
left medial anterior apex 3+4 
left medial anterior base 3+4 
right medial anterior apex 3+4 
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right medial anterior base 3+4 
left para posterior base 3+3 
left para posterior base 3+3 
11 67 
15.00 
& 
11.00 
left para anterior apex 3+3 
left medial anterior base 3+3 
right para anterior base 3+4 
right para anterior apex 3+3 
left mid anterior apex 3+3 
right medial anterior base 3+4 
right medial anterior apex 3+3 
right medial posterior base 3+4 
12 63 6.92 
left para anterior base 3+3 
mid apex 3+4 
mid base 3+4 
left mid anterior apex 3+4 
left mid anterior base 3+4 
left lateral 3+3 
left para posterior apex 3+4 
left para posterior base 3+4 
right para posterior apex 3+4 
right para posterior apex 3+4 
right para posterior base 3+3 
left medial posterior base 3+4 
13 68 11.35 
left para anterior base 3+3 
right para anterior apex 3+3 
right para anterior base 3+3 
left medial anterior base 3+3 
right medial anterior apex 3+3 
right medial anterior base 3+4 
left lateral 3+3 
right lateral 3+4 
left para posterior apex 3+3 
right para posterior apex 3+3 
left medial posterior apex 3+4 
left medial posterior base 3+3 
right medial posterior base 3+3 
14 59 3.68 
left mid anterior apex 3+3 
left para posterior apex 3+4 
left medial posterior apex 3+4 
15 70 4.21 No tumour 
16 61 4.06 No tumour 
17 63 3.80 
left mid anterior apex 3+3 
right medial anterior apex 3+3 
left lateral 3+3 
left para posterior apex 3+3 
right para posterior apex 3+3 
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left medial posterior apex 3+4 
19 68 3.90 
right para anterior base 3+3 
left lateral 3+4 
left medial posterior apex 3+4 
right medial posterior apex 3+4 
20 60 4.74 No tumour 
21 69 10.32 
mid apex 3+4 
right lateral 3+4 
right medial posterior apex 3+4 
right medial posterior base 3+4 
22 60 9.66 
left para anterior apex 3+3 
left mid anterior apex 3+4 
left lateral 4+3 
left medial posterior apex 3+3 
 
 
